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The incidence of Alzheimer’s disease (AD) worldwide has been accelerating at a 
staggering rate, demonstrating the need to understand its origins clearly. Misfolded 
proteins such as amyloid- (A) have been believed to contribute to the disease. 
Additionally, it has been suggested that the normal functions and localization of metal 
ions such as Fe(II/III), Cu(I/II), and Zn(II) could be disrupted in the AD brain. There has 
been evidence to support the possible interplay between Cu(II) and/or Zn(II) with A-
related pathology (i.e., metal–amyloid hypothesis); however, this relationship has yet 
been to be fully elucidated. A growing interest this possible association with AD 
pathology has led to new strategies for interrogating the metal–A relationship using 
small molecule metal chelators. Flavonoids are abundant plant-derived molecules that 
have been known to bind metal ions and interact with A peptides; however, the 
synergism of these properties toward metal-associated A has previously received little 
attention. In this thesis, selected flavonoid derivatives were investigated to formulate a 
structure-interaction-reactivity relationship among chemical structures, metal ions, and 
A/metal–A species. The molecules myricetin and luteolin, found in fruits and 
vegetables, were initially screened and found to influence the reactivity of metal–A 
species. Building upon these initial observations, the interaction and reactivity of the 
well-known green tea polyphenol (−)-epigallocatechin-3-gallate (EGCG) were explored 
at the molecular level through biochemical and biophysical investigations. These 
findings suggest that metal–A–flavonoid species can be generated and possibly lead 
to off-pathway aggregation in vitro. We further identified the specific contributions of 
structural features by synthetic manipulation of the flavonoid framework to 
aminoisoflavone derivatives. Appropriate tuning of hydrophilic and hydrophobic 
properties within the structural backbone can modify the balance of metal binding and 
A interaction, which may account for their reactivity toward A and/or metal–A. Taken 
xxii 
 
together, the studies presented herein demonstrate the utility of flavonoids as a source 
of structures for direct use and/or synthetic modification from which a structure-
interaction-reactivity relationship can be formulated for metal-free and metal-associated 
A species, which will provide insight into development of chemical tools to uncover the 
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1.1. Bioinorganic chemistry in the brain 
 Bioinorganic chemistry is an interdisciplinary field that seeks to understand the 
role of metal ions in living systems.1,2 Metals have unique chemical properties that 
render them useful in an array of scenarios. For example, metal ions can mediate 
catalysis in an enzyme, confer structural stability to a protein, participate in chemical 
signaling, or facilitate electron transfer.1,3 As a result of their prevalence in biology, 
interest in metal involvement in human health has continued to develop in the last 
several decades. In particular, studies on the roles of metal ions in the brain and central 
nervous system (CNS) comprise a sub-field of bioinorganic chemistry called 
metalloneurochemistry.4 Bioinorganic chemists are uniquely qualified to address 
questions in metalloneurochemistry by applying knowledge of the fundamental 
principles of inorganic chemistry and biochemistry to characterization of the structure, 
function, and reactivity of metals in the CNS.4 Methods of traditional inorganic 
spectroscopy (e.g., electron paramagnetic resonance (EPR), Mössbauer) have been 
developed and modified to investigate details of these complex systems at the 
molecular level, such as the coordination chemistry of metal ions in protein active sites. 
Moving forward, the field has also taken an interest in the mechanisms of storage, 
transport, and uptake of metal ions (i.e., homeostasis), particularly for those that are 
abundant (e.g., Ca(II), K(I)) and for trace elements (e.g., transition metals).5 
Metal ion homeostasis must be tightly controlled, especially in the brain, to 
maintain health. Fe, Cu, and Zn are important in brain function; the accessibility of 
multiple oxidation states for Fe (i.e., +2, +3) and Cu (i.e., +1, +2) makes these ions 
important for a variety of redox processes, while Zn, which exists only in the +2 state, 
often confers structural stability and participates in signal transduction.1,4,6 Ensuring that 
the metals are available and directed to the appropriate sites involves a variety of 
transporters and chaperone proteins.1,2,5-7 The proteins transferrin and ferritin are mainly 
responsible for transport and storage of Fe in the ferric form. Fe is also found within 
heme-proteins such as hemoglobin and myoglobin, where Fe(II) participates in storage 
of dioxygen (O2).6  There are several proteins involved in Cu homeostasis; among them, 
ceruloplasmin is a key player for Cu storage in the blood and facilitates the cycling of 




Cu across the blood-brain barrier (BBB) where it resides within metallothionein-3 (MT-
3).6,8 The MT proteins are important for maintaining Zn homeostasis as well, but Zn(II) is 
also found in the brain in vesicles and in a “free” pool.8 Zn transporters, ZnT, sequester 
and export Zn(II), while uptake is mediated by various receptors (e.g., N-methyl-D-
aspartate (NMDA)-dependent voltage gated channels). Zn(II) has been shown to play 
an important role in signal transduction and memory, and deficits have been implicated 
in cognitive decline.8  It is becoming more apparent that dysfunction of these regulatory 
mechanisms can be detrimental. Failure of the Cu transporter ATP7A, for example, is 
implicated in Cu overload associated with Wilson’s disease.6 Therefore, recent interest 
in metal ion homeostasis as an underlying cause of neurodegenerative disease (e.g., 
Alzheimer’s, Parkinson’s) has gained attention. The involvement of metal ion 
homeostasis in Alzheimer’s disease (AD) will be discussed further (vide infra). 
   
1.2. Protein misfolding and human neurodegenerative diseases 
Proteins have a multitude of responsibilities in biology owing to their great 
structural diversity. Since protein structure is closely linked to function, proper 
adaptation of secondary, tertiary, and quaternary structure is critical. Often, the protein 
folding process is mediated by other proteins, such as chaperones, which help newly 
synthesized peptides achieve their functional state.9 When these processes are 
interrupted or misregulated, it is possible for a protein to adopt a stable, but non-native 
conformation.10 As a result, misfolded proteins have been implicated in a wide variety of 
human diseases, many of which involve neurodegeneration. 
Neurodegenerative diseases commonly associated with protein misfolding 
include AD, Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic 
lateral sclerosis (ALS or Lou Gehrig’s disease). Some other diseases have been 
recently reclassified as neurodegenerative diseases as new insights on their 
pathologies are discovered (e.g., glaucoma; see Appendix A for more details). In 
general, each of these diseases is related to aging, affects different regions of the brain 
and CNS, and can occur sporadically or be inherited.10 Insoluble protein deposits in 
affected tissues were found to be another connection among these diseases. Upon 




proteins within the aggregates from AD, PD, HD, and ALS had similar conformations. 
They were long and fibrillar, as observed by transmission electron microscopy (TEM) 
and atomic force microscopy (AFM), had cross- structure, and reacted with dyes such 
as Congo red and thioflavin-T (ThT).10-12 Currently, proteins with these characteristics 
are classified as amyloids.  
Most amyloidogenic proteins are categorized as “misfolded,” since they can 
aggregate into a variety of intermediate forms and may be related to toxicity.13 Amyloid 
formation typically occurs through a nucleation-dependent model with a sigmoidal 
growth pattern, in which a slow lag phase precedes rapid fibril formation (Figure 
1.1).14,15 In the lag phase, self-association of monomers and oligomer formation are 
thermodynamically unfavorable; however, when the proper “seed” has been produced, 
fibril growth can occur. Fibril growth can be accelerated by incubating a solution of the 
peptide with preformed seeds. Aggregation is also impacted by modifying conditions, 
such as pH, temperature, salt concentration, and agitation.16 For example, nearing the 
isoelectric point (pI) of the protein accelerates aggregation as solubility is minimal near 
the pI. Growth of amyloid aggregates typically occurs upon self-association via 
hydrophobic contacts in an effort to exclude water. Owing to their thermodynamic 
stability, biophysical characterization of fibril structures has been more easily achieved. 
There have also been methods developed to stabilize monomeric peptides (e.g., lower 
temperatures, addition of detergents) allowing for their structure determination.15 The 
intermediates between monomers and fibrils include oligomers and protofibrils.10 In 
contrast to monomers or fibrils, oligomers have been difficult to characterize due to their 
transient nature. Protofibrils tend to be somewhat more stable than oligomers as they 
immediately precede fibril formation. Structurally, protofibrils begin to display some 
characteristics of fibrils, including cross- structure. They are usually 4-11 nm in 
diameter and less than 200 nm long while mature fibrils are larger in size (ca. 10 nm 
diameter) and their length is on the m scale. 
The contribution of amyloid protein aggregates to toxicity remains controversial 
and several theories have been proposed.10 First, it has been proposed that aggregates 
directly cause toxicity from a “gain of toxic activity.” Several possible “toxic activities” 






Figure 1.1. Nucleation polymerization model of amyloid aggregation. Soluble 
monomeric forms of the peptides, such as amyloid- (A), self-associate during the lag 
phase (nucleation). This forms a nucleus that can be rapidly extended during the fibril 
growth period called the elongation phase. Amyloid fibrils are the end product of this 
process, and their thermodynamic stability allows them to reach a stage called the 
plateau. The aggregation processes produce a sigmoidal kinetic trace that is depicted in 
the figure (blue).  
 
(e.g., that initiate apoptosis), to disrupt membranes leading to pore formation, or to 
cause oxidative damage to biomolecules.10 An alternative view is that amyloid 
aggregates can also cause a “loss of function” that leads to disease. For example, 
aberrant metal chelation by metal-binding amyloidogenic peptides could disrupt metal 
homeostasis and compromise cell health (vide infra). Finally, inflammation caused by 
the presence of aggregates has been suggested.10 Each of these possibilities is 
reasonable to consider, which likely accounts for the difficulties in clearly defining the 
relationship among amyloid protein deposits, neurodegeneration, and disease with 
certainty. Overall, it appears that these diseases share common traits that could be 
beneficial targets for therapeutics in the future. In addition, it is important to consider the 
impact of additional factors (e.g., metal ions, proteins, reactive oxygen species (ROS)) 
and how key players from multiple hypotheses may govern disease progression. 




misfolding diseases, the remainder of this chapter will emphasize a specific example, 
AD, including how its misfolding may be perpetuated by metal ions and current efforts to 
address the interrelationship between these factors using small molecules.  
 
1.3. Bioinorganic chemistry and protein misfolding in Alzheimer’s disease 
 
1.3.1. Alzheimer’s disease (AD) and amyloid- (A)  
AD is the most prevalent form of dementia primarily among elderly adults, which 
is associated with severe cognitive impairment and memory loss.15,17 Currently, over 5 
million Americans are afflicted by AD, placing a severe burden on socioeconomic 
resources.17 Although the symptomatic and pathological signs of AD have been 
identified, a complete understanding of their origins remains elusive. This uncertainty 
has impeded progress toward developing effective preventive and disease modifying 
therapeutics; the presently available drugs only alleviate the symptoms temporarily and 
are unable to deter or cure the disease.15,17-19 While some cases of AD are attributed to 
genetic inheritance, the majority of cases are sporadic.18 Confirmation of the AD 
diagnosis is contingent upon the identification of misfolded protein aggregates, including 
neurofibrillary tangles composed of hyperphosphorylated tau protein and senile plaques 
mainly composed of A peptides, as well as extensive oxidative damage and neuronal 
loss in the brain post mortem.18,19 Within the mature plaques from diseased brains, high 
concentrations of metals, such as Fe, Cu, and Zn, have been also found, possibly 
representing their dyshomeostasis and miscompartmentalization in the diseased 
state.15,19,20 This finding implies that along with protein aggregate accumulation, metals 
may contribute to AD onset and progression.19-27 Taken together, misfolded A species, 
metal ion dyshomeostasis/miscompartmentalization, and oxidative stress partially 
represent AD etiology.18-27 Herein, the generation and aggregation of A and the role of 
metal ions in AD and A-related events, along with development of multifunctional small 
molecules to illustrate some current approaches to understand the nature of the metal–





1.3.2 Amyloid precursor protein (APP) and A generation 
The A peptide is the predominant component of the senile plaques that 
accumulate in various brain regions and pathologically represent the AD condition.10,18-
22,24-26,28-30 Its involvement in AD neuropathogenesis has been extensively studied 
following the establishment of the amyloid cascade hypothesis, which implicated A as 
a causative agent in AD.28 The A peptide is composed of 38-43 amino acid residues 
and is generated through sequential proteolytic cleavage of the amyloid precursor 
protein (APP).18,19,31 APP is a transmembrane protein with three common isoforms, 
APP695, APP751, and APP770, which among them, APP695 is most common in the 
neuronal cells.18,31 The function of APP is still incompletely defined, but with two metal 
binding domains E1 (residues 124-189; APP770 numbering) and E2 (residues 376-554), 
it has been suggested that APP could be involved in regulating metal ion (e.g., Cu) 
transport and homeostasis.6,27,31-34 A recent report suggested that APP exhibits 
ferroxidase activity in a similar manner to that of ceruloplasmin (a Cu transport protein) 
whereby APP facilitates Fe export from neuronal cells; inhibition of this activity by 
reserves of Zn(II) could be connected to elevated levels of Fe measured in AD (vide 
infra).35 
The proteases responsible for APP cleavage and A generation distinguish the 
resulting forms of A as either non-amyloidogenic (normal) or amyloidogenic (disease-
related) (Figure 1.2).18,19,27,31 Processing of APP by -secretase initiates the non-
amyloidogenic cleavage pathway, with initial scission between K687 and L688 (APP770 
numbering) affording a large soluble fragment (sAPP) and leaving a portion of the APP 
molecule membrane-bound (Figure 1.2). The amyloidogenic pathway begins with APP 
cleavage by -secretase (-site APP cleaving enzyme, BACE1) nearer to the N-
terminus of APP between residues M671 and D672. The remaining membrane-bound 
fragments from both paths are finally processed by -secretase, which requires four 
protein components for its activity: presenilin (PS1 or PS2), nicastrin, anterior pharynx-
defective-1 (APH-1), and presenilin enhancer-2 (PEN-2).18,31,36 The -secretase 
complex cleaves the C-terminal fragments within the membrane to produce monomeric 




A40 and A42, are produced through the amyloidogenic pathway (the amino acid 
sequence of A42 is DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) 
(Figure 1.2). Monomeric A tends to aggregate, forming low molecular weight (MW) A 





Figure 1.2. Cleavage of APP by -, -, and -secretases in the non-amyloidogenic and 
amyloidogenic pathways, respectively. The common full-length peptides, A40 and A42, 
in AD are formed through the amyloidogenic pathway. 
 
1.3.3. Aggregated A species and their contribution to neurotoxicity 
A is a relatively small peptide for which the innate function has not been fully 
established. The structure of A monomer features hydrophilic N-terminus and 
hydrophobic C-terminus, which play a role in driving its aggregation in an effort to 
minimize unfavorable interactions with the aqueous environment.19 Residues contained 
in the region from L17-A21 are identified as key contributors to self-recognition, due to 
their primarily hydrophobic nature, which might be influential in producing the higher-
order structures.19,37 Fibrils of A40 adopt -strand characteristics in two regions, from 




within the fibrillar structure.38 Within the peptide, a turn occurs in the region from G25-
G29 that is stabilized by a combination of electrostatic interactions such as a salt bridge 
between D23 and K28.19,37,38 
A42 is the primary constituent of the senile plaques; the two additional 
hydrophobic residues at the C-terminus enhance its tendency to aggregate over A40, 
although the shorter peptide (A40) accounts for the major product of -secretase 
cleavage yielding A peptides.18,19 A undergoes conformational changes during 
aggregation where the native random coil structure can be modified to either -helical or 
-strand-like forms.37,39 The conformational changes, however, are highly conditional 
and slight changes in parameters such as pH, peptide concentration, and metal ion 
concentration may lead to diverse amyloid aggregates that may be ordered or may be 
amorphous.20,40 The array of known polymorphic forms of A aggregates aside from the 
monomers and fibrils, which includes oligomers, protofibrils, annular structures, A-
derived diffusible ligands (ADDLs), and globulomers, has been reviewed.40  
It is still not clear which A conformation is directly linked to neuropathogenesis. 
Some recent evidence implicates soluble low molecular weight (MW) A species, such 
as dimers, instead of the plaques as the relevant neurotoxic species.19,30,36,41 In the 
early stages of AD, reduction of synaptic function and impairment of learning and 
memory formation processes (e.g., long-term potentiation) may be caused by the 
smaller A assemblies, such as oligomers; these species possibly interfere with 
neurotransmission and/or other signaling pathways in the cells.36 The occurrence of 
physiological responses in the brain such as inflammation and neuronal death as the 
disease progresses, however, could be attributable to these soluble aggregated 
species, the plaques, or a combination of various species in association with each 
other. Additional mechanisms proposed for the toxicity of A aggregates are related to 
interactions with other biomacromolecules (e.g., pore formation within lipid membranes) 





1.3.4. Metal ions in AD and their interactions with A 
As described in Section 1.1, essential transition metal ions, such as Cu(I/II) and 
Zn(II), have important functions in the brain, such neurotransmission.20,42 Due to the 
association of high levels of Fe, Cu, and Zn with A aggregates from diseased brain 
tissue, these metals have been suspected to be linked to the pathological events of AD; 
however, this area remains contested.18-21,43-46 Cu(I/II) and Zn(II) have recently garnered 
the most attention for being able to directly bind to the A peptides.18-21,43-46 Both metals 
are usually found in association with biological ligands, but a pool of “free” or loosely 
bound (i.e., chelatable) ions can exist in the synaptic cleft, making them accessible to 
A peptides that are released into the synapse.22,24,43 The concentrations of Cu(II) and 
Zn(II) can reach up to 15 M and 300 M, respectively, in the glutamergic synapses 
during neurotransmission, from which only a fraction may be sufficient to be related to 
the disease pathology.20,22,42,43 An early study estimated the levels of metals in the A 
plaques to be in the high micromolar to low millimolar range, with total plaque content 
being reported at ca. 0.9 mM for Fe, 0.4 mM for Cu, and 1 mM for Zn.20,22,23,44 While the 
original paper47 likely sparked interest in the connection of metal ions in AD, it has been 
argued that its excessive citation may have biased the field toward believing the metal 
contents in the brain increase.7,48 Currently, it is believed that concentrations of Fe and 
Cu are relatively unchanged between AD and control brains; Zn is known to be depleted 
with aging, so a slightly greater loss of Zn may be associated with AD.7 Instead, an 
alternative view worthy of more attention is that the miscompartmentalization/relocation 
of metal ions in AD, which may be the result of its association with A in discrete areas, 
is a factor that contributes to the disease.6,7,15  
Despite the uncertain nature of the metal–A interaction in vivo, it has been 
established that metal ions are able to bind to A in vitro (Figure 1.1).19,20,27,45,46 Both 
Cu(II) and Zn(II) have been shown to bind to Ain a 1:1 fashion, although it has been 
also reported that A can bind up to approximately two equivalents of Cu(II). The 
coordination environment of the Cu(II) and Zn(II) has been investigated using an array 
of spectroscopic methods including nuclear magnetic resonance (NMR), EPR, UV-




fine structure (EXAFS).27,43,45,46,49 Several probable coordination modes have been 
proposed, but the exact identity of the ligands for these ions has not been fully 
elucidated. The current evidence suggests a binding environment containing a mixture 
of nitrogen and oxygen donor atoms for both Cu(II) and Zn(II), for which three histidine 
residues (H6, H13, and H14) are likely to be included (vide infra). 
The previous studies of Cu-bound A monomers suggest several metal binding 
features, given the complexity of the solution speciation measured under various 
experimental conditions.20,27,43,45,46 Depending on the oxidation state of Cu (e.g., Cu(I) or 
Cu(II)), different binding modes and coordination environments on the metal center 
have been observed. The reducing conditions of the brain validate the determination of 
Cu(I) binding properties, but there have been fewer studies on Cu(I)–A compared to 
Cu(II)–A. Cu(I) binding to the monomer was found to occur in a linear environment via 
the imidazole rings of two His ligands.50,51 More recently, the interaction of Cu(I) to A42 
oligomers was reported.52 These results indicated that the coordination environment of 
Cu(I) in oligomers was different from that in monomers; a tetrahedral environment was 
identified. Unlike Cu(I)–A monomer species, the Cu(I)–A oligomers were found to be 
highly reactive to O2.52 These findings may be valuable to understanding Cu–A redox 
chemistry since the cycling of Cu(I/II) could facilitate production of ROS (Figure 1.3), 












Figure 1.3. Reactive oxygen species (ROS) generated by redox cycling of Cu-bound A 





The coordination environment of Cu(II)-bound A has been widely studied, with 
the general agreement that the binding mode is dynamic and conditional (e.g., pH-
dependent).27,45,46 The current consensus is that in the physiologically relevant range 
(ca. pH 7.4), A tends to involve three nitrogen and one oxygen (3N1O) donor atoms 
coordinated to Cu(II). Commonly referred to as “species I,” two binding modes for 
Cu(II)–A have been suggested. The first involves the three histidine residues (H6, H13, 
and H14) along with the carboxylate of D1 and the second involves two histidine 
residues, the N-terminal amine, and the D1–A2 or A2–E3 backbone carbonyl.27,34,45,46,55 
Above pH 8 the coordination mode for Cu(II), there is evidence that the coordination 
mode is altered giving rise to “species II.” Likely maintaining a 3N1O coordination 
environment, the deprotonated D1–A2 backbone amide, A2–E3 backbone carbonyl 
oxygen, N-terminal amine, and a His side chain or the three histidine residues and the 
carbonyl oxygen from the backbone of A2 have been suggested.27,34,46 While Cu(II)–
Acomplexes likely form a four-coordinate species, Zn(II)–A may coordinate four to six 
ligands. There is a consensus that the three histidine residues are responsible for 
binding; however, the fourth, fifth, and/or sixth ligands have been more difficult to 
identify.15 Thus, Cu and Zn in A plaques could be directly bound to the peptides. 
Previously, it has been suggested that Fe accumulation could be due to its 
association with other proteins or biological ligands (e.g., heme) that are found within 
the aggregates and not directly to the peptide. Recently, the binding mode of Fe(II) to 
A has been proposed.55 An octahedral geometry was suggested with similar residues 
used as for Cu(II). The current model suggests that three histidine imidazole rings could 
participate, along with the N-terminal amine, the carboxylate of D1 or E3, and the 
carbonyl of D1 or H6. Continued efforts to characterize Fe(II) binding to A peptides will 
be critical toward formulating the relationship of metals to AD. 
Metal binding to A has been suggested to initiate peptide aggregation and 
neurotoxicity.18-27,43,45,46 When considering the A aggregation according to the 
nucleation polymerization model (vide supra, Figure 1.1), the formation of the initial 
nucleus and subsequent elongation into the familiar cross--sheet nature of the fibrils 




in the presence of metal ions like Cu(II) and Zn(II), the aggregation kinetics can be 
accelerated.43,56 Substoichiometric amounts of Cu(II) have been shown to reduce fibril 
generation time by half pH 7.4 as a result of the peptide nearing its isoelectric point.56 
Cu(II) also facilitates A aggregation under slightly acidic conditions.57 Treatment of A 
with micromolar concentrations of Zn(II) leads to insoluble amorphous peptide species 
in a rapid process occurring within milliseconds.58  
Dissociation constants (Kd) indicative of the binding affinity of metal ions to A 
have been measured though calorimetric and spectroscopic methods.20,43,45,46 For 
Cu(II), the reported Kd values range from attomolar to nanomolar. The affinity of A for 
Zn(II) is on the order of micromolar concentrations. The length of A does not 
significantly impact these binding affinities in A40 versus A42, and similar binding 
affinities are observed for the monomer and preformed A aggregates; however, the 
experimental conditions used to attain these data can dramatically influence the 
outcomes.46 Nevertheless, it is valuable to be aware of the approximate range of the 
dissociation constants for metal ions with A. Such information may be helpful for 
selecting chemical tools that are directed toward the metal ions associated with various 
A species. In general if the small molecules have similar affinity for metal ions as A 
(approximately within the same order of magnitude), then there exists a possibility for 
competition between the ligand and peptide for metal binding (vide infra).46,59-61 
Another effect of metal binding to Ain AD includes the exacerbation of 
neurotoxicity and oxidative damage.18-27,43,45,46 Toxicity has been demonstrated to be 
higher for Cu–A species in vitro, particularly because the Fenton-type redox cycling 
between Cu(II) and Cu(I) could be sustainable under the reducing environments of the 
brain (Figure 1.3). ROS produced from this chemistry, such as hydrogen peroxide 
(H2O2) and hydroxyl radical, can cause oxidative damage to biological molecules, 
membranes (e.g., lipid peroxidation), and organelles (e.g., mitochondria).7 Usually, 
oxidative stress is avoided by a variety of endogenous antioxidant defense systems 
(e.g., catalases, Cu,Zn-superoxide dismutase (SOD)). MT-3 has also been suggested to 
offer some antioxidant protection by exchanging its bound Zn for the Cu associated with 




overwhelmed, however, extensive oxidative stress may prevail and cause neuronal 
death.7,62 
 
1.3.5. Small molecule-based approaches to understanding metal–A interaction 
and neurotoxicity 
Several studies have identified the deleterious effects caused by metal binding, 
the relationship between Cu/Zn–A interaction and AD remains to be clarified. The 
pursuit of small molecules as chemical tools to interrogate the metal–A interaction and 
associated events such as aggregation and neurotoxicity may provide a handle for 
further dissecting the etiology of this disease. Not only could effective compounds lead 
to new molecular-level insights but they may also be promising chemical candidates for 
developing potential AD therapeutics. Initially, metal chelation therapy was explored by 
employing general metal chelating compounds to remove or potentially block these 
metal ions from interacting with A to alleviate aggregate deposition and ROS 
production (Figure 1.4; e.g., clioquinol (CQ), EDTA).18-22,63-65 From this approach, the 
involvement of metal ions in AD has been acknowledged and new methods to design 
compounds for potentially elucidating how metal-associated A species (metal–A 
species) are connected to the neuropathology of AD have been explored.  
 Investigations with 8-hydroxyquinoline derivatives, CQ (Figure 1.4) and PBT2, in 
vitro and in vivo have suggested their ability to interrupt the associations between metal 
ions and A, to sequester redox active metal ions, and to transport metal ions across 
the membrane leading to their redistribution (i.e., ionophore activity).20-22,63 Due to 
limited utility and adverse effects of CQ,20,22,63 its analogue PBT2 has been of recent 
interest as it leads to better ionophore behavior, greater depletion of amyloid deposits, 
and improved performance on neuropsychological tests in AD patients.66 These 
observations have provided evidence that metal ion homeostasis is misregulated in AD 
and that mitigating this dyshomeostasis may be of therapeutic value. Although showing 
progress and lending credibility to metal chelation therapy in AD, these 8-
hydroxyquinoline compounds have disadvantages for probing the direct correlation 
between metal ions and A due to the lack of A interaction functionality, such as 




species.21,22,59,63,67 Therefore, rational structure-based design approaches have been 
attempted for the construction of more versatile metal chelators containing additional 
modes of action for specifically targeting and elucidating the role of metal ions 
associated with A.  
Expanding upon the concept of metal chelation, multifunctional compounds that 
incorporate various functionalities for direct A interaction, ROS mediation, or improved 
BBB permeability in tandem with capturing metals ions have evolved. Combining more 
than one function into a single molecule may assist in localizing compounds near metal-
A species in the brain (Figure 1.4).20,59,67,68 For one of these classes, the strategy has 
been to promote metal complexation by increasing the number of donor atoms to 
generate multidentate ligand frameworks.69 Along with sequestration of the redox active 
metal ions (e.g., Cu(I/II)) from A species, multidentate ligands could orient the metal 
center to disfavor geometric reorganization with changing oxidation states.69 Another 
approach is to prepare prochelators with concealed metal binding sites that, in principle, 
prevent systemic metal coordination by activating only upon reaching a biological target 
or stimulus (e.g., enzymes, ROS).20,68,70-72 In one prochelator framework, a boronic acid 
masks the hydroxyl group of 8-hydroxyquinoline (QBP; Figure 1.4) until activation by 
H2O2 resulting in the cleavage of the boron protecting group. In the presence of redox 
active Cu–A and O2, the production of H2O2 will stimulate the delivery of 8-
hydroxyquinoline, which can chelate metal ions, mitigate ROS production, and reduce 
metal-induced A aggregation in vitro.70 Orvig and co-workers have developed a family 
of glycosylated 3-hydroxy-4-pyridinones capable of metal binding and antioxidant 
activity upon cleavage of the sugar group (Figure 1.4).71 Inclusion of the sugar moiety 
would exploit GLUT-1 transporters at the BBB allowing for more facile penetration into 
the brain whereby it could be readily hydrolyzed by -glucosidase enzymes to reveal the 
active chelators. These compounds have demonstrated comparable antioxidant activity 
to -tocopherol (vitamin E) and were able to solubilize metal-induced A aggregates. 
Taking this approach one step further, pyridinone glycoside derivatives that also include 
A interaction moieties have been recently reported (Figure 1.4).72 Combining 




successfully within one molecule is attractive for not only understanding the relationship 
of metal–A species and neurotoxicity in AD but also for a future therapeutic direction. 
 
 
Figure 1.4. Multifunctional small molecules that can be used to investigate Cu(II)/Zn(II)-
associated A species in AD by combining properties of A interaction (orange), metal 
chelation (blue), and/or ROS regulation (green). Other structural moieties can be 
implemented in the design to introduce different reactivity (e.g., ROS-activated metal 
chelation ability (prochelators), enhanced BBB permeability). Multifunctional molecules 
are shown in the purple box. Flavonoids such as EGCG have demonstrated 
antioxidative properties. Abbreviations for compounds: ThT = thioflavin-T, 2-[4-
(dimethylamino)phenyl]-3,6-dimethylbenzothiazolium; IMPY = 6-iodo-2-(4'-
dimethylamino)phenylimidazo[1,2-a]pyridine; p-I-stilbene = N,N-dimethyl-4-[(1E)-2-(4-
iodophenyl)ethenyl]benzenamine; CQ = 5-chloro-7-iodo-8-hydroxyquinoline; EDTA = 
N,N'-1,2-ethanediylbis[N-(carboxymethyl)]glycine; EGCG = epigallocatechin-3-gallate, 
XH1 = N,N-bis[2-[[2-[[4-(2-benzothiazolyl)phenyl]amino]-2-oxoethyl](carboxymethyl) 
amino]ethyl]glycine; HBT = 2-(2-hydroxyphenyl)benzothiazole; L2-b = N1,N1-dimethyl-
N4-(pyridin-2-ylmethyl)benzene-1,4-diamine; K1 = 6-(imidazo-[1,2-a]pyridin-2-yl)-N,N-
dimethylpyridin-3-amine; QBP = quinoline boronic acid, pinanediol ester; the prochelator 





The third synthetic approach to this problem has been to design compounds that 
could specifically target metal ions associated with A species is the installation of metal 
chelation properties into molecules previously determined to interact with A. This 
strategy has branched into two similar approaches through synthetic manipulation: 
linkage and incorporation.20,59,67,68 In the former case, either a small molecule A 
imaging agent or a complementary peptide recognition sequence (e.g., KLVFF) is 
tethered to a metal chelating framework (e.g., ThT-based compound XH1, Figure 
1.4).73,74 In the latter approach, a metal chelation site is directly placed into the known 
A recognition framework. Molecules from the second strategy include modified neutral 
ThT derivatives (e.g., HBT; Figure 1.4) and two generations of compounds based on the 
stilbene and IMPY frameworks that present different degrees of biocompatibility and 
reactivity toward metal–A species (e.g., L2-b, K1; Figure 1.4).20,59-61,67,68,75,76 Limited in 
vivo studies have been conducted with the designed compounds so far (i.e., XH1 
reduced amyloid burden in a double-transgenic mouse model), and one study showed 
the ability of L2-b to disassemble biologically derived high molecular weight A species 
from human AD brain tissue homogenates.61,67,73 Following these studies, further 
designs have emerged, including incorporation of heteroatoms into the 
diphenylpropynone imaging agent framework and linkage of a ThT derivative/o-vanillin 
hybrid to an N-(2-pyridylmethyl)amine for metal chelation.77,78 Ongoing investigations 
with these and other molecules will surely provide clarity on the relationship between 
metal ions, A, and AD in the future. 
 
1.4. Conclusion 
The unique properties of amyloid proteins pose a challenge for traditional drug 
design; however, the significance of AD and other amyloidogenic diseases, and their 
shared pathological hallmarks, drives development of novel therapeutic strategies. 
Efforts to clarify the current understanding of these diseases and the factors impacting 
them are progressing at an encouraging pace. Innovative ideas to apply small molecule-
based approaches to define the roles of metal ions in AD could be used as a stepping-
stone into similar approaches for other aspects of protein misfolding conditions. 




accelerate drug and diagnostic discovery for AD. To successfully accomplish this in the 
future, however, a full understanding of the pathophysiological relationship between the 
formation of misfolded proteins, their interactions with other biological components, and 
the onset and progression of the diseases is compulsory. 
 
1.5. Scope of this thesis 
In addition to the synthetic design approach described above, selective rational 
screening of known molecules was pursued as part of this dissertation to identify 
beneficial frameworks that target and modulate metal-associated A species. Reports 
connecting diet to incidence of AD hinted that certain molecules could play a role in 
maintaining brain health.79,80 For example, the occurrence of AD is as much as four 
times lower in India compared to the United States.81 Many have cited this trend to the 
high consumption of curcumin, which is found in the turmeric of curry-based dishes of 
the Indian diet.81,82 Curcumin has been known to inhibit amyloid aggregation and 
attenuate neurotoxicity, which could account for this dramatic trend.82,83  
Additionally, naturally occurring flavonoids have been shown to mitigate A 
aggregation and offer neuroprotection.84,85 Although these molecules have been well-
studied and have attractive structural moieties for this purpose, their application to 
metal-associated A in AD had not been investigated previously. Thus, the studies 
presented in this thesis illustrate the first example where flavonoids have been used to 
target and modulate metal-induced A aggregation and neurotoxicity in vitro. Chapter 2 
details the studies using myricetin and luteolin for this purpose. Following this, Chapter 
3 describes use of (−)-epigallocatechin-3-gallate (EGCG) as a mechanistic probe to 
understand small molecule interactions with metal–A species and how they influence 
reactivity. Ultimately, the successful application of these initial studies to a design 
strategy was achieved with the aminoisoflavone derivatives in Chapter 4. Chapter 5 and 
Appendix A describe experiments to quantify metals in AD and glaucoma, respectively, 
using -X-ray fluorescence (-XRF), which could be used to further elucidate the role of 
metals in these neurodegenerative diseases. 
Therefore, the multifunctionality of designed and naturally occurring compounds 




induced A aggregation, to reverse the degree of amyloid aggregation, and to prevent 
toxicity from metal-A species. Toward applications to understand the role of metal ions 
associated with A in AD, these strategies motivated by metal chelation are in 
promising initial stages. The attempts thus far to rationally design multifunctional 
molecules have provided a foundation on which the details of metal–A interaction may 
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Chapter 2: Myricetin and Luteolin: Naturally Occurring Regulators of Metal-











The results presented in this chapter for myricetin were previously published (DeToma, 
A. S.;ǂ Choi, J.-S.;ǂ Braymer, J. J.; Lim, M. H. ChemBioChem 2011, 12, 1198-1201. ǂ 
Equal contribution.). In vitro aggregation studies were obtained in collaboration with Dr. 
Jung-Suk Choi. Dr. Choi also conducted the cell experiments. Joseph J. Braymer 





One of the most severe and incurable forms of neurodegeneration, Alzheimer’s 
disease (AD), is identified by the accumulation of aggregated amyloid- (A) peptides in 
the brain.1-7 It has been proposed that disruption of metal ions in the brain, such as 
Cu(II) and Zn(II), along with the misfolded A peptides, could influence the disease 
progression as well.1-12 Namely, it has been found that Cu(II) and Zn(II) can bind to A, 
which can enhance peptide aggregation and in the case of redox active metal ions (e.g., 
Cu(I/II))), facilitate the generation of reactive oxygen species (ROS) leading to oxidative 
stress.1-12 While peptide aggregation and oxidative stress have been implicated in AD, 
the connection between metal ions and A species in the development of this disease 
remains unclear. 
To clarify the function of metal ions in A-related pathological events, small 
molecule-based tools that have structural characteristics to simultaneously interact with 
both metal ions and A have been sought.3,5,6,12-23 Several small molecules have been 
designed to target metal-associated A (metalA) species and to interrogate metal-
induced A aggregation and toxicity according to a rational structure-based design 
strategy.3,5,6,12-15 Many of these structures have been derived from known A plaque 
imaging agents;16-20 however, due to the multiple factors that may be involved in AD 
neuropathogenesis, discovery of novel structural frameworks is an ongoing effort and 
will be a valuable component toward advancement of this design strategy. In order to 
identify new classes of basic scaffolds and to formulate a structure-interaction-reactivity 
relationship, structural modifications developed via a rational structure-based design 
approach or through systematic screening and/or selection of naturally occurring 
compounds can be envisioned. 
Flavonoids are a class of polyphenolic compounds that are abundant in natural 
products, such as berries, fruits, and vegetables, and they have been investigated as 
potential therapeutic agents in human diseases such as cancer, cardiovascular 
diseases, and neurodegenerative diseases.24-32 Over 60 clinical trials focusing on 
flavonoids have been initiated; however, none has succeeded in bringing forth approval 

























Figure 2.1. Chemical structures of myricetin (Myr, left) and luteolin (Lut, right). The rings 
are labeled A, B, and C to identify the rings in the core flavonoid framework. Numbered 
positions indicate sites with OH groups (blue) for potential metal binding.  
 
a few different flavonoid structures to target numerous conditions, presumably due to 
multitude of possible modes of action for these compounds in vivo.30 
A number of flavonoid molecules representing the various structural classes have 
been independently shown to chelate metal ions and interact with A.28,32,34-37 Chelation 
properties for various flavonoids have been characterized, providing some useful 
insights into its binding properties (e.g., stoichiometry of complex formation, donor 
atoms, stability constants) (vide infra). The previous studies have demonstrated that 
flavonoids can have multiple potential sites for metal chelation, including positions 
between the 4-oxo and the 3- or 5-OH groups in the A and C ring or in catechol or 
pyrogallol groups in the B ring (Figure 2.1). In addition, flavone-based imaging agents 
developed for in vivo detection of A plaques were found to have 5-321 nM binding 
affinity, supporting that the flavonoid framework could interact with aggregated A 
species.38 The influence of flavonoids on A aggregation has also been investigated, 
and some of these structures can block A assembly.25,28,31,32 Akaishi et al. defined a 
structure-interaction relationship among several flavonoid structures and A in an effort 
to account for the inhibitory activity of a specific example, fisetin; they reported that the 
presence of OH groups in the 3’ and 4’ position on the B ring were more capable of 
inhibiting A aggregation due to OH groups in the 3 or 7 position of the A ring did not 
significantly impact the reactivity.32 Taken together, one of the well-studied flavonols, 
myricetin, was found to produce metal complexes with binding stoichiometries of 1:1 or 
1:234,35 and its anti-amyloidogenic activity toward metal-free A species has been 




Despite the known interactions of myricetin and other members of the flavonoid 
family with metal ions and/or A, their effect on metal-induced A aggregation pathways 
and toxicity was not previously reported. To investigate whether naturally occurring 
flavonoids could exhibit bifunctionality (i.e., metal chelation and A interaction) to target 
metal–A species and modulate their aggregation and toxicity, myricetin and luteolin 
were initially selected.22 These investigations were also pursued in order to identify 
chemical structures with utility for development of novel molecules to target metal ions, 
A species, and other factors that might be involved in AD neuropathogenesis. Herein, 
we present that myricetin and luteolin were capable of modulating Cu(II)- and Zn(II)-
induced A aggregation in vitro and toxicity in human neuroblastoma cells. To the best 
of our knowledge, these were the first studies to establish the reactivity of naturally 
occurring flavonoids toward metalA-related events and could lead to further 
investigations of a wide range of flavonoids as useful chemical reagents or templates for 
applications in AD research.22 
 
2.2. Results and discussion 
 
2.2.1. Metal binding properties of myricetin and luteolin 
In order to describe the potential bifunctionality of these molecules (i.e., metal 
chelation, A interaction), the metal binding properties of myricetin and luteolin were 
confirmed by UV-Visible (UV-Vis) spectroscopy (Figure 2.2). In agreement with the 
previous UV-Vis studies,34 a bathochromic shift of the optical band (ca. 377 to 450 nm) 
was observed upon addition of CuCl2 (1 equiv) to myricetin (40 M) in 20 mM HEPES, 
pH 7.4, 150 mM NaCl (Figure 2.2). Under the same conditions, an optical change was 
also observed for luteolin (40 M) with CuCl2 (1 equiv). The addition of 5 equiv of ZnCl2 
to a solution of either myricetin or luteolin in similar conditions was required to produce 
a noticeable shift in the spectrum. Overall, these studies suggest that both molecules 











































































Figure 2.2. Cu(II) and Zn(II) binding studies with myricetin (Myr, left) and luteolin (Lut, 
right) by UV-Vis spectroscopy. A 40 M solution of Myr or Lut was prepared in a 
buffered solution containing 20 mM HEPES, pH 7.4, 150 mM NaCl and treated with (a) 
1 equiv of CuCl2 or (b) 5 equiv of ZnCl2 for 5 min. 
 
Although the observed spectral changes provided evidence that Cu(II) and Zn(II) 
are able to bind to these structures, the exact donor atoms involved in metal binding 
cannot be clearly identified by this method. Recently, Cheng and coworkers have 
systematically investigated stability constants for Fe(III) complexes with three flavonoids 
(Figure 2.3), each possessing only one of the commonly proposed chelation sites (i.e., 
3-OH/4-keto, 5-OH/4-keto, 3’,4’-dihydroxy (catechol)).39 Their goal was to differentiate 
the influence of various binding moieties in other flavonoids by treating the individual 
components separately. Their results indicated that the catechol moiety on the B ring of 
the flavonoid to be most influential for binding Fe(III) at physiological pH.39  
The catechol structure has reported stability constants of 7.95 and 13.5 with 
Fe(II), 13.9 and 24.9 with Cu(II), and 9.9 and 17.4 with Zn(II) for 1:1 and 1:2 complexes, 
respectively.40 Myricetin and luteolin contain a combination of the chelation sites 




moieties; thus, it could be suggested that elements of the catechol moiety may also be 
involved in Cu(II) and Zn(II) chelation for these molecules. Myricetin, however, has an 
additional OH group in the 5’ position and in the 3 position that may complicate the 
mixture of metalmyricetin complexes in solution. Thus, delineating the exact 
coordination environment and stoichiometry of metal-bound complexes could be 
complicated due to the multiple binding sites.  
 
 
Figure 2.3. Structures used to investigate metal chelation sites of flavonoids in the 
study by Cheng and co-workers.39  
 
Several spectrophotometric procedures have been described in the literature to 
measure the stoichiometry of metalligand complexes and were developed according to 
the work of Job, Bent and French, and Nach.41 Job’s method, which is more widely 
applied, employs various ratios of equimolar ligand and metal solutions to find a ratio of 
maximum absorbance.41,42 For several of the flavonoids (e.g., rutin, quercetin, morin, 3-
hydroxyflavone), these methods indicated 1:1 or 1:2 stoichiometry (metal/ligand) with 
the divalent cations of Cu, Zn, Co, Ni, and others.41 Applying Job’s method of 
continuous variation, the binding stoichiometry between Cu(II) and myricetin or luteolin 
was investigated (Figure 2.4).16,42 Equimolar solutions of the ligand and CuCl2 (40 M 
for myricetin, 50 M for luteolin) were mixed in various molar ratios from 01 in 20 mM 
HEPES buffer (pH 7.4, 150 mM NaCl). The change in absorbance of the metalligand 
absorption band was monitored and plotted against the molar ratio of Cu(II) in solution. 
For both molecules, the maximum absorption occurred near a molar ratio of 0.5, 
indicating a binding stoichiometry of 1:1 Cu(II)/ligand.  
While these results indicate the metal binding properties of myricetin and luteolin 
in an A-free solution, the ability of these compounds to compete for metal binding with  
A would support their utility in further investigations using metal-induced A 
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Figure 2.4. Job plots of Cu(II) with myricetin (Myr, left, 40 M initial) and luteolin (Lut, 
right, 50 M initial) in 20 mM HEPES, pH 7.4, 150 mM NaCl.42  
 
determine if myricetin could interact with Cu(II) or Zn(II) that may already be associated 
with A (Figure 2.5). After myricetin (25 M) was added to the preincubated solution of 
A (25 M) and CuCl2 or ZnCl2 (25 M), new absorption bands that resembled the 
metal–myricetin complexes in an A-free solution appeared after 5 min. These results 
suggest that the possible interaction of myricetin with metal ions surrounded by A 
could lend this molecule to be classified as bifunctional molecules, which may be used 
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Figure 2.5. UV-Vis studies showing the interaction of myricetin (Myr) with metal ions in 
the presence of A. (a) The spectra of Myr in the absence (blue) and presence (red) of 
CuCl2 or ZnCl2 following 5 min incubation. (b) The spectra of the samples containing A, 
metal ions, and/or myricetin. To A (black), CuCl2 or ZnCl2 was added immediately and 
incubated for 2 min (green). The solution containing A and CuCl2 or ZnCl2 was treated 
with Myr for 5 min (red). The spectrum of metal-free A and Myr is shown in blue. 
Experimental conditions: [A] = 25 M, [CuCl2 or ZnCl2] = 25 M, [Myr] = 25 M, 20 mM 
HEPES, pH 7.4, 150 mM NaCl, room temperature. 
 
2.2.2. Modulation of metal-associated A aggregation by myricetin and luteolin 
The reactivity of myricetin toward metalA species was probed using in vitro A 
aggregation studies conducted in the presence and absence of metal ions (Figures 2.6, 
2.7, and 2.8) according to reported procedures.16-23,43 To understand the degree to 
which myricetin and luteolin were able to prevent the formation of metal-associated A 
aggregates (inhibition experiment, Figure 2.6 and 2.7), fresh A (25 M) was treated 
with CuCl2 or ZnCl2 (25 M) for 2 min followed by 24 h incubation with myricetin or 
luteolin (50 M). The alteration of metal-associated A aggregate formation was 
visualized using gel electrophoresis with Western blotting (6E10 anti-A antibody) and 
by transmission electron microscopy (TEM). First, the Western blots from the inhibition 
experiment showed that for A incubated with CuCl2 or ZnCl2, the inclusion of myricetin 
or luteolin in the sample solution increased the amount of soluble peptides that were 
small enough to to enter the gel compared with the untreated metalA control samples 
(Figures 2.6 and 2.7). In particular, those A species having molecular weight (MW) ≤ 
32 kDa were more prominent. It has been reported that upon A fibrillogenesis, mature 
A fibrils, such as those observed by TEM, cannot enter the gel, causing them to either 
be retained at the gel entrance or to be insufficiently delivered to the gel.44,45 Since 
these compounds may interfere with A fibrillogenesis, the amount of A species that 
are therefore small enough to permeate the gel matrix is increased and more of these 
species are able to be separated in the gel. Second, TEM images were collected for 
samples containing A, metal ions, and myricetin and those without myricetin (Figure 
2.7). The A aggregates formed in the presence of Cu(II) or Zn(II) were large and 
contained fibrillar morphological features. When those solutions also contained 




blot results (Figure 2.6). These aggregates were also morphologically different from the 
control samples as they appeared to be amorphous instead of fibrillar. Therefore, these 
results and observations might suggest that myricetin and luteolin are capable of 
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Figure 2.6. Inhibitory effect of luteolin (Lut) and myricetin (Myr) on the formation of 
metal-induced A aggregates. Top: Scheme of the inhibition experiment. Bottom: A 
species visualized by gel electrophoresis using Western blot with an anti-A antibody 
6E10. Experimental conditions: [A] = 25 M, [CuCl2 or ZnCl2] = 25 M, [Lut or Myr] = 
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As a comparison, the effect of both flavonoids on metal-free A aggregation in 
the inhibition experiment was investigated (Figures 2.6 and 2.7). By Western blot, the 
difference in the distribution of A species for myricetin- or luteolin-treated A species 
was not as noticeable among lower MW A species. In the absence of metal ions at the 
same condition, long fibrillar A aggregates were observed by TEM. With myricetin, the 
morphology closely resembled the untreated control sample of only A. Upon 
comparison of the metal-free A species in the presence of myricetin with the Cu(II)- 
and Zn(II)-treated A samples (Figure 2.6 and 2.7), myricetin had a stronger ability to 
modulate metal-induced A aggregation compared to metal-free A aggregation. 
In addition to the inhibition experiments, the ability of myricetin and luteolin (50 
M) to disaggregate metal-free and metal-associated A aggregates generated after 24 
h incubation of fresh A (25 M) without or with metal chloride salts (25 M) was also 
evaluated (disaggregation experiment, Figure 2.8).16-23,43 Similar to the inhibition 
experiment, neither myricetin nor luteolin had a noticeable influence on the metal-free 
A aggregate size distribution according to the Western blot. Unlike the inhibition 
experiment, however, where both compounds could modulate metal-mediated A 
aggregation, myricetin and luteolin demonstrated different reactivity toward the 
preformed metalA aggregates. Following 4 h treatment, luteolin had only a moderate 
impact on metal-associated A aggregates. A slightly larger amount of gel permeable 
Cu(II)A species were observed in the presence of luteolin compared to the control, 
but almost no difference was detected between the Zn(II)A control and the sample 
containing luteolin. Myricetin was able to disrupt the A aggregates preformed in the 
presence both Cu(II) and Zn(II) to produce a variety of smaller A species capable of 
entering the gel matrix relative to those from control samples containing no ligand 
(Figure 2.8). The effect of myricetin on these aggregates appeared to be dependent on 
whether the A samples were treated with Cu(II) or Zn(II). For the Cu(II)-treated 
samples, a wider distribution of low MW A species are observed as visualized by the 
smearing throughout the lane. The Zn(II)-treated A samples presented a less 
dispersed distribution of sizes, however. Instead, more of the gel permeable Zn(II)A 




TEM, where a mixture of species was observed. In contrast to the conformation of 
metalA species that were seen by TEM for the control samples (Cu(II)- or Zn(II)-
treated A), there were amorphous aggregates along with fragmented fibrillar A 
species in the samples containing myricetin. Therefore, it is plausible to attribute the 
increased amounts of A species that are small enough to enter the gel and have 
altered morphology to the myricetin-induced disassembly of metalA aggregates. 
Overall, these results suggest that flavonoids may be effective to preferentially 
target and modulate a variety A species generated in metal-triggered over metal-free 
A aggregation pathways. Comparison of the reactivity for myricetin and luteolin 
suggests that certain structural differences, such as the additional OH groups of 
myricetin, may improve the versatility of one ligand framework over another for this 
purpose. Both molecules, however, could control metal-mediated A aggregation to a 
greater extent than metal-free A aggregation from early stages of aggregation. The  
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Figure 2.8. Transformation of metal-induced A aggregates by luteolin (Lut) or myricetin 
(Myr). Top: Scheme of the disaggregation experiment. Bottom: (a) A species 
visualized by gel electrophoresis using Western blot with an anti-A antibody 6E10. (b) 
TEM images of the samples from (a) with myricetin. Experimental conditions: [A] = 25 






flexibility of monomeric and other low MW species might facilitate both compounds’ 
accessibility for metal binding. According to the disaggregation results, the more 
structured metalA aggregates appeared to be more sensitive to myricetin, which 
could be related to the minor structural differences of myricetin and luteolin. Thus, 
naturally occurring flavonoids offer an accessible library of known molecules with 
potential to target and modulate metal-associated A aggregation to varying extents. 
 
2.2.3. Regulation of H2O2 production from Cu(II)-associated A species in vitro 
There has been great interest in the anti- and pro-oxidant capabilities of flavonoid 
compounds since oxidative damage is a hallmark of many diseases including AD.46-48 In 
AD, the production of ROS by redox active metals (e.g., Cu(I/II), Fe(II/III)) bound to A 
peptides may occur via processes such as Fenton chemistry.49,50 Along with the 
breakdown of endogenous antioxidant systems, ROS production has been suggested to 
cause oxidative stress leading to the pervasive neuronal damage in AD.51-53 There have 
been some efforts to use antioxidants to potentially combat this aspect of AD, but they 
have been met with limited success.54 
To investigate this aspect of reactivity, a horseradish peroxidase/Amplex Red 
assay was conducted to measure the ability of myricetin and/or luteolin to mitigate the 
production of H2O2 in vitro (Figure 2.9).16,17,19,21,55,56 To mimic the conditions that may 
facilitate H2O2 production in the brain, A40 was incubated with CuCl2 before introducing 
the compounds, along with ascorbate as a reducing agent to sustain Fenton cycling. 
Oxidation of Amplex Red by H2O2 to fluorescent resorufin was used to quantify H2O2 
production in the system. As expected, CuA species produced H2O2, indicated by the 
fluorescence increase. The fluorescence values for the samples treated with 
compounds were normalized to that of the CuA control. When CuA species were 
treated with either myricetin or luteolin, there was a reduced amount of H2O2 produced 
(ca. 30% less for myricetin and 70% less for luteolin).21 As a positive control, the known 
chelator EDTA (EDTA = ethylenediaminetetraacetic acid; 2-((2-
[bis(carboxymethyl)amino]ethyl)(carboxymethyl)amino)acetic acid) resulted in ca. 15% 




Although the antioxidant properties of myricetin and luteolin have been 
reported,57 another plausible mechanism for this activity could be connected to their 
ability to chelate free transition metal ions (e.g., Fe(II/III)) that are redox active and 
participate in Fenton chemistry.47,48 In one sense, sequestration of the metal ion may 
prevent its redox cycling and, subsequently, production of ROS; alternatively, the 
polyphenolic ligands could be responsible for reducing the metal ion to produce a 
species that could perpetuate the Fenton cycle (pro-oxidant).48 Some mass 
spectrometric (MS) studies have also directly detected the oxidation of flavonoid ligands  
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Figure 2.9. Modulation of Cu(II)A-induced H2O2 production by myricetin (Myr) and 
luteolin (Lut). The amount of H2O2 was measured by the horseradish peroxidase 
(HRP)/Amplex Red assay. Experimental conditions: [A] = 200 nM, [CuCl2] = 400 nM, 
[compound] = 800 nM, [ascorbate] = 10 M, [Amplex Red] = 50 M, [HRP] = 1 U/mL, 
phosphate buffered saline (PBS), pH 7.4; ex/em = 530/590. Catalase attenuates the 
fluorescence signal.  
 
in the presence of metal ions by loss of hydrogen atoms (e.g., in the 2 and 3 position of 
the saturated molecule naringenin)58 and connected this to other studies indicated the 
necessity of hydrogen-donating properties for antioxidant behavior.58 Some recent 
observations have supported the conclusion that the antioxidant activity is derived 
primarily from the 3-OH/4-keto site unless a catechol or gallol moiety is present.46 It has 
also been proposed that structures having fewer OH groups might favor oxidation of the 
flavonoid over deprotonation as a mechanism for counteracting the reduction of the 
metal ion. These possibilities validate the consideration of stability constant and 
reduction potential measurements for fully understanding the reactivity of flavonoids in 




could partially attenuate CuA mediated H2O2 production, but their inability to 
completely quench ROS production, perhaps due to their potential pro-oxidant 
properties, may limit their use for this aspect. 
 
2.2.4. Regulation of toxicity from metal-associated A species in human 
neuroblastoma cells by myricetin and luteolin 
Whether these molecules might also display beneficial properties in biological 
systems, the toxicity of myricetin and luteolin to living cells in the absence and presence 
of metal ions and/or A was investigated. The cytotoxicity of the metal ions, myricetin, 
and the corresponding metalmyricetin complexes were measured by the MTT (MTT = 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay following incubation 
of human neuroblastoma SK-N-BE(2)-M17 cells (M17) for 24 h. The cells, which were 
maintained in media containing 10% fetal bovine serum (FBS), presented suitable cell 
survival with metal ion alone (10 M), flavonoid alone (20 M), or flavonoid and CuCl2 or 
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Figure 2.10. Modulation of metal-free and metal-induced A toxicity in human 
neuroblastoma SK-N-BE(2)-M17 cells. Cells were treated with A (10 M), CuCl2 or 
ZnCl2, and/or myricetin (Myr) or luteolin (Lut) (20 M, 1% v/v DMSO) for 24 h. Cell 
viability was measured by the MTT assay and was calculated relative to cells containing 





The neuroprotective properties of myricetin against toxicity generated in the M17 
cells by externally introduced metal ions and A was pursued. With only A (10 M), no 
toxicity was detected, while the treatment of cells with A (10 M) and CuCl2 or ZnCl2 
(10 M) for 24 h resulted in 81(3.2)% and 89(1.4)% cell survival, respectively (Figure 
2.10). The moderate toxicity of A incubated with metal chloride salts in this setting 
occurred even in the presence of bovine serum albumin (BSA), a well-known metal 
chelator that is a major component of FBS, demonstrating that A can compete for 
metal ions under these relevant conditions, which may be a factor in neurotoxicity.59,60 
In the cells containing A (20 M), CuCl2 or ZnCl2 (10 M), and myricetin or luteolin (20 
M) with 24 h incubation, cell survival was improved. Luteolin was able to block toxicity 
of Cu(II)-treated A, but had a lesser impact on Zn(II)A-induced toxicity, consistent 
with the observation that luteolin could influence disaggregation of Cu(II)A but not 
Zn(II)A. In the case of myricetin, cell viability for the Cu(II)- and Zn(II)-treated A was 
recovered to over 100%. Potentially contributing to the improved cell viability was the 
interaction of myricetin with the metalA species to generate metalmyricetin 
complexes. It has been previously reported that transition metal complexes of 
flavonoids (e.g., epigallocatechin-3-gallate, rutin) were beneficial to cell survival 
potentially through stabilization of the flavonoid structure and/or generation of additional 
sites for dismutation of the ROS, superoxide (O2
•−).61,62 Thus, despite having some pro-
oxidant properties, it could be possible for myricetin or luteolin to mitigate neurotoxicity 
in living systems by other mechanisms. Details of this neuroprotective function are 
deserving of further attention. Overall, enhanced cell survival in these samples can be 
attributed to interaction of myricetin with metal ions associated with A, thereby implying 




In summary, myricetin and luteolin are naturally occurring flavonoids that can 
chelate metal ions and have anti-amyloidogenic activity toward A; however, the 




neurotoxicity had not been studied prior to this work. The investigations herein 
demonstrated that both molecules may be able to modulate metal-induced A 
aggregation more effectively than metal-free A aggregation. Both compounds were 
able to inhibit metal-induced A aggregation, but myricetin displayed greater control on 
preformed A aggregates containing Cu(II) or Zn(II) than luteolin. Furthermore, both 
compounds could attenuate the cytotoxicity of A treated with metal ions, but myricetin 
could accomplish this more effectively than luteolin. Interestingly, the ability to quench 
ROS production may not be an accurate indicator of the ability of a molecule to 
modulate metal-induced A toxicity in living cells, as luteolin more effectively quenched 
H2O2 production than myricetin. Overall, our studies demonstrate the high potential of 
the flavonoid family as a class of chemical tools and/or therapeutic agents for AD. 
Moreover, this work may also provide insight into current efforts for developing a new 
class of small molecules with bifunctionality that can target metal-associated A species 
and regulate metal-induced A events in the AD brain.3,5,6,12,14-22,43 
 
2.4. Experimental  
 
2.4.1. Materials and methods 
All reagents were purchased from commercial suppliers and used as received 
unless stated otherwise. A40 was purchased from AnaSpec (Fremont, CA, USA). The 
amino acid sequence for the A40 peptide is DAEFRHDSGYEVHHQKLVFF-
AEDVGSNKGAIIGLMVGGVV. Myricetin was purchased from AvaChem Scientific (San 
Antonio, TX, USA) and luteolin was purchased from Alfa Aesar (Ward Hill, MA, USA); 
both compounds were used without further purification. Optical spectra were collected 
on an Agilent 8453 UV-Vis spectrophotometer. TEM images were taken at the 
Microscopy and Image Analysis Laboratory at the University of Michigan using a Philips 
CM-100 transmission electron microscope (Andover, MA, USA). A SpectraMax M5 
microplate reader (Molecular Devices, Sunnyvale, CA, USA) was used for 
measurements of fluorescence for the horseradish peroxidase/Amplex Red assay and 




2.4.2. Metal binding studies 
To understand metal binding properties, optical spectra were obtained for the 
solutions of either myricetin or luteolin (40 M in 20 mM HEPES (2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid), pH 7.4, 150 mM NaCl) as well as 
myricetin or luteolin incubated with CuCl2 (40 M) or ZnCl2 (200 M) for 5 min. To verify 
if metal chelation occurs by myricetin in the presence of A, optical studies were carried 
out on the samples of A (25 M) and CuCl2 or ZnCl2 (25 M, 2 min incubation, room 
temperature) in the absence and presence of myricetin (25 M, incubation for 5 min, 
room temperature). 
Job’s method of continuous variation was employed to measure the 
stoichiometry for CuCl2 with myricetin and luteolin in solution.16,42 The molar fraction of 
CuCl2 in the solution was varied from 0–1 with the initial myricetin concentration of 40 
M and initial luteolin concentration of 50 M. The samples were prepared in a buffered 
solution of 20 mM HEPES, pH 7.4, 150 mM NaCl. The UV-Vis spectra of each sample 
were recorded and the change in absorbance at max corresponding to the metalligand 
absorption band (450 nm for both compounds) was plotted against the molar fraction of 
Cu(II) in solution. 
 
2.4.3. Amyloid- (A) peptide experiments 
A samples were prepared according to the previously reported procedures.16-
23,43 The A peptide was dissolved in NH4OH (1% v/v aq), aliquoted, lyophilized, and 
stored at −80 °C. Stock solutions of A were prepared prior to the experiments by 
redissolving the lyophilized A with NH4OH (1% v/v aq, 10 L) and diluting with ddH2O. 
All solutions for inhibition and disaggregation studies were prepared in a buffered 
solution (20 M HEPES, pH 7.4, 150 M NaCl). For the inhibition studies, fresh A (25 
M) was incubated with either CuCl2 or ZnCl2 (25 M) for 2 min at room temperature 
followed by addition of myricetin or luteolin (50 M, 1% v/v DMSO). The solutions were 
incubated for 24 h at 37 °C with constant agitation. For the disaggregation studies, A 
aggregates were prepared by treating fresh A (25 M) with CuCl2 or ZnCl2 (25 M) for 




and the resulting solutions were incubated for 4 h at 37 °C with agitation. Metal-free A 
samples for the inhibition and disaggregation experiments were prepared at the same 
condition in the absence of metal chloride salts. The degree of A aggregation and the 
morphology of A species samples from the inhibition and disaggregation studies were 
analyzed using gel electrophoresis using Western blotting with an anti-A antibody 
6E10 and by TEM, respectively.16-23,43  
 
2.4.4. Gel electrophoresis and Western blotting  
The reactions described in Section 2.4.3. were visualized by gel electrophoresis 
followed by Western blotting using an anti-A antibody (6E10).16-23,43 Each sample (25 
M A, 10 L) was separated on a 10-20% gradient Tris-tricine gel (Invitrogen, Grand 
Island, NY, USA). The gel was transferred onto a nitrocellulose membrane, blocked with 
bovine serum albumin (BSA, 3% w/v, Sigma, St. Louis, MO, USA) in Tris-buffered 
saline (TBS, Fisher, Pittsburgh, PA, USA) containing 0.1% Tween-20 (Sigma,TBS-T) for 
3 h at room temperature, and incubated with an anti-A antibody 6E10 (1:2,000, 
Covance, Princeton, NJ, USA) in 2% BSA (v/v, TBS-T) for 3 h at room temperature. The 
membrane was probed with the horseradish peroxidase-conjugated goat anti-mouse 
secondary antibody diluted (Cayman Chemical, Ann Arbor, MI, USA) in 2% BSA (v/v, 
TBS-T) for 1 h at room temperature. The Thermo Scientific Supersignal West Pico 
Chemiluminescent Substrate was used to visualize protein bands.  
 
2.4.5. Transmission electron microscopy (TEM) 
Samples for TEM were prepared by following the previously reported method.16-
20,22,43 Glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy 
Sciences, Hatfield, PA, USA) were treated with samples from the inhibition or 
disaggregation experiments (5 L) for 2 min at room temperature. Excess sample 
solution was removed using filter paper followed by washing three times with ddH2O. 
Each grid was incubated with uranyl acetate (1% v/v ddH2O, 5 L) for 1 min. Extra 
uranyl acetate was removed and the grids were dried for 15 min at room temperature. 
Images from each sample were taken by a Philips CM-100 transmission electron 




2.4.6. H2O2 production measured by the horseradish peroxidase/Amplex Red 
assay  
 The production of H2O2 by Cu(II)A species in the presence of dioxygen (O2) 
and a reducing agent (ascorbate) was monitored by the horseradish peroxidase 
(HRP)/Amplex Red assay.16,17,19,21,55,56 To a black polystyrene 96-well assay plate 
(Corning, Corning, NY, USA), A40 (200 nM) was diluted in phosphate buffered saline 
(PBS, pH 7.4, Invitrogen, Grand Island, NY, USA) and incubated with CuCl2 (400 nM) 
for 1 h with agitation at room temperature. Afterward, the CuA mixture was treated 
with each compound (800 nM, 1% v/v DMSO) for 1 h with agitation at room 
temperature. The solutions were treated with ascorbate (10 M) and after 5 min, with a 
solution containing HRP (1 U/mL, Invitrogen) and Amplex Red (100 M, Anaspec, 
Fremont, CA, USA) mixture. The plate was incubated for 15 min with agitation at room 
temperature before measuring the fluorescence emission intensity (ex/em = 530/590 
nm). Catalase (10 L of 100 U/mL) was added to verify H2O2 production in the samples. 
The total volume was 100 L in each well at the end of the experiment. 
 
2.4.7. Cell viability measurements by the MTT assay 
Human neuroblastoma SK-N-BE(2)-M17 (M17) cells were purchased from the 
American Type Culture Collection. The M17 cells were maintained in media containing 
[Minimum Essential Media (MEM, GIBCO)] (50%) and [Ham’s F12K Kaighn’s 
Modification Media (F12K, Cellgro)] (50%), supplemented with 10% (v/v) fetal bovine 
serum (FBS, Atlanta Biologicals, Atlanta, GA, USA), 100 U/mL penicillin and 100 g/mL 
streptomycin (Invitrogen). The cells were grown at 37 °C in a humidified atmosphere of 
5% CO2. Cell viability was measured using the MTT (MTT = 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, Sigma) assay.16,17,19,20,22 Cells were seeded in a 96 
well plate (16,000 cells in 100 L per well) and treated with A (10 M) and CuCl2 or 
ZnCl2 (10 M) immediately followed by myricetin or luteolin (20 M). After 24 h 
incubation of the cells at 37 °C, the cells were treated with 25 L MTT (5 mg/mL in PBS) 
for 4 h at 37 °C. The cells were lysed in an acidified solution containing N,N-




w/v, Sigma) overnight at room temperature in the dark. The absorbance (A600) was 
measured using a microplate reader and cell viability (%) was calculated relative to that 
of cells containing 1% DMSO (v/v).  
 
2.5. References 
1. Jakob-Roetne, R.; Jacobsen, H. Angew. Chem. Int. Ed. 2009, 48, 3030-3059. 
2. Rauk, A. Chem. Soc. Rev. 2009, 38, 2698-2715. 
3. Scott, L. E.; Orvig, C. Chem. Rev. 2009, 109, 4885-4910. 
4. Gaggelli, E.; Kozlowski, H.; Valensin, D.; Valensin, G. Chem. Rev. 2006, 106, 
1995-2044. 
5. DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H. Chem. Soc. Rev. 
2012, 41, 608-621. 
6. Pithadia, A. S.; Lim, M. H. Curr. Opin. Chem. Biol. 2012, 16, 67-73. 
7. Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem. Biol. 2013, 8, 856-865. 
8. Huang, X.; Moir, R. D.; Tanzi, R. E.; Bush, A. I.; Rogers, J. T. Ann. N. Y. Acad. 
Sci. 2004, 1012, 153-163. 
9. Zhu, X.; Su, B.; Wang, X.; Smith, M. A.; Perry, G. Cell. Mol. Life Sci. 2007, 64, 
2202-2210. 
10. Faller, P. ChemBioChem 2009, 10, 2837-2845. 
11. Faller, P.; Hureau, C. Dalton Trans. 2009,  1080-1094. 
12. Perez, L. R.; Franz, K. J. Dalton Trans. 2010, 39, 2177-2187. 
13. Rodríguez-Rodríguez, C.; Telpoukhovskaia, M.; Orvig, C. Coord. Chem. Rev. 
2012, 256 2308-2332. 
14. Braymer, J. J.; DeToma, A. S.; Choi, J.-S.; Ko, K. S.; Lim, M. H. Int. J. 
Alzheimers Dis. 2011, 2011, 623051. 
15. Hureau, C.; Sasaki, I.; Gras, E.; Faller, P. ChemBioChem 2010, 11, 950-953. 
16. Hindo, S. S.; Mancino, A. M.; Braymer, J. J.; Liu, Y.; Vivekanandan, S.; 
Ramamoorthy, A.; Lim, M. H. J. Am. Chem. Soc. 2009, 131, 16663-16665. 
17. Choi, J.-S.; Braymer, J. J.; Nanga, R. P. R.; Ramamoorthy, A.; Lim, M. H. Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107, 21990-21995. 
18. Choi, J.-S.; Braymer, J. J.; Park, S. K.; Mustafa, S.; Chae, J.; Lim, M. H. 
Metallomics 2011, 3, 284-291. 
19. Braymer, J. J.; Choi, J.-S.; DeToma, A. S.; Wang, C.; Nam, K.; Kampf, J. W.; 
Ramamoorthy, A.; Lim, M. H. Inorg. Chem. 2011, 50, 10724-10734. 
20. Pithadia, A. S.; Kochi, A.; Soper, M. T.; Beck, M. W.; Liu, Y.; Lee, S.; Detoma, A. 
S.; Ruotolo, B. T.; Lim, M. H. Inorg. Chem. 2012, 51, 12959-12967. 
21. He, X.; Park, H. M.; Hyung, S. J.; DeToma, A. S.; Kim, C.; Ruotolo, B. T.; Lim, M. 
H. Dalton Trans. 2012, 41, 6558-6566. 
22. DeToma, A. S.; Choi, J.-S.; Braymer, J. J.; Lim, M. H. ChemBioChem 2011, 12, 
1198-1201. 
23. Hyung, S.-J.; DeToma, A. S.; Brender, J. R.; Lee, S.; Vivekanandan, S.; Kochi, 
A.; Choi, J.-S.; Ramamoorthy, A.; Ruotolo, B. T.; Lim, M. H. Proc. Natl. Acad. 
Sci. U. S. A. 2013, 110, 3743-3748. 




25. Porat, Y.; Abramowitz, A.; Gazit, E. Chem. Biol. Drug Des. 2006, 67, 27-37. 
26. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. J. 
Neurochem. 2003, 87, 172-181. 
27. Ong, K. C.; Khoo, H. E. Gen. Pharmacol. 1997, 29, 121-126. 
28. Hirohata, M.; Hasegawa, K.; Tsutsumi-Yasuhara, S.; Ohhashi, Y.; Ookoshi, T.; 
Ono, K.; Yamada, M.; Naiki, H. Biochemistry 2007, 46, 1888-1899. 
29. Hamaguchi, T.; Ono, K.; Murase, A.; Yamada, M. Am. J. Pathol. 2009, 175, 
2557-2565. 
30. Di Carlo, G.; Mascolo, N.; Izzo, A. A.; Capasso, F. Life Sci. 1999, 65, 337-353. 
31. Carver, J. A.; Duggan, P. J.; Ecroyd, H.; Liu, Y.; Meyer, A. G.; Tranberg, C. E. 
Bioorg. Med. Chem. 2010, 18, 222-228. 
32. Akaishi, T.; Morimoto, T.; Shibao, M.; Watanabe, S.; Sakai-Kato, K.; Utsunomiya-
Tate, N.; Abe, K. Neurosci. Lett. 2008, 444, 280-285. 
33. clinicaltrials.gov. 
34. Mira, L.; Fernandez, M. T.; Santos, M.; Rocha, R.; Florencio, M. H.; Jennings, K. 
R. Free Radical Res. 2002, 36, 1199-1208. 
35. Cao, S.; Jiang, X.; Chen, J. J. Inorg. Biochem. 2010, 104, 146-152. 
36. Ehrnhoefer, D. E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; 
Engemann, S.; Pastore, A.; Wanker, E. E. Nat. Struct. Mol. Biol. 2008, 15, 558-
566. 
37. Bieschke, J.; Russ, J.; Friedrich, R. P.; Ehrnhoefer, D. E.; Wobst, H.; 
Neugebauer, K.; Wanker, E. E. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 7710-
7715. 
38. Ono, M.; Watanabe, R.; Kawashima, H.; Kawai, T.; Watanabe, H.; Haratake, M.; 
Saji, H.; Nakayama, M. Bioorg. Med. Chem. 2009, 17, 2069-2076. 
39. Engelmann, M. D.; Hutcheson, R.; Cheng, I. F. J. Agric. Food Chem. 2005, 53, 
2953-2960. 
40. Martell, A. E.; Smith, R. M., Critical Stability Constants. Plenum Press: New York 
City, 1974; Vol. 3. 
41. Malešev, D.; Kuntić, V. J. Serb. Chem. Soc. 2007, 72, 921-939. 
42. Huang, C. Y. Methods Enzymol. 1982, 87, 509-525. 
43. Mancino, A. M.; Hindo, S. S.; Kochi, A.; Lim, M. H. Inorg. Chem. 2009, 48, 9596-
9598. 
44. Hartley, D. M.; Walsh, D. M.; Ye, C. P.; Diehl, T.; Vasquez, S.; Vassilev, P. M.; 
Teplow, D. B.; Selkoe, D. J. J. Neurosci. 1999, 19, 8876-8884. 
45. Klug, G. M. J. A.; Losic, D.; Subasinghe, S. S.; Aguilar, M. I.; Martin, L. L.; Small, 
D. H. Eur. J. Biochem. 2003, 270, 4282-4293. 
46. Verdan, A. M.; Wang, H. C.; Garcia, C. R.; Henry, W. P.; Brumaghim, J. L. J. 
Inorg. Biochem. 2011, 105, 1314-1322. 
47. Perron, N. R.; Wang, H. C.; Deguire, S. N.; Jenkins, M.; Lawson, M.; Brumaghim, 
J. L. Dalton Trans. 2010, 39, 9982-9987. 
48. Perron, N. R.; Brumaghim, J. L. Cell Biochem. Biophys. 2009, 53, 75-100. 
49. Smith, D. G.; Cappai, R.; Barnham, K. J. Biochim. Biophys. Acta 2007, 1768, 
1976-1990. 
50. Allsop, D.; Mayes, J.; Moore, S.; Masad, A.; Tabner, B. J. Biochem. Soc. Trans. 




51. Wang, X.; Michaelis, E. K. Front. Aging Neurosci. 2010, 2, 12. 
52. Palacios, H. H.; Yendluri, B. B.; Parvathaneni, K.; Shadlinski, V. B.; Obrenovich, 
M. E.; Leszek, J.; Gokhman, D.; Gasiorowski, K.; Bragin, V.; Aliev, G. CNS 
Neurol. Disord.: Drug Targets 2011, 10, 149-162. 
53. Nakamura, T.; Cho, D. H.; Lipton, S. A. Exp. Neurol. 2012, 238, 12-21. 
54. Faller, P.; Hureau, C. Chem. Eur. J. 2012, 18, 15910-15920. 
55. Deraeve, C.; Boldron, C.; Maraval, A.; Mazarguil, H.; Gornitzka, H.; Vendier, L.; 
Pitie, M.; Meunier, B. Chem. Eur. J. 2008, 14, 682-696. 
56. Himes, R. A.; Park, G. Y.; Siluvai, G. S.; Blackburn, N. J.; Karlin, K. D. Angew. 
Chem. Int. Ed. 2008, 47, 9084-9087. 
57. Rice-Evans, C. A.; Miller, N. J.; Paganga, G. Free Radical Biol. Med. 1996, 20, 
933-956. 
58. Fernandez, M. T.; Mira, M. L.; Florȇncio, M. H.; Jennings, K. R. J. Inorg. Biochem. 
2002, 92, 105-111. 
59. Masuoka, J.; Saltman, P. J. Biol. Chem. 1994, 269, 25557-25561. 
60. Zhang, Y.; Akilesh, S.; Wilcox, D. E. Inorg. Chem. 2000, 39, 3057-3064. 
61. Kagaya, N.; Kawase, M.; Maeda, H.; Tagawa, Y.; Nagashima, H.; Ohmori, H.; 
Yagi, K. Biol. Pharm. Bull. 2002, 25, 1156-1160. 
62. Afanas'eva, I. B.; Ostrakhovitch, E. A.; Mikhal'chik, E. V.; Ibragimova, G. A.; 







Chapter 3: Insights into the Anti-Amyloidogenic Properties of the Green Tea 
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3.1. Introduction  
The brain of individuals suffering from Alzheimer’s disease (AD) has protein 
aggregates composed of misfolded amyloid- (A) peptide. The A peptides are 
produced endogenously through enzymatic cleavage of amyloid precursor protein. A 
monomers can misfold and oligomerize into various intermediates prior to the formation 
and elongation of fibrils that exhibit a characteristic cross- sheet structure.1-5 The 
accumulation of aggregated A species has been a key feature of the amyloid cascade 
hypothesis, which cites that these aggregates are possible causative agents in AD. In 
addition, transition metals, such as Cu and Zn, whose misregulation leads to aberrant 
neuronal function, have a suggested link to AD pathology.1,3-9 Both in vitro and in vivo 
studies have provided evidence for the direct interactions of metal ions with A and their 
presence within A plaques, indicating the formation of metal-associated A (metal–A) 
species. These metal–A species have been implicated in processes that could lead to 
neurotoxicity (e.g., metal-induced A aggregation and metal–A-mediated reactive 
oxygen species (ROS) generation).1,3-9 The involvement of metal–A species in AD 
pathogenesis, however, has not been clearly elucidated. In order to advance our 
understanding of the potential neurotoxicity of metal-A species, efforts to develop 
chemical tools capable of interacting directly with metal–A species and modulating 
their reactivity in vitro and in biological systems are underway.1,9-21 In particular, novel 
bifunctional compounds that contain elements for metal chelation and A interaction 
have recently been prepared or identified via rational structure-based design strategies 
or systematic selection of natural products.  
Naturally occurring flavonoids have been shown to interact with amyloidogenic 
peptides and arrest or redirect aggregation pathways.22-29 These studies have mainly 
been conducted under metal-free conditions. For example, the green tea extract, (–)-
epigallocatechin-3-gallate (EGCG; Figure 3.1) is known as an anti-oxidative and anti-
inflammatory agent for numerous human diseases30 and has exhibited anti-
amyloidogenic reactivity with various disease-related peptides (e.g., A, -synuclein, 
islet amyloid polypeptide, semen-derived enhancer of viral infection (SEVI)).22-24,27,28,31-










Figure 3.1. Structure of (−)-epigallocatechin-3-gallate [(2R,3R)-5,7-dihydroxy-2-(3,4,5-
trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate] (EGCG). 
The letters A, B, and C identify the rings of the flavonoid core structure and numbers 
indicate positions of OH groups. 
 
and metal-free A with EGCG, presumably through the direct peptide–EGCG 
interactions that were proposed to alter the peptide assembly from the expected fibrillar 
structures in favor of an off-pathway intermediate.23,24 EGCG has also been shown to 
restructure preformed metal-free A aggregates into unstructured, stable, and nontoxic 
conformations.24 These observations suggest a broad ability for EGCG to disrupt both 
early-stage and late-stage aggregation processes. Although EGCG is also able to 
chelate metal ions,35,36 its influence on metal-bound A structure and reactivity has not 
fully elucidated.37  
Here, we present the ability of EGCG to modulate metal (Cu(II) or Zn(II))-induced 
A aggregation to produce small, unstructured peptide aggregates to a different extent 
than metal-free A aggregationwhich may translate to reduced metal–A toxicity in 
living cells. In order to rationalize the anti-amyloidogenic reactivity of EGCG at the 
molecular level, A interaction properties in the absence and presence of metal ions 
were investigated using ion mobility-mass spectrometry (IM-MS)38,39 and two-
dimensional (2D) NMR spectroscopy. Our IM-MS and 2D NMR results were also 
supported by molecular dynamics simulations to create a comprehensive molecular-
level mechanism of EGCG action and reactivity. The interaction of EGCG with metal-
free A monomers and dimers induced structurally compact peptide conformations that 
likely led to the generation of amorphous A aggregates. In addition, our biophysical 




complexes, which may explain the remarkable ability of this molecule to influence metal-
induced A aggregation over the metal-free case. Overall, these studies provide a clear 
structure-based mechanism for EGCG action toward both metal-free and metal-
associated A species and build a foundation for development and application of small 
molecules as chemical tools for elucidating AD pathogenesis. 
 
3.2.  Results and discussion 
 
3.2.1. EGCG distinctly modulates A aggregation induced by Cu(II) or Zn(II) 
We investigated the ability of EGCG to inhibit the formation of metal-free or 
metal-associated A40 aggregates (inhibition experiment, Figures 3.2 and 3.3) or to 
disassemble preformed aggregated species with or without metal ions (disaggregation 
experiment, Figure 3.4) by gel electrophoresis with Western blotting using an anti-A 
antibody (6E10), as well as by transmission electron microscopy (TEM). These methods 
were employed to visualize the changes in size distribution and morphology that are not 
accurately represented using other biological assays (e.g., thioflavin-T (ThT) assay).40,41  
As shown in Figures 3.2 and 3.3 (inhibition experiment), EGCG displayed an 
enhanced ability to generate and stabilize low molecular weight (MW) A aggregates 
when metal ions such as Cu(II) and Zn(II) were present. In comparison, only a modest 
amount of low MW aggregates was detected at long incubation times in metal-free A 
samples treated with EGCG (lane 2, Figure 3.2(a)). Aggregates with a distribution of 
sizes (MW ≤ 25 kDa or ≤ 32 kDa for EGCG-treated Cu(II)–A or Zn(II)–A species (lane  
4 or 6)) were observed even after only a 2 or 4 h incubation of Cu(II)- or Zn(II)-
containing A solutions with EGCG and were mostly maintained following a 24 h 
incubation. There was a slight dependence on the EGCG concentration for Cu(II)-
treated A species at the 4 h time point, where smaller sizes of A species (MW ≤ 25 
kDa) could be produced even using substoichiometric equivalents of EGCG (e.g., 1:4:4 
EGCG:Cu(II):A, Figure 3.3). TEM images showed that A samples incubated with 






Figure 3.2. Assessment of the ability of EGCG to modulate metal-free and metal-
associated A40 aggregation in vitro. (a) A species (from the inhibition experiment) 
visualized by gel electrophoresis using immunoblotting with an anti-A antibody (6E10). 
Inhibition experiment (Scheme, top): A (25 M) with or without CuCl2 or ZnCl2 (25 M) 
were incubated with EGCG (50 M) for 2, 4, 8, 12, or 24 h (20 M HEPES, pH 6.6 or 
7.4, 150 M NaCl; 37 °C; constant agitation). (b) TEM images of the samples from (a) 
after 24 h incubation. 
 
process compared to those treated only with metal ions (Figure 3.2(b)). In those 
systems, fibril growth was arrested and the aggregates were observed to be smaller in 
size. Furthermore, the unstructured shapes of the aggregates were distinct from the 
fibrillar forms found in the metal–A samples without EGCG;37 EGCG alone did not 
significantly change the morphology of metal-free A species, which remained mostly 
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[EGCG] 
Lanes: 
1. Ab + CuCl2 
2. Ab + CuCl2 + 0.25 equiv EGCG 
3. Ab + CuCl2 + 0.5 equiv EGCG 
4. Ab + CuCl2 + 1 equiv EGCG 
5. Ab + CuCl2 + 2 equiv EGCG 
6. Ab + CuCl2 + 5 equiv EGCG 
 
 
Figure 3.3. Concentration dependence of EGCG on modulation of Cu(II)-induced A 
aggregation. A samples were incubated with CuCl2 and varying amounts of EGCG (0–
125 M) for 4 h and were visualized by gel electrophoresis and Western blotting (6E10). 
Experimental conditions: [A] = 25 M; [CuCl2] = 25 M; 20 M HEPES, pH 6.6, 150 M 
NaCl; 37 °C; constant agitation; final concentration of DMSO (1% v/v). 
 
To investigate the effect of EGCG on transformation of aggregated A forms 
(disaggregation experiment, Figure 3.4), the compound was incubated with preformed, 
metal-free or metal-treated A40 aggregates for various time periods and analyzed by 
Western blotting and TEM. From these results, differences in aggregate distribution 
were detected for metal–A samples compared to metal-free A samples (Figure 
3.4(a)). The results for Cu(II)– or Zn(II)–A indicated that even for short time periods 
(i.e., 2 or 4 h), a varied amount of low MW (≤ 32 kDa) A species was present. Cu(II)–
A aggregates treated with EGCG showed progressively weakening intensities in the 
Western blot upon longer incubation, while Zn(II)–A aggregates treated with EGCG 
maintained a fairly constant intensity as time progressed. TEM analysis revealed some 
shorter fibrillar segments for EGCG-treated Cu(II)–A while the EGCG-treated Zn(II)–
A samples mainly produced amorphous species (Figure 3.4(b)). Metal-free A species 
incubated with EGCG partially retained fibrillar morphology, but some species were 
smaller in size than those observed in EGCG-untreated samples. Taken together, our 
results indicate that EGCG could discriminate between metal-free and metal-associated 
A species driving the formation of low MW aggregates at the expense of larger ones, 








Figure 3.4. Disaggregation of preformed metal-free and metal-associated A 
aggregates by EGCG. (a) Samples from the disaggregation experiment were analyzed 
by gel electrophoresis followed by immunoblotting with an anti-A antibody (6E10) 
(Scheme, top). A (25 M) and/or CuCl2 or ZnCl2 (25 M) were incubated for 24 h to 
produce A aggregates. Afterward, EGCG (50 M) was added to the preformed metal-
free and metal-associated A aggregates followed by incubation for 2, 4, 8, 12, or 24 h 
(20 M HEPES, pH 6.6 or 7.4, 150 M NaCl; 37 °C; constant agitation) and analysis by 
gel electrophoresis. (b) TEM images of the 24 h incubated samples from (a). 
 
3.2.2. EGCG diminishes metal-free and metal–A toxicity in living cells 
Previous studies have suggested that EGCG is able to alleviate toxicity of metal-
free A species in living cells;23,24 however, a comparison of its influence on the toxicity 
of both metal-free and metal-A species has not been reported. Murine Neuro-2a (N2a) 
neuroblastoma cells were used to probe the toxicity of EGCG, metal chloride salts (i.e., 




20 M) with and without metal ions (10 M) was relatively nontoxic to the living cells. In 
addition, the toxicity presented with both metal-free and metal-treated A was negligible 
upon incubation with EGCG. Overall, these cell studies suggest that EGCG may 
mitigate the effect of metal-free or metal-A-induced processes in complex, 
heterogeneous environments, which may be related to EGCG-mediated alteration of 
metal-free or metal–A conformations. 23,24,27,28,37 
 
Figure 3.5. Effect of EGCG on A40 or metal–A40 species in living cells. Cell viability 
measurements in the presence of metal-free and metal-treated A species with or 
without EGCG in murine Neuro-2a (N2a) neuroblastoma cells. Cells treated with A, 
metal ions, and/or EGCG were incubated for 24 h at 37 °C. Cell viability was measured 
using the MTT assay and viability was calculated relative to cells containing equivalent 
amounts of DMSO (0-1%, v/v). Error bars represent the standard error from three 
independent experiments. 
 
3.2.3. EGCG directly binds to A peptide and causes conformational changes 
To characterize the interactions between EGCG and A40, we first recorded 2D 
1H/15N SOFAST-HMQC NMR spectra on samples with different molar ratios of EGCG in 
25 mM HEPES, pH 7.3, with 25 mM NaCl at 4 °C (Figure 3.6(a); 2D band-selective 
optimized flip-angle short transient (SOFAST)-heteronuclear multiple quantum 
correlation (HMQC)). Under these conditions, the addition of EGCG to freshly dissolved 
A40 (76 M) caused partial precipitation in the sample even with substoichiometric 
concentrations of EGCG, suggesting EGCG could result in the production of aggregates 




near-uniform decrease in intensity of all resonances of monomeric A, most likely due 
to the depletion of A monomers and enrichment of both soluble and insoluble higher-
order oligomers of A (Figure 3.6(a)).  
To gain more insight into soluble oligomeric species invisible to NMR, IM-MS 
experiments were performed on samples with varying molar ratios of EGCG under 
conditions designed to probe their solution stoichiometry and structure.38,39,42 IM-MS 
has been emerging as a useful technique to uncover protein structure of soluble species 
in the gas phase generated from heterogeneous solutions.38,39,43 The coupling of IM and 
MS techniques allows samples to be separated not only by the mass/charge (m/z) ratio, 
but also according to their size/conformation.38,43 This is useful especially for uncovering 
unique peptide conformations and overall topology even when m/z is identical. IM-MS 
uses soft ionization methods like electrospray ionization (ESI) to generate protein 
complex ions in the gas phase that are separated by IM. The mobility of the ions is 
quantified by their drift time, which depends on several physical features (e.g., mass, 
charge, and collision cross section (CCS or ) area).43 More compact peptide ions, 
having a smaller CCS, will have higher mobility and therefore lower drift times; 
conversely, less compact ions will require a longer time to travel through the IM. Mass 
separation and ion detection are the final steps before generating a multi-dimensional 
contour plot representing the drift time/CCS, mass/charge (m/z), and intensity.38,43 IM-
MS is often nicely complemented by additional biophysical methods, including 
molecular dynamics simulations and NMR, to validate the gas phase structural 
information that was obtained. The use of this technique to investigate the A 
aggregation equilibrium has been well established,39,43 and current investigations on 
amyloid aggregation mediated by small molecules will be aided by this method. 
In the absence of EGCG, A (10 µM) existed primarily as a mixture of monomers 
and dimers as found by IM-MS (Figure 3.6(b)). The mass spectrum of A contained 
peaks for the 4+ and 3+ states at 1083 and 1444 m/z, respectively. The formation of 
complexes between A and EGCG was apparent from a solution containing A (10 µM) 
and EGCG (20 µM) (Figure 3.6(c)). At this molar ratio, the signal corresponding to a 
complex composed of 1:1 stoichiometry was dominant in this dataset, as shown by the 
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Figure 3.6. Interaction of EGCG with A40. (a) Titration of A with EGCG monitored by 
2D 1H/15N SOFAST-HMQC NMR spectroscopy. Substoichiometric amounts of EGCG 
caused a large uniform drop in intensity. (b) A plot of ion mobility (IM) drift time versus 
m/z for metal-free A40 (10 µM) showed monomeric and dimeric forms of the peptide 
under conditions used for our experiments (100 mM ammonium acetate buffer, pH 7.4). 
(c) Similar IM-MS data as in (b) for samples containing EGCG added in solution (20 µM) 
revealed multiple binding modes for EGCG with the monomeric and dimeric form of A. 
(d) MS-based time course experiments revealed that EGCG (green circles) could 
solubilize larger amounts of the dimeric forms of the peptide in solution when compared 
to ThT (blue squares) and only peptide (red diamonds) control data. (e) Close 
inspection of the IM drift time profiles for the 4+ state of the peptide indicated at least 
three resolved conformational families and that EGCG binding could produce a larger 
population of compact A40 peptides (CCS: 796, 716, and 633 Å2, top to bottom, Table 
3.1).  
 
Additional binding modes were also observed with ratios of 1:2, 2:1, and 2:2 
A/EGCG. A dimers and their EGCG complexes were resolved in the 5+ state at m/z 
1733, 1824, and 1916, respectively. The relative abundance of A dimers was 
significantly increased in samples incubated with EGCG compared to A samples 




but not monomers or small oligomers)44 (Figure 3.6(d)). This finding suggests that 
EGCG could facilitate the generation of soluble higher-order A structures in solution, 
which was also supported through gel analysis of the samples prepared under 
conditions similar to the IM-MS experiment (Figure 3.7). As shown in Figure 3.6(d), the 
gradual decrease of soluble dimeric A species over monomeric A species in the 
absence of EGCG or ThT was observed by IM-MS across time likely as a result of 
aggregation.45 Analysis of samples over 8 h, which was within the typical lag phase for 
A of 8 to 18 h,46 was found to be complicated due to the formation of aggregates 
similar to those seen in the higher concentration NMR sample that were likely unstable 
under our electrospray ionization conditions. Throughout this time interval, however, A 
samples containing EGCG showed consistently higher levels of dimeric species 
confirming that EGCG may promote and stabilize the formation of A dimers. 
 
Figure 3.7. Analysis of the A species resulting from the inhibition experiment (Figure 
3.2) in the same buffer used for IM-MS (Figures 3.6 and 3.13) by gel electrophoresis 
using immunoblotting (6E10). A (25 M) with or without CuCl2 or ZnCl2 (25 M) was 
incubated with EGCG (50 M) for 2 or 4 h (100 mM ammonium acetate, pH 6.6 or 7.4, 
37 °C, constant agitation).  
 
IM-MS data also revealed the basis for a molecular level explanation for the 
observed preference of EGCG for Adimers over monomers (Figure 3.6(c)). For A40 
incubated with excess EGCG, IM arrival time distributions (ATDs) showed at least three 
resolved structural features, similar to previous data recorded for A423–,47 allowing us to 
conformationally resolve distinct binding states. Binding of EGCG to A shifted this 
distribution dramatically toward the most compact state (CCS, centered at ca. 654 Å2; 
Figure 3.6(e) and Table 3.1); additional binding of EGCG shifted this distribution even 




bound to EGCG existed exclusively in a compact configuration (Figure 3.6(c)). The ion 
intensity values from mass spectra can be converted to EGCG dissociation constants 
(Kd) given certain assumptions and careful experimental protocols (Table 3.2).48 These 
measurements revealed that the affinity of EGCG for the dimeric forms of A was higher 
than that for monomers [Kd values of 139 M for 2:1 and 43.5 M for 2:2 (A 
dimer/EGCG) compared to of 331 M for the 1:1 and 47.1 µM for 1:2 (A 
monomer/EGCG)]. These dissociation constants are in the range of previously reported 
Kd values, which varied based on temperature, concentration, and pH.49 The results 
imply that the collapse of A monomer and dimer into more compact conformations 
following initial EGCG binding could facilitate additional EGCG binding. In addition, A 
dimers may have greater affinity for EGCG compared to monomers due to their 
preformed compact configuration, further suggesting that EGCG may bind to a region of 
the peptide that does not participate in dimer formation. Thus, IM-MS and NMR results 
indicate that EGCG interacts directly with A species, leading to a structural 
transformation to more compact form. 
 




Conformation   
  1 2 3 
A40(m)4+ 633.3 ± 1.2   715.6 ± 2.5 795.8 ± 8.3 
[A40(m) + Cu]4+ 621.3 ± 2.6   745.6 ± 2.7 826.7 ± 9.5 
[A40(m) + 2Cu]4+ 602.8 ± 1.8   744.5 ± 5.1 843.1 ± 13.2 
[A40(m) + EGCG]4+ 653.7 ± 7.0   785.5 ± 11.7 
 
[A40(m) + EGCG + Cu]4+ 645.1 ± 8.9   795.3 ± 7.1 
 
[A40(m) + EGCG + 2Cu]4+ 641.0 ± 12.4   807.5 ± 6.0 
 
[A40(m) + 2EGCG]4+ 689.5 ± 6.5   833.7 ± 1.3 
 
A40(m)3+ 695.8 ± 8.0     
[A40(m) + Cu]3+ 695.9 ± 6.2 
  
[A40(m) + 2Cu]3+ 698.3 ± 10.4 
  
[A40(m) + EGCG]3+ 757.0 ± 8.0 
  
[A40(m) + EGCG + Cu]3+ 757.3 ± 5.9 
  
[A40(m) + EGCG + 2Cu]3+ 761.4 ± 3.1 
  
[A40(m) +2EGCG]3+ 827.8 ± 12.1     
 




Table 3.2. Dissociation constants of A40–EGCG complexes. 
 
 
Dissociation Constant (M) 
Monomer Kd1 330.5 ± 327.0 
 
Kd2 47.1 ± 27.9 
Dimer Kd1 138.6 ± 102.6 
 
Kd2 43.5 ± 20.7 
 
In order to calculate the dissociation constants of EGCG (L) with A40 monomer or dimer (P), we 
assumed that the relative intensity of the ions corresponds to the equilibrium concentration of the 
monomer/dimer complexes formed in solution. The binding and dissociation event is also assumed occur 
in a sequential manner where the dissociation constant corresponds to the equations below: 
 
      
      
 
3.2.4. Molecular modeling studies present that EGCG could interact directly with 
A monomer 
To aid the interpretation of the IM-MS and NMR data, peptide-ligand docking 
studies were conducted against ten structures of A selected from a previously 
determined NMR structure of A40 (PDB 2LFM)50 (Figure 3.8). According to the docking 
results, EGCG had a tendency to associate with A primarily near the hydrophilic N-
terminus and the-helical region spanning residues H13–D23.50  This binding pocket is 
situated near the H6, H13, and H14 residues that may be involved in metal binding to 
A, as well as to residues near the hydrophobic self-recognition sequence, suggested to 
be linked to A aggregation pathways.1,3,5,9,51-53 A combination of both polar (e.g., 
hydrogen bonding, electrostatic interaction) and hydrophobic interactions was likely 
responsible for the close proximity of EGCG to both hydrophilic and hydrophobic 
portions of A in solution. Furthermore, it appeared that the flexibility of EGCG was 
important in allowing the molecule to optimize several binding configurations with 
peptide and may be a contributing factor in its anti-amyloidogenic properties.49 
Molecular dynamics (MD) simulations based on the ten docked structures of 




conformers observed in the experimental IM-MS data and explore structural elements 
involved in the A–EGCG interaction (Figures 3.9, 3.10, and 3.11). Specifically, the 
docked structures were allowed to anneal by exposing the positively charged, 
desolvated A–EGCG complex to a series of rapid heating and cooling cycles. For each 
starting structure, 100 structures were sampled at 300 K and their force field energy 
was recorded. In addition, the orientationally averaged CCS values were determined for 
these model structures using the trajectory method.54,55 The plot of CCS against force 
field energy showed the structures determined for A–EGCG in the gas-phase possess 
a diverse range of sizes, with CCS values ranging from 600 to 900 Å2 (Figures 3.9(a) 
and 3.10). While the structures did not cluster either to a narrow range of CCS or 
energy, we note that the docked conformation with the lowest binding energy led to 
structures with relatively smaller CCS values when compared to those starting 
structures having less favorable binding energies (Figure 3.11). Interestingly, A 
simulated without EGCG occupied an even wider range of conformations than the A–
EGCG complexes as revealed by the broader distribution of CCS values (Figure 3.9(b)). 
In all cases, the experimentally determined values and trends were in good agreement 














































































Figure 3.8. Docking studies of EGCG with A40 monomer (PDB 2LFM) by AutoDock 
Vina. Cartoon (left) and surface (right) representations of top poses of EGCG with 
conformations (1-10) of A are shown. Possible hydrogen bonding contacts are 
indicated with a dashed line (1.9-2.5 Å) and the -helical region of the peptide is 
highlighted in gray for the surface images of A. Binding energies predicted for EGCG 
with A40 monomer are summarized in the table. Hydrogen atoms in the peptide are 
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Figure 3.9. Molecular modeling of EGCG-bound A40. (a) A plot of collision cross-
section (CCS) against the potential energy of A40–EGCG complexes generated by 
molecular dynamics simulation. Two binding states of the A40–EGCG complex 
(conformations 1 and 10) visualized by docking studies (Figure 3.8) were subjected to a 
simulated annealing run, and 100 snapshots were sampled from the trajectory. (b) The 
corresponding run using the A40 monomer structure is shown (green diamonds). The 
values of CCS of the discrete conformations observed by IM-MS are marked as dotted 
lines. A representative gas-phase structure from the molecular dynamics simulation 
(left) with the corresponding starting structure (right) are shown for the A40–EGCG 











































































































Figure 3.10. Molecular modeling of EGCG-bound A40 based on docking structures 
(Figure 3.8). Ten conformation snapshots taken from molecular modeling of EGCG with 
the A40 monomer (PDB 2LFM) from Figure 3.8 were chosen for molecular dynamics 
simulation. The 4+ states of EGCG docked with A40 monomer were subjected to 
simulated annealing cycle in vacuo for 20 ns and 100 structures were sampled at 300 K. 
(a-j) A plot of CCS against the potential energy. The corresponding energies (kJ/mol) 
are summarized in the list (top, right). 
 
For those low-energy conformations whose CCS was close to the experimentally 
determined value of the compact structural feature of A–EGCG complex, EGCG was 
slightly displaced from the residues considered to be associated with metal binding (H6, 




more extended conformation showed that EGCG was in proximity to those residues in 
similarly to the docked pose (Figure 3.9(d)). Gas-phase MD simulations led to 
significant perturbations in peptide secondary structure, but retained a helical motif 
region both in the absence and presence of EGCG (Figure 3.9(c-e)). In all cases, the 
most favorable docked structures depicted in Figure 3.9 provided the starting structures 
that generated the best-fit gas-phase structures for the IM-MS data. Moreover, the 
magnitude of the compaction observed in our IM-MS experiments was reproduced 
computationally in our MD simulations, supporting the experimentally determined 
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Figure 3.11. Histogram of the frequency of the structures with the corresponding CCS. 
The distribution of CCS across the trajectory run of 100 structures obtained from MD 
simulation is represented by this histogram. Color code: Red, low binding energy A40–
EGCG; blue, high binding energy A40–EGCG; green, A40. The histogram shows that 
structures generated from both complexes are relatively compact compared to that of 
EGCG-untreated A40. 
 
3.2.5. Metal binding of EGCG occurs in both the absence and presence of A
In the framework of EGCG, OH groups found on the B ring and within the gallic 
acid moiety (Figure 3.1) could potentially be involved in Cu(II) and Zn(II) chelation.35,36 
In a buffered aqueous solution (pH 7.4), the UV-Vis absorption spectrum of EGCG 
(Figure 3.12(a)) showed features ca. 275 nm and 320 nm, consistent with previous 
reports.36 The addition of 0.5 or 1 equiv of CuCl2 enhanced the absorption around 320. 
Based on previous spectroscopic studies of Cu(II) with EGCG, it is possible that the UV-






Figure 3.12. Cu(II) and Zn(II) binding of EGCG determined by UV-Vis. (a) The spectra 
were obtained upon 30 min incubation of 0.5 or 1 equiv of CuCl2 (left) or ZnCl2 (right) to 
EGCG (50 M, black). The spectra of the buffered solutions were also acquired in the 
absence (gray) and presence of CuCl2 (25 M, left, purple) or ZnCl2 (25 M, right, 
brown) without EGCG. (b) The spectra were recorded from the samples containing A40 
(25 M), one equivalent of CuCl2 (left) or ZnCl2 (right) (2 min incubation), and/or EGCG 
(50 M, 30 min incubation) at room temperature. All spectra were acquired in a buffered 
solution containing 20 mM HEPES, pH 7.4, 150 mM NaCl at room temperature. 
 
Treatment of EGCG with 0.5 or 1 equiv of ZnCl2 also caused an optical change, which 
confirmed Zn(II) binding to EGCG as well. Metal binding of EGCG in the presence of A 
species was also investigated by UV-Vis (Figure 3.12(b)). Optical bands from the 
samples containing A, Cu(II) or Zn(II), and EGCG modestly resembled those from the 
samples at the peptide-free conditions, indicating the possibility that EGCG has an 
appropriate binding affinity for Cu(II) and/or Zn(II) to sufficiently compete with A for the 
metal ions. This observation could indicate a possibility for ternary complex formation 
among A, metal ions, and EGCG (vide infra), which could be related to the previously 




3.2.6. EGCG forms ternary complexes with metal-treated A 
To elucidate interactions of A40, EGCG, and Cu(II) or Zn(II), IM-MS and 2D 
NMR investigations were performed (Figure 3.13). Mass spectra showed peaks 
corresponding to Cu(II)–Aspecies in 1:1 and 1:2 stoichiometries, and both types of 
Cu(II)–Acomplexes bound to either 1 or 2 equiv of EGCG (Figure 3.13(a); [A] = 10 
M; [Cu(II)] = 20 M).56 IM data recorded for the monomeric A complexes showed that 
Cu(II) binding had a similar influence on A404+ as that observed for A–EGCG 
complexes (Figure 3.6). As presented in Figure 3.13(c), Cu(II) binding could cause the 
peptide to favor the most compact of the three conformational families observed in apo-
A datasets, and such structural features became more pronounced in IM arrival time 
distribution (ATD) profiles upon additional Cu(II) binding. Likewise, IM ATDs acquired 
for ternary complexes, involving EGCG, Cu(II), and A, exhibited that the relative 
abundance of compact structural conformations was augmented for higher 
stoichiometry Cu(II) to A–EGCG complexes (Figure 3.13(d)). The structural 
compaction of Cu(II)–A even with EGCG suggests that Cu(II) could interact with A in 
a non-cooperative manner. 
Under the same conditions as the experiments of Cu(II)–A above, IM-MS 
analysis of Zn(II) with A40 showed weaker association, even in the presence of excess 
Zn(II) (Figure 3.14). Thus, to understand the interaction of EGCG with Zn(II)-treated 
A40 species, 2D SOFAST-HMQC NMR was employed. The addition of ZnCl2 to A40 at 
a 1:1 molar ratio broadened and shifted resonances for the region around H6, H13, and 
H14, previously identified as the primary Zn(II) binding site in the peptide(Figure 3.13(e-
g)).1,3,5,9,51-53 The C-terminal region of the peptide (L17-V40) was mostly unaffected, 
except for the K28 and G29 resonances which were significantly broadened or shifted, 
respectively, upon treatment with Zn(II). The reasons for changes in this region of the 
peptide are not immediately clear; however, the C-terminus is involved in contacts with 
central hydrophobic core50 and there is evidence that Zn(II) affects this interaction.52 
Addition of 1 equiv of EGCG to this sample of A and Zn(II) largely reversed both the 
broadening and chemical shift changes for most of the peptide residues affected by 





Figure 3.13. Interactions of EGCG with metal–A40 species. (a) MS data for samples 
containing A (10 M), Cu(OAc)2 (20 M), and EGCG (20 M) revealed the presence of 
ternary complexes. (b) A plot of IM drift time versus m/z indicated that monomeric A 
species generated in (a) followed one IM-MS trend, whereas higher-order A 
complexes and chemical noise components were clearly distinguished from these 
signals using IM-MS. (c) IM drift time spectra for control data where EGCG was not 
bound to the peptide revealed that Cu(II) binding acted to compact the peptide 
substantially. (d) Similar IM data as in (c) above showed that EGCG–Cu(II)–A40 
complexes further preferred compact configurations. (e) Analysis of EGCG and Zn(II) 
binding to A40 by 2D SOFAST-HMQC NMR spectroscopy at 4 °C. On the left, addition 
of ZnCl2 (38 M) to A (38 M) caused the broadening and disappearance of specific 
peaks, primarily in the N-terminus. On the right, subsequent addition of EGCG (38 M) 
to the Zn(II)–A complex partially restored the signal intensity. (f) Expanded view of the 
highlighted regions of the 2D NMR spectra (e). (g) Changes in the chemical shift (left) 




restored were H13 and H14, which have been identified as ligands in Zn(II) binding to 
A.1,3,5,9,51-53 This may imply that some amount of Zn(II) remains associated with A 
while the remainder is displaced by EGCG. Alternatively, the partial restoration of the 
resonance could represent the formation of a ternary complex of EGCG–Zn(II)A, as 
seen for the EGCG–Cu(II)A complexes studied by IM-MS. Finally, a combination of 
metal chelation/displacement by EGCG and ternary complex generation could occur 
simultaneously. Overall, our studies suggest that EGCG is able to interact with Cu(II)– 
or Zn(II)–A species directly, likely leading to generation of ternary complexes with 
metal-associated A, which may account for its anti-amyloidogenic reactivity with 
metal–A species (Figures 3.2, 3.3, 3.4, and 3.7). 
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Figure 3.14. Interactions of A40 with Cu(II) and Zn(II) by MS. (a) MS data for A40 with 
Cu(OAc)2 added in a ratio of 1:3. Both singly and doubly Cu(II)-bound peptides 
dominated the spectrum with little evidence of metal-free A. (b) MS data for A40 with 
Zn(OAc)2 added in the same molar ratio as in (a). As observed in previous studies, very 
little evidence of Zn(II) binding was observed, and most of the peptide was shown to be 
in its apo form. (c) IM arrival time distribution for A in the 4+ state. Three 
conformational families were observed, with the middle population dominant. (d) IM 
arrival time distribution for the Zn(II)–A complex in the 4+ state. A greater population of 
the compact form and the elongated state were observed, when compared to the IM 
arrival time distribution for A only. 
 
3.3. Conclusion 
The green tea extract EGCG, having a structure capable of both metal chelation 
and A interaction, was selected to further explore the reactivity of a well-known natural 
flavonoid with metal-free and metal-associated A species and to provide structure-




addition of EGCG to samples containing Cu(II)– or Zn(II)–A species produced small 
amorphous A aggregates, while EGCG-untreated samples generated mainly 
structured A aggregates. This reactivity with A was more noticeable in conditions 
containing metal ions, suggesting that EGCG was more capable of disrupting metal-
mediated A aggregation as compared to metal-free conditions. Furthermore, in living 
cells, incubation of EGCG with metal-free or metal-Aenhanced cell survival, which 
may represent its inhibitory effect on aggregation in complex settings. Our IM-MS and 
NMR results suggest that the overall mechanism of reactivity of EGCG with metal-free 
and metal-associated A species could be driven by its ability to influence the structure 
of A monomers and dimers (i.e., formation of more compact conformations of A 
and/or ternary complexes containing A, Cu(II) or Zn(II), and EGCG in multiple 
stoichiometries). Taken together, the natural product, EGCG, could modulate the 
reactivity (i.e., aggregation, toxicity) of metal–A species through direct interactions with 
the peptide and its metal complexes. In addition, the molecular-level insights that 
underlie this altered reactivity suggest that EGCG might generate off-pathway A 
intermediates preferentially in the presence of metal ions. Thus, the fundamental 
information on the structure-interaction-reactivity relationship presented here will 
undoubtedly aid in rational design and structure-based screening strategies for 
identifying chemical tools to elucidate the contributions of multiple and/or inter-




3.4.1. Materials and procedures 
All reagents were purchased from commercial suppliers and used as received 
unless otherwise noted. A40 was purchased from Anaspec (Fremont, CA, USA). EGCG 
was purchased from Sigma-Aldrich (St. Louis, MO, USA) and used without further 
purification. Trace metal contamination was removed from buffers and solutions used 
for metal binding and A aggregation experiments (vide infra) by treating with Chelex 




8453 UV-Visible (UV-Vis) spectrophotometer. Transmission electron microscopic 
images were taken using Philips CM-100 transmission electron microscope (Microscopy 
and Image Analysis Laboratory, University of Michigan, Ann Arbor, MI, USA). 
Measurements of absorbance for cell viability assays were measured by a SpectraMax 
M5 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Mass spectra for 
studying the interaction of A with EGCG in the absence and presence of Cu(II) were 
acquired on a quadrupole ion mobility time-of-flight mass spectrometer (Synapt G2 
HDMS, Waters, Milford, MA, USA) and LCT Premier mass spectrometer (Waters, 
Milford, MA, USA) fitted with a nano-electrospray ionization (nESI) source. The NMR 
investigation of the Ainteraction of EGCG with Zn(II) was conducted on a 600 MHz 
Bruker spectrometer equipped with a cryogenic probe at 4 °C. 
 
3.4.2. Metal binding experiments 
Unless otherwise stated, metal binding properties of EGCG (50 M, 1% v/v 
DMSO) were studied in a Chelex-treated buffered solution containing 20 mM 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), pH 7.4, 150 mM NaCl. To the 
solution containing EGCG, 0.5 or 1 equiv of CuCl2 or ZnCl2 was added and incubated 
for 30 min at room temperature. Additionally, UV-Vis spectra of A (25 M), 
Aincubated with CuCl2 or ZnCl2 (25 M) for 2 min, and Apretreated with CuCl2 or 
ZnCl2 followed by 30 min incubation with EGCG (50 M) were acquired.  
 
3.4.3. A aggregation experiments 
A experiments were performed according to previously published methods.13,16-
20,29,40,57 Prior to experiments, A40 was dissolved in ammonium hydroxide (NH4OH, 1% 
v/v aq), aliquoted, lyophilized overnight, and stored at −80 °C. For experiments 
described herein, a stock solution of the A was prepared by dissolving the peptide in 
1% NH4OH (10 L) and diluting with ddH2O. The concentration of the solution was 
determined by measuring the absorbance of the solution at 280 nm ( = 1450 M−1 cm−1). 
The peptide stock solution was diluted to a final concentration of 25 M in a Chelex-




metal-free and Zn(II) samples) and NaCl (150 M). For the inhibition studies,13,16-
20,29,40,57 EGCG (50 M, 1% v/v DMSO) was added to the sample of A (25 M) in the 
absence and presence of metal ions (CuCl2 or ZnCl2, 25 M) followed by incubation at 
37 °C with constant agitation for 2, 4, 8, 12, and 24 h. For the disaggregation 
studies,13,16-20,29,40,57 A with and without metal ions was incubated for 24 h at 37 °C with 
constant agitation prior to the addition of EGCG (50 M) to the sample. The resulting 
samples were incubated at 37 °C with constant agitation for 2, 4, 8, 12, and 24 h. 
 
3.4.4. Gel electrophoresis and Western blotting 
Samples from the inhibition and disaggregation experiments were analyzed by 
gel electrophoresis (10-20% Tris-tricine gel, Invitrogen, Grand Island, NY, USA) and 
visualized by Western blot using an anti-A antibody (6E10).13,16-20,29,40,57 Following 
separation, the proteins were transferred onto nitrocellulose that was blocked with 
bovine serum albumin (BSA, 3% w/v, Sigma-Aldrich, St. Louis, MO, USA) in Tris-
buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) overnight. The membranes 
were incubated with the antibody (6E10, 1:2000, Covance, Princeton, NJ, USA) in a 
solution of 2% BSA (w/v in TBS-T) for 4 h at room temperature. After washing, the 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:5000; 
Cayman Chemical, Ann Arbor, MI, USA) in 2% BSA was added for 1 h at room 
temperature. The ThermoScientific SuperSignal West Pico Chemiluminescent Substrate 
(Rockford, IL, USA) was used to visualize the protein bands. 
 
3.4.5. Transmission electron microscopy (TEM) 
Samples for TEM were prepared according to a previously reported method.13,17-
20,29,40,57 Glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy 
Sciences, Hatfield, PA, USA) were treated with A samples from the inhibition and 
disaggregation experiments (5 L) for 2 min at room temperature. Excess sample was 
removed using filter paper followed by washing with ddH2O twice. Each grid was 
incubated with uranyl acetate (1% w/v ddH2O, 5 L, 1 min) and upon removal of excess 
was dried for 15 min at room temperature. Images from each sample were taken by a 




3.4.6. Cell viability measurements 
The murine neuroblastoma Neuro-2a (N2a) cell line was purchased from the 
American Type Cell Collection (ATCC, Manassas, VA, USA). The cell line was 
maintained in media containing 45% DMEM, 50% OPTI-MEM, 5% fetal bovine serum 
(FBS, Atlanta Biologicals, Lawrenceville, GA, USA), 100 U/mL penicillin, and 100 g/mL 
streptomycin (Gibco, Grand Island, NY, USA). The cells were grown in a humidified 
atmosphere with 5% CO2 at 37 °C. For the MTT assay (MTT = 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide), N2a cells were seeded in a 96 well 
plate (15,000 cells/100 L).13,17,19,20,29,57 The cells were treated with A (10 M) with or 
without CuCl2 or ZnCl2 (10 M), followed by the addition of EGCG (10 or 20 M, 1% v/v 
final DMSO concentration) and incubated for 24 h in the cells. The N2a cells were 
treated in parallel with only metal salts (CuCl2 or ZnCl2, 10 M), EGCG (10 or 20 M), or 
metal/EGCG (1:1 or 1:2 metal/EGCG ratio). After incubation, 25 L MTT (5 mg/mL in 
phosphate buffered saline (PBS, pH 7.4, Gibco, Grand Island, NY, USA) was added to 
each well and the plate was incubated for 4 h at 37 °C. Formazan produced by the cells 
was solubilized using an acidic solution of N,N-dimethylformamide (50%, v/v aq) and 
sodium dodecyl sulfate (SDS, 20%, w/v) overnight at room temperature in the dark. The 
absorbance was measured at 600 nm using a microplate reader. Cell viability was 
calculated relative to cells containing an equivalent amount of DMSO. Error bars were 
calculated as standard error from three independent experiments. 
 
3.4.7. Ion mobility-mass spectrometry (IM-MS) 
Protein ions were generated using a nESI source and optimized to allow 
transmission of noncovalent protein complexes unless stated otherwise. Nanoflow 
electrospray capillaries were prepared in-house as previously described.58 To generate 
protein complex ions, an aliquot of the sample (ca. 5 L) was sprayed from the nESI 
emitter using capillary voltages ranging from 1.4–1.6 kV, with the source operating in 
positive ion mode and the sample cone operated at 20 V. The mass spectra were 
acquired with the following settings and tuned to avoid ion activation and preserve non-
covalent protein–ligand complexes. The bias voltage was 40 V, with backing pressure at 




operated at a pressure of approximately 3.5 mbar of nitrogen and helium. Mass spectra 
were calibrated externally using a solution of cesium iodide (100 mg/mL) and analyzed 
using Masslynx 4.1 and Driftscope 2.0 software (Waters, Milford, MA, USA). Collision 
cross-section (CCS, Ω) measurements were externally calibrated using a database of 
known Ω in helium, including peptides, proteins, and protein complexes.38,59 Samples 
were prepared by mixing stock solutions of Cu(OAc)2, EGCG or ThT (1% v/v DMSO), 
and A40, dissolved in the aqueous solvent containing 100 mM NH4OAc at pH 7.0, to 
generate a final peptide concentration of 10 M. In order to study the relative 
abundance of dimeric to monomeric A40 the solution in the presence of EGCG or ThT, 
an aliquot of sample was analyzed at different time points by mass spectrometry and 
the intensity of the 3+ and 4+ ion of A40 monomer was compared with that of 5+ ion of 
A40 dimer. 
 
3.4.8. Docking studies 
Flexible ligand docking studies using AutoDock Vina60 for EGCG were conducted 
against the A40 monomer from the previously determined aqueous solution NMR 
structure (PDB 2LFM)50. Ten conformations were selected from among 20 within the 
PDB file (conformations 1, 3, 5, 8, 10, 12, 13, 16, 17, and 20). The MMFF94 energy 
minimization in ChemBio3D Ultra 11.0 was used to optimize the structure of EGCG for 
the docking studies. The structures of A and EGCG were prepared in AutoDock 
Tools61 and imported into PyRx62, which was used to run AutoDock Vina. The entire 
peptide was contained within the search space having dimensions (x, y, z) (Å) of (25.76, 
39.52, 38.63) and centered at (3.3428, −3.3088, −17.7921). The exhaustiveness for the 
docking runs was set at 1024. Docked models of EGCG were visualized with A40 using 
Pymol. 
 
3.4.9. Molecular dynamics simulations 
All simulations were started from the minimized solution NMR structure (PDB 
2LFM)50 of the A40 peptide. The simulations were performed using periodic boundary 
conditions in a cube with the minimum distance between the simulated molecules and 




software package63 and GROMOS96 force field.64 The LINCS algorithm was used to 
constrain all bond lengths in the peptides and EGCG, allowing an integration time step 
of 2 fs. The nonbonding pair list cutoff was set to 1.0 nm with the pair list updated every 
five time steps. The long-range electrostatic interactions were treated with the particle 
mesh Ewald method. The temperature and the pressure were maintained by coupling 
temperature and pressure baths using the method of Berendsen et al.65 The peptide 
and ligand were separately coupled to external temperature and pressure baths. The 
temperature-coupling constant was 0.1 ps. The pressure was kept at 1 bar using weak 
pressure coupling with τp = 2.0 ps.65 
The system was energy-minimized by steepest descent for 500 steps. After 
equilibration, simulated annealing was performed for A40 and A40–EGCG complex 
ions in the gas-phase, having charged the three most-basic A side chains (R5, K16, 
and K28) and the N-terminus (D1). The system was heated from 300 K to 500 K over 
100 ps, then cooled to 300 K over the next 100 ps. The cycle was repeated over 20 ns. 
This leads to escape from low-lying energy traps and enhanced equilibration. For the 
A40–EGCG complex, ten 20 ns independent simulated annealing runs were performed 
from the A40–EGCG complexes generated by AutoDock Vina (vide supra). From the 
MD trajectory, 100 structures were sampled at 300 K and the CCS was calculated using 
Mobcal using a trajectory method algorithm.54,55 
 
3.4.10. 2D NMR spectroscopy 
The interactions of A40 with EGCG in the absence and presence of Zn(II) were 
followed by 2D band-selective optimized flip-angle short transient (SOFAST)-
heteronuclear multiple quantum correlation (HMQC) experiments at 4 °C.66 15N-labeled 
A40 (rPeptide, Bogart, GA, USA) was first dissolved in 1% NH4OH and lyophilized. 
NMR samples were prepared from resuspending the solid in 1 mM NaOH (pH 10) and 
diluting with 10x HEPES–NaCl for a final buffer concentration of 25 mM HEPES, pH 7.3, 
with 25 mM NaCl and a final peptide concentration of either 38 M (for samples 
containing [A and Zn(II)] or [A Zn(II), and EGCG]) or 76 M (for the sample of A with 
EGCG). The pH was verified before the start of each titration and large aggregates were 




t1 experiments using either 32 or 64 transients (for the 76 and 38 M samples, 
respectively) and a 100 ms recycle delay. 2D data were processed using TOPSPIN 2.1 
(from Bruker). Resonance assignment and volume fit calculations were performed by 
SPARKY 3.113 with published assignments for A as a guide.49,67 
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Chapter 4: Reactivity of Synthetic Aminoisoflavone Derivatives with Metal–A 
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Alzheimer’s disease (AD) is rapidly becoming one of the prominent public health 
concerns worldwide, especially due to the present lack of a curative treatment.1-5 AD is 
commonly classified as a protein misfolding disease due to the observation of 
proteinaceous aggregates in diseased brain tissue, including senile plaques and 
neurofibrillary tangles.2-8 The primary components of the senile plaques are aggregated 
forms of amyloid- (A) peptides, which provided early evidence to propose the amyloid 
cascade hypothesis of AD.3,9-12 According to this principle, self-association of 
monomeric A into various amyloid assemblies produces neurotoxic species, leading to 
pathogenesis;13,14 however, plaques can have heterogeneous composition, with other 
components in addition to aggregated forms of A having been identified in the 
deposits. For example, metal ions have been found in association with the plaques and 
could be linked to neurotoxicity in AD. Furthermore, oxidative stress in the brain is 
indicated in AD and could also originate from several causes, including metal ions and 
their association with A species, suggesting the complicated etiology of this 
disease.4,5,8,15-20 
In particular, elucidating the role of metal ions (i.e., Fe, Cu, Zn) found in senile 
plaques has been challenging.2-5,8,11,21 Cu(I/II), Zn(II), and more recently Fe(II) have 
been shown to bind to A peptides in vitro.2-5,8,19,20,22-25 Consequently, Cu(II)- and Zn(II)-
bound A peptides have been found to aggregate more rapidly than their metal-free 
counterparts.26,27 It has also been proposed that redox active metal ions, such as 
Cu(I/II), bound to A could participate in redox cycling, leading to an overproduction of 
reactive oxygen species (ROS) and, subsequently, elevated oxidative stress.17,18,28 As 
metal binding to A may have multiple potential consequences, consideration of the 
direct interaction between these metal ions and A peptides as a pathological factor is 
warranted; however, little evidence has been accumulated to clarify the involvement of 
metal-associated A (metalA) species in vivo and their contribution to AD.  
 In an attempt to explore the connection between metal–A species and AD, 
employing small molecules as chemical tools may be useful. For this purpose, there 




with specific structural moieties for simultaneous interaction with metal ions and A (i.e., 
bifunctionality).2,3,29-44 The majority of molecules for this purpose have been designed by 
direct modification of known A plaque imaging agents.29-31,45-53 In the incorporation 
design approach, heteroatoms for metal chelation are directly installed into the imaging 
agent framework.30,31,34-40,43,44 This design strategy affords several advantages for future 
applications, including careful selection of moieties that could facilitate brain 
uptake.2,29,30 Although several compounds with bifunctionality have provided useful 
insights into the reactivity of metal–A, there remains much to be understood about 
these molecules’ functions at the molecular level and the impact of their structural 
features on interaction and reactivity with metal-free and metal–A species (i.e., 
structure-interaction-reactivity relationship). 
To expand on this idea, rational screening or selection of natural products has 
identified flavonoids as a source of chemical structures suitable for investigation and 
modification.12,54,55 Flavonoids are plant-derived compounds that have been studied in 
models of inflammation, cancer, oxidative stress, and dementia.56-58 Initially, myricetin 
(Figure 4.1a) was found to modulate of metal-mediated A aggregation and 
neurotoxicity in vitro due to its metal chelation and A interaction properties.12 More 
recently, the influence of (−)-epigallocatechin-3-gallate (EGCG, Figure 4.1a) on both 
metal-free and metal-induced A aggregation was characterized in detail at the 
molecular level through biochemical and biophysical studies.54 This investigation 
indicated that EGCG binding to A could generate metal–A complexes with a compact 
conformation; in both cases, off-pathway A aggregation occurred leading to 
amorphous A aggregates.54,59 In order to reconcile the previously reported findings 
using myricetin and EGCG with the rational design approach, it would be worthwhile to 
identify the essential structural moieties within a flavonoid framework required to target 
metal-free and metalA species and modulate their reactivity, which will offer small 
molecule candidates for chemical tools. 
Herein, we report the design and preparation of simple flavonoid derivatives, 
aminoisoflavones (1-4, Figure 4.1b), as well as a detailed evaluation of their Cu(II), 
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Figure 4.1. Chemical structures of (a) naturally occurring flavonoids (myricetin, EGCG, 
and genistein) and (b) synthetic aminoisoflavones (1-4). (a) Left to right: Myricetin, 
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one; EGCG, (−)-
epigallocatechin-3-gallate/(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-
yl 3,4,5-trihydroxybenzoate; genistein, 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-





induced A aggregation and cytotoxicity. These compounds were designed on the basis 
of naturally occurring isoflavones that are found in soy (e.g., genistein, Figure 4.1a) and 
have been shown to block metal-free A aggregation.56,60 Previously, aminoisoflavones 
have been reported to have some biological applications, including aryl hydrocarbon 
receptor agonist/antagonist activity and carbonic anhydrase inhibition, suggesting the 
versatility of this class of molecules.61,62 In the present study, several modifications were 
made to produce a small flavonoid library. A chemical moiety common to natural 
flavonoids, catechol, was incorporated in the isoflavone framework to provide a 
chelation site for Cu(II) and Zn(II). Although the coordination chemistry of catechol and 
its corresponding metal complexes is well known, knowledge of its role in flavonoid 
derivatives for targeting and modulating metal-free and metal-induced A aggregation 
has received little attention. Additionally, incorporation of an amine functionality (e.g., 
NH2) could be used to gauge the tolerance of the framework to unnatural substituents, 




rational structure-based modifications in later stages. The studies presented herein 
demonstrate that deconstruction of naturally occurring flavonoids for redesign with 
selective inclusion of only a few functional groups is sufficient to effectively target metal 
ions, A, and metal–A and to subsequently influence their reactivity in vitro. Using our 
aminoisoflavone derivatives, the foundation of a structure-interaction-reactivity 
relationship for flavonoids toward metal-free and metal-associated A is strengthened 
by detailed characterization of their properties at the molecular level. 
 
4.2. Results and discussion 
 
4.2.1. Design and synthesis of aminoisoflavone derivatives 
In search of small molecules to interrogate the relationship between metal ions 
and A species, selection of naturally occurring flavonoids has offered a new avenue for 
chemical tool development due to their multiple targeting capabilities, which may include 
various enzymes and ROS.12,54,63,64 According to the initial results of myricetin (Figure 
4.1a for structure),12 an attempt to modify the flavonoid structure in order to influence 
metal-induced A aggregation was made previously.40 In that report, simplified flavonoid 
structures were selected; however, they were unable to alter the reactivity of metal–A 
species, possibly due to the imbalance between metal binding and A binding 
affinities.40 Recognizing that certain structural moieties are common to natural 
flavonoids (e.g., catechol group), we designed and prepared a new family of synthetic 
flavonoids, aminoisoflavones (1-4, 4.1b) with tractable structural modifications. 
The aminoisoflavones are derived from the structures of soy isoflavones, such as 
genistein (Figure 4.1), which are known to have multiple biological effects, and they 
have been employed as A aggregation inhibitors and as neuroprotective molecules.60 
Synthetic aminoisoflavone derivatives have been demonstrated previously to have 
inhibitory activity against various isoforms of human carbonic anhydrase (hCAI and 
hCAII),62 a metalloenzyme that has been occasionally linked to AD.65 Thus, we were 
curious to know whether the family of compounds could target and modulate another 
aspect of AD-related reactivity. The design of the new aminoisoflavones 1-4 (Figure 4.1) 




substituents such as OH or Cl in the A ring to modify the electronics or sterics of the 
molecules to influence their reactivity with A or metal–A(vide infra). Compound 1 was 
prepared as an analogue of 4 that lacks the catechol group for comparison of interaction 
and reactivity with metal ions, A, and metal–A. The design further employs an 
unnatural substituent, a primary amine, in the 2 position of the C ring within the core 
framework of the isoflavone, which may be beneficial for improving solubility compared 
to naturally occurring flavonoids66 (Figure 4.1). The inclusion of the amine group is also 
related to the design of A plaque imaging agents and multifunctional small molecules, 
which have used amine derivatives to interact with the peptide.45-48,53,67 Among them, 
the dimethylamino functionality has been commonly used;45-48 however, the reported 
derivatives containing the primary amine can also enable interaction with A.48 The 
aminoisoflavones (1-4) presented here are synthesized by acidic cleavage of the 
methoxylated aminoisoflavone precursors,62 and they were obtained in relatively high 
yield (76-86%) (Scheme 4.1). Thus, the multiple structural aspects of these 
aminoisoflavones, including the isoflavone framework, the catechol motif, and the 
primary amine, make them attractive candidates for detailed characterization of their 
chemical properties and subsequently their influence on metal-free and metal-induced 
A aggregation in vitro, and toxicity induced by A and metal–A in living cells. 
 

























































4.2.2. Solution speciation studies of aminoisoflavones 
The acidity constants (pKa) for the aminoisoflavones were determined by 
variable-pH spectrophotometric titrations (I = 0.1 M, room temperature) following 
previously reported procedures (Figure 4.2).34,36-40,43,44,68,69 The primary amine common 
to all four aminoisoflavones was assigned to the most acidic pKa values, consistent with 
the predicted values for these structures.70 Deprotonation of the ammonium (RNH3+) to 
the primary amine (RNH2) was represented by pKa values of 1.3 ± 0.1 for 1, 1.8 ± 0.5 for 
2, 2.2 ± 0.9 for 3, and 1.5 ± 0.4 for 4. With the exception of 1, each of the structures 
contains the catechol moiety that has expected pKa values for the hydroxyl groups of 
ca. 9 and 13.71-73 The pKa values for the catechol/catecholate equilibrium were 8.9 ± 0.2 
and 12.3 ± 0.4 for 2, 8.9 ± 0.3 and 11.7 ± 0.2 for 3, and 9.1 ± 0.2 and 12.0 ± 0.2 for 4, 
with the more basic pKa value corresponding to deprotonation of the hydroxyl group in 
the para position.71-73 An additional pKa value corresponding to deprotonation of the 
hydroxyl substituent on the A ring in 1 and 4 was 7.9 ± 0.1 and 5.8 ± 0.3, respectively.  
Based on these pKa values, speciation diagrams were drawn to illustrate the fraction of 
ligand protonation states at each pH in solution. Each ligand would exist mainly in its 
fully deprotonated form above pH 12 (i.e., L), and would have an overall negative 
charge. At pH 7.4, the dominant species is expected to be neutral for 1 (LH), 2 (LH2), 
and 3 (LH2), or monodeprotonated for 4 (LH2). For future applications of these 
molecules, neutral species would be favored for facilitating brain uptake via passive 
diffusion across the blood-brain barrier (BBB).74 Furthermore, characterization of the 
species distribution could be valuable for rationalizing the metal/A binding properties 
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Figure 4.2. Solution speciation studies of aminoisoflavones (1-4). (a) Variable-pH UV-
Vis titration spectra and (b) solution speciation diagrams for 1-4 (FL = fraction of species 
in solution). (c) Summary of solution equilibria and acidity constants. Experimental 
conditions: [1 or 4] = 30 M, [2] = 20 M, [3] = 15 M; I = 0.1 M NaCl; room 
temperature. Charges are omitted for clarity. a The error in the last digit is shown in 
parentheses. 
 
4.2.3. Metal binding studies 
The aminoisoflavones 2, 3, and 4 were designed to be capable of metal binding 
via a catechol group, similar to other polyphenols.12,54,75,76 The catechol moiety is a 
prevalent ligand in biology, appearing in naturally occurring molecules such as 
flavonoids and in neurotransmitters (e.g., dopamine, epinephrine).72,77 Known to be a 
strong metal chelator, the inclusion of this functionality in the aminoisoflavone 
framework was anticipated to interact with metal ions surrounded by A species.72,73,78 
Thus, the Cu(II) and Zn(II) binding properties of the aminoisoflavones were investigated 
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Figure 4.3. Cu(II) binding studies of the aminoisoflavones. Treatment of (a) 1, (b) 2, (c) 
3, or (d) 4 (black) with 0.5 equiv of CuCl2 (light gray, incubated for 1-2 h), 1 equiv of 
CuCl2 (medium gray, incubated for 10-30 min), or 5 equiv of CuCl2 (dark gray, incubated 
for 5-30 min). Experimental conditions: [aminoisoflavone] = 20 M; 1% v/v DMSO; 20 
mM HEPES, pH 7.4, 150 mM NaCl; room temperature. 
 
detailed Cu(II) binding properties were also characterized by variable-pH UV-Vis 
titrations and electron paramagnetic resonance (EPR) spectroscopy (vide infra). 
 Upon incubation of the aminoisoflavones 2, 3, and 4 (20 M, 1% v/v DMSO) with 
CuCl2 in an aqueous buffered solution (20 mM HEPES, pH 7.4, 150 mM NaCl), 
differences in the optical spectrum of the free ligand were observed (Figure 4.3). With 
0.5 equiv of CuCl2, new absorption features at ca. 480 nm were detected; additionally, 
prolonged incubation of the solution resulted in the appearance of a broad feature 
centered at ca. 800 nm.79 Subsequent addition of CuCl2 (1 or 5 equiv) enhanced the 
intensity of these peaks. When the experiment was conducted with 1, which lacks the 
catechol group, there were no noticeable changes in the optical spectra (Figure 4.3).  
Zn(II) binding to the aminoisoflavones was also investigated by UV-Vis. It should 
be noted that the ligand concentration was increased to a ten-fold excess (i.e., 100 M) 
relative to ZnCl2 (10 M) to detect an optical change upon metal binding (Figure 4.4). 
Similar to the Cu(II) binding data, addition of Zn(II) had no effect on the spectrum of 1 
(Figure 4.4a). There were also no significant changes for 3 with Zn(II); however, 2 and 4 
showed new features in the UV-Vis spectra after ca. 12-24 h incubation. For 2, an 
increase in the peak at ca. 285 nm and a shift to ca. 390 nm were observed (Figure 
4.4b). Similarly, 4 displayed a progressive bathochromic shift from ca. 320 nm to 350 
nm over 24 h (Figure 4.4d). These spectral variations could be indicative of partial 




might also cause a weak, broad feature around 800 nm that is similar to, but less 
intense than, that of the Cu(II) binding spectra.79 This observation correlates to the 
Cu(II) speciation results at pH 7.4 detailed below, which suggests partial deprotonation 
of the catechol upon metal binding.72,77 Thus, deprotonation of 4 from LH2 to its LH form 
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Figure 4.4. Zn(II) binding properties of aminoisoflavones [(a) 1, (b) 2, (c) 3, or (d) 4 
(black) with ZnCl2 (dark green, 2 h incubation; gray, 12 h incubation; light green, 24 h 
incubation)]. Experimental conditions: [aminoisoflavone] = 100 M; [ZnCl2] = 10 M; 1% 
v/v DMSO; 20 mM HEPES, pH 7.4, 150 mM NaCl; room temperature. 
 
To anticipate whether the aminoisoflavones might bind to metal ions in the 
presence of A, UV-Vis studies were conducted with A40, CuCl2 and 4 (Figure 4.5). A 
solution of A40 (10 M) was treated with CuCl2 for 2 min followed by 4 for up to 3 h, 
resulting in final [A]:[CuCl2]:[4] ratios of 1:1:2, 2:1:2, 2:1:1, or 2:2:1. The first condition 
using a 1:1:2 ratio was representative of the concentrations used in the in vitro 
aggregation studies (vide infra), and the resulting Cu(II) binding spectra in the presence 
of A were observed to have similar features as those acquired without peptide present 
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Figure 4.5. Interaction of 4 with Cu(II) in the presence of A40. A solution containing 
A40 (black) was treated with CuCl2 (red) for 2 min followed by 4 (gray) for 3 h (blue). 
The ratios of A40/CuCl2/4 were (a) 1:1:2,  (b) 2:1:2, (c) 2:1:1, and (d) 2:2:1. 
Experimental conditions: [A40] = 10 M; [CuCl2] = 5 or 10 M; [4] = 5, 10, or 20 M; 1% 
v/v DMSO; 20 mM HEPES, pH 7.4, 150 mM NaCl; room temperature. 
 
was presumed that free Cu(II) in solution was minimal.2-5,20 Incubation of 4 with the 
solution of A and Cu(II) produced slight changes in the spectra indicating Cu(II)–4 
complex formation, supporting that this compound can possibly compete with A as a 
ligand for Cu(II). 
 Overall, these investigations demonstrate binding of the catechol-containing 
aminoisoflavone derivatives to Cu(II) and Zn(II). The samples of solutions containing 
Cu(II) and the aminoisoflavones generated a unique optical feature, dominated by a low 
intensity transition bordering on the near-infrared region of the spectrum. This feature 
could correspond to changes in the electronic structure leading to a charge transfer 
process that populates a lower energy transition, as has been observed for different 
ligand frameworks.80 Another possibility is that this feature represents a radical 
intermediate that was generated upon metal binding.79,81,82 It has been well established 




oxidized semiquinone and fully oxidized quinone.81 In the presence of divalent cations 
such as Cu(II), this process might involve concomitant reduction of Cu(II) to Cu(I), while 
forming an oxidized ligand intermediate.72,81,83 In a few cases, however, Cu(II)-
semiquinone complexes have been reported; most of these complexes display are 
relatively colorless (800 ≈ 500 M-1cm-1) and are paramagnetic,79,84 which is consistent 
with our result. To advance the understanding of the Cu(II) binding properties of the 
aminoisoflavones, 4 was used as a model ligand for more detailed spectroscopic 
investigations.  
 First, stability constants (log) and the dissociation constants (Kd) of Cu(II)4 
complexes in solution (1:2 [Cu(II)]/[4], I = 0.1 M, room temperature) were determined 
(Figure 4.6).34,36,38-40,43,44,68,69 Based on the calculated log values, a solution speciation 
diagram was generated and indicated a mixture of Cu(II)4 complexes in 1:1 and 1:2 
Cu(II)/ligand ratios. At pH 7.4, Cu(LH) existed relatively predominantly (ca. 60%; log = 
30.0 ± 0.1; LH represents the monoprotonated form of 4 where the hydroxyl group in the 
para position of the B ring is protonated). There were additional species present at pH 
7.4 such as Cu(L)(LH) (ca. 13%, log = 40.7 ± 0.1) and Cu(LH)2 (ca. 26%, log = 48.4 ± 
0.1). Upon titration, the solution was mainly 1:1 complexes below pH 7 (i.e., Cu(LH2), 
log = 35.8 ± 0.1; Cu(LH3), log = 39.8 ± 0.1; Cu(LH4), log = 42.2 ± 0.7). In addition to 
these species, Cu(L) (log = 19.9 ± 0.3) and Cu(L)2 (log = 31.2 ± 0.3) were used to 
obtain a reasonable fit to the data; however, they accounted for a minor fraction of the 
solution speciation at pH 8. Above pH 9, Cu(L)2 complexes were observed to be the 
main species. From this model, 4 was found to have high binding affinity for Cu(II) 
estimated based on the free Cu(II) concentration measured at a given pH (i.e., pCu = 
−log[Cu(II) unchelated]).34,36,39,40,43,44,68,69 At pH 7.4, which was used for the in vitro 
experiments and is physiologically relevant, the pCu value for 4 was 16.2, suggesting 
an estimated Kd for Cu(II)4 in the femtomolar range.  
In order to minimize the number of ligand components in solution available to 
bind to Cu(II) and to optimize Cu(II) binding, the initial pH of the solution was adjusted to 
8. Although the expected ligand form at this pH is the doubly protonated LH2, upon 
Cu(II) binding the pKa values for the catechol site could be lowered such that both the 




this condition, a mixture of Cu(L)(LH) and Cu(LH) existed; however, there was also a 
minor contribution from Cu(LH)2 and Cu(L)2. These studies demonstrate that the 
aminoisoflavone ligands possessing a catechol moiety are capable of chelating Cu(II) 
showing 1:1 and 1:2 metal/ligand stoichiometry with different protonated ligand forms. 
The Kd value for 4 to Cu(II) was found to be ca. 0.1 fM, which is slightly stronger than 
most reported Kd values for Cu(II)–A peptides (i.e., nanomolar to picomolar) and could 
be used to rationalize the partial chelation of Cu(II) by 4 in the presence of A observed 
by UV-Vis (vide supra).2-5,19,20 Along with the Cu(II) binding studies in the presence of  
 
 
Figure 4.6. Solution speciation studies of Cu(II)4 complexes. Top: Variable-pH UV-Vis 
titration spectra (left) and solution speciation diagram (right) for Cu(II)4 (FCu = fraction 
of species in solution relative to Cu(II)). Bottom: Summary of solution equilibria and 
stability constants (log). Experimental conditions: [CuCl2] = 15 M, [4] = 30 M; pH 8; I 
= 0.1 M NaCl; room temperature. Charges are omitted for clarity. a The error in the last 
digit is shown in parentheses. b Cu(L) was introduced in the calculation to provide the 
best fit to the data, but was shown to constitute a negligible amount to the overall 
solution speciation. 
 
A (Figure 4.5), these data represent that it is possible for 4 and other catechol-
containing aminoisoflavone compounds (e.g., 2, 3) to be competitive ligands for Cu(II) 
with A. Taken together, it might be possible for these ligands to partially sequester 




that generated for the flavonoid EGCG with metal–A species,36,43,54 which may be 
correlated to their ability to modulate metal-induced A aggregation in vitro.  
 
4.2.4. EPR investigations of Cu(II)4 complexes 
As a result of its redox properties, catechol can be oxidized to a semiquinone 
(one electron oxidized form) or quinone (two electron oxidized form), each with 
distinguishable spectral properties.81 In the presence of Cu(II), the deprotonated 
catechol (catecholate) could bind 4 and displayed metal-based EPR spectra. Electron 
transfer from catecholate to Cu(II), however, can yield a Cu(I)semiquinone species that 
would appear as a ligand-based radical by EPR. As described above, Cu(II) binding to 
the aminoisoflavones produced a distinct optical feature at ca. 800 nm, which has been 
observed with other ligand frameworks and could correspond to a Cu(II)-semiquinone 
complex.79,80 Given that several possible species have been reported as outcomes in 
similar reactions, it would be beneficial to characterize the Cu(II)aminoisoflavone 
complexes generated in solution in more detail to better understand their contribution to 
reactivity with metalA species. Thus, the Cu(II) complexes with 4 formed in solution 
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Figure 4.7. EPR spectra of (a) Cu(II)4 and (b) CuSO4. (a) The EPR spectrum from the 
sample of 4 (500 M) treated with CuSO4 (250 M) (top, black); EPR spectrum 
simulated by SpinCount (bottom, gray). (b) The EPR spectrum of the sample of CuSO4 
(250 M) with EDTA (2.5 mM). Experimental conditions: 20 mM HEPES, pH 7.4, 150 
mM NaCl. The spectra were recorded at 77 K with the instrument operating at 9.23 
GHz, microwave power of 20 mW, a modulation frequency of 100 kHz, and a 




All solutions were prepared aerobically in HEPES buffer (20 mM, pH 7.4, 150 
mM NaCl), similar to the UV-Vis metal binding studies (vide supra) and frozen for 
spectral acquisition. A sample of CuSO4 (250 M) with EDTA (2.5 mM) showed a typical 
axial Cu(II) EPR signal (g = 2.053, g// = 2.288, A// = 560 MHz)87,88 (Figure 4.7). Upon 
addition of CuSO4 (250 M) to a solution of 4 (500 M), a spectrum with a well-resolved 
metal-based hyperfine splitting pattern was measured.89 The spectrum was simulated in 
SpinCount with the following parameters: g = 2.046, g// = 2.257, A = 75 MHz, A// = 560 
MHz, sg = 0.005, sg// = 0.01 (Figure 4.7). Solutions frozen at different incubation time 
points over the course of 1 h displayed decreasing EPR intensity, with continued 
increase in the optical feature at 800 nm (data not shown). Due to possible formation of 
EPR detectable ligand-based intermediates with a catechol moiety, a solution of 4 that 
was partially oxidized via bulk electrolysis was investigated. To the solution, ZnCl2 was 
added because Zn(II) has been known to stabilize semiquinone radicals.90,91 When 
measured by EPR, an isotropic peak was observed at g = 1.995, indicating an organic 
radical form. No signal was observed, however, for the oxidized 4 in the absence of 
Zn(II), however, suggesting the generated radicals present in solution might couple to 
produce polymeric species that are EPR silent (Figure 4.8).90 
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Figure 4.8. EPR spectra of partially oxidized 4 in absence (black) and presence (green) 
of ZnCl2. The isotropic peak in (b) of oxidized 4 with Zn(II) was simulated with g = 2.00. 
All samples ([4] = 250 M; [ZnCl2] = 125 M) were prepared in a buffered solution of 20 
mM HEPES, pH 7.4, 150 mM NaCl. The EPR spectra were recorded with the 
instrument operating at 9.23 GHz, microwave power of 20 mW, a modulation frequency 





The features of the EPR spectra from the sample of Cu(II)4 could represent a 
multitude of possible origins, especially owing to the redox properties of the catechol 
metal chelation group, which has an E1/2 of ca. 75 mV versus SCE in 4 (Figure 4.9). In 
the literature, the valence tautomerization of Cu(II)catechol interactions has been 
extensively investigated by Kaim and co-workers.89,92 The spectrum shown in Figure 
4.6is well matched to the reported spectrum for the catecholate form of the 3,5-di-tert-
butoxy-o-benzoquinone complexed with Cu(II).89,93 Reduction of Cu(II) to Cu(I) by the 
ligand to produce a Cu(I)–semiquinone that is not detectable by EPR, is plausible as 
well, which might be responsible for an overall decrease in EPR intensity. A Cu(I)-
semiquinone would be expected to resemble an organic radical by EPR more than 
Cu(II), perhaps producing a spectrum similar to that in the presence of Zn(II) (Figure 
4.8). The EPR spectra, however, do not suggest strong evidence for formation of the 
organic radical. Instead, the hyperfine splitting pattern appears to be mainly Cu(II)-












































Figure 4.9. Cyclic voltammetry of 4. Experimental conditions: [4] = 250 M, 10% v/v 
DMSO; 20 mM HEPES, pH 7.4, 150 mM NaCl; room temperature, 10 mV/s scan rate. 
 
There are several additional scenarios to account for the observed spectra. First, 
it has been suggested that coupling between Cu(II) in solution or the ratio of Cu(II) to 
ligand could reduce the EPR signal intensity in other polyphenolic ligand systems 




Cu(II)catecholate) and prevent it from undergoing oxidation.90 Coupled with the UV-Vis 
spectra of the Cu(II)4 complexes, however, formation of a Cu(II)semiquinone 
complex is supported by the experimental evidence. The Cu(II)–semiquinone complex 
would be EPR silent due to antiferromagnetic coupling between the Cu(II) center and 
semiquinone radical,84,93,95 and this complex typically displays low intensity transitions in 
the near-IR region of the spectrum. Therefore, this proposed intermediate is consistent 
with our results and would afford an overall decrease in EPR intensity with progressive 
generation of the intermediate.79,95 Since the solution speciation studies indicate a 
mixture of 1:1 and 1:2 binding stoichiometries at pH 7.4 (Figure 4.6), it is not surprising 
that the EPR results also reveal the complexity of the solution. As described above, it is 
likely that our solution initially includes a Cu(II)catecholate complex (1:1 or 1:2 Cu(II)/4) 
and over time could become partially oxidized to represent a heterogeneous species 
that containing either Cu(II)–semiquinone (1:1 or 1:2 Cu(II)/ligand) or 
Cu(II)(catecholate)(semiquinone) that is not detectable by EPR but has a spectral 
change by UV-Vis.93 Overall, these investigations provide information on Cu(II) binding 
properties of 4 in detail.  
 
4.2.5. Interaction of aminoisoflavones with A species 
The interaction between aminoisoflavones and A species in solution was 
investigated by isothermal titration calorimetry (ITC), NMR, and docking studies. ITC 
was first used to measure thermodynamic parameters for the interaction of A with 1, 2, 
and 4 (Table 4.1). Using a sequential binding model with one identical site to fit the 
data, these ligands were found to bind to A40 with ca. low mM affinity (KA = (6.8 ± 3.0) x 
104, (7.9 ± 2.9) x 103, and (3.2 ± 0.7) x 103 M-1 for 1, 2, and 4, respectively) and with 
favorable values of Gibbs free energy (G = −27.3 ± 1.1, −22.2 ± 0.9, and −19.9 ± 0.6 
kJ/mol for 1, 2, and 4, respectively) (Table 4.1). Different peptide–ligand interactions, 
however, likely accounted for favorable binding. For 1, which lacks the catechol moiety, 
entropic contributions (−TS = −38.7 ± 1.6 kJ/mol) were greater than enthalphic 
contributions (H  +11.3 ± 1.2 kJ/mol). Conversely, the enthalpic term for 4 is large 




entropy is unfavorable (−TS = +96.4 ± 19.6 kJ/mol). Similar to 4, compound 2 showed 
unfavorable entropic (−TS = +36.9 ± 22.6 kJ/mol) and favorable enthalpic (H = −59.1 
± 22.6 kJ/mol) contributions (Table 4.1). The thermodynamic parameters governing 
these peptidesmall molecule interactions can be related to the variations in their 
chemical structures. Since 1 and 2 or 4 are distinguished by the absence or presence of 
a catechol moiety for metal binding, it is reasonable to expect that they may favor 
dissimilar interactions with the peptide. Compound 1 contains an unsubstituted phenyl 
ring, which might suggest that their interactions are mainly driven by hydrophobic 
interaction with the peptide; these types of interactions usually translate to an increase 
in the entropy as measured by ITC.96 Conversely, 4 would potentially facilitate the 
formation of hydrogen bonding contacts between the molecule and the peptide in 
solution due to the o-dihydroxy groups from the catechol moiety, resulting in favorable 
interaction indicated by the large, negative H value.96 The compound 2, which has a 
catechol group in the B ring but has no functionality on the A ring, presented a similar 
result to 4, suggesting that these molecules interact with A similarly due to the 
presence of the catechol group which facilitates mainly hydrophilic contacts. Despite 
distinctive direct contacts predicted with the peptide for 1 compared to 2 and 4, each of 
these molecules have favorable Gibbs free energy values that could be used to 
rationalize the ability of both of these molecules to modulate metal-free A aggregation 
(vide infra). 
 
Table 4.1. Thermodynamic values for the interaction of 1, 2, and 4 with A40 determined 
by isothermal titration calorimetry (ITC). 
 
 
1 2 4 
KA (M-1) (6.8 ± 3.0) x 104 (7.9 ± 2.9) x 103 (3.2 ± 0.7) x 103 
G (kJ/mol) −27.3 ± 1.1 −22.2  ± 0.9 −19.9  ± 0.6 
H (kJ/mol) 11.3 ± 1.2 −59.2  ± 22.6 −116.3 ± 19.6 





 The ITC results suggest compounds 1, 2, and 4 bind freshly dissolved, low MW 
A40. The mechanism of binding, however, appears to differ with the relative balance of 
enthalpic and entropic contributions to binding for each compound varying depending 
on the presence of the catechol group. Accordingly, the binding of compounds 1 and 4 
to low MW A40 was subjected to further analysis by NMR. Previously, we have shown 
that low MW species in freshly dissolved A40 can adopt a 310 helical structure in the 
central hydrophobic region at moderate ionic strength and low temperature (PDB ID 
2LFM).97 Using similar conditions, we attempted to map the regions of A40 responsible 
for binding the aminoisoflavones. 
 Changes in the SOFAST-HMQC spectra of freshly dissolved A40 upon titration 
with 1 and 4 confirm both species were capable of binding low MW A40 (Figures 4.10 
and 4.11). The chemical shift perturbations were slightly larger for compound 1 (Figures 
4.11a and 4.11b) than 4 (Figures 4.11a and 4.11c), in agreement with the larger free 
energy change upon binding low MW A40 for compound 1 as measured by ITC. 
Moderate (0.02-0.15 ppm on the scaled chemical shift scale) chemical shift 
perturbations were detected for both compounds in two specific regions of the peptide 
near the N-terminus (R5-S8) and the N-terminal part of the 310 helix (H13-L17) (Figure 
4.11a). These two regions are close together in the A40 structure (Figure 4.11d) and 
appear to form a specific binding site for the compounds. A third area of chemical shift 
perturbation is closer to the C-terminus (M35-V40). The chemical shifts near the C-
terminus may reflect either the rearrangement of the disordered C-terminus to pack 
against the aminoisoflavone or may be an indication of a second lower affinity binding 
site. The perturbation of the chemical shifts on specific residues of A40 by 
aminoisoflavones was notably different than what was observed with the related 
catechol EGCG with A40 and -synuclein, where large nearly uniform decreases in 
intensity have been observed suggestive of non-specific binding54,59,98 and indicated 
polyphenols do not have a single uniform mechanism.99 To visualize the potential 
contacts of 1, 2, and 4 with A40, flexible ligand docking studies were employed with the 
solution NMR structure of metal-free A40 (PDB 2LFM) (Figure 4.12).97 The docked 




the peptide, situated nearer to the N-terminus or 310-helix, similar to the chemical shift 
perturbations observed by NMR and similar to previous results obtained with the 
structurally related catechin, EGCG.54 Interaction near the N-terminus of A40 is 
desirable because the residues that bind Cu(II) and Zn(II) exist in this portion of the 
sequence, while interaction with the helical portion of the peptide could be beneficial to 




Figure 4.10. Interaction of 1 and 4 with low MW A40 at near stoichiometric ratios. 
SOFAST-HMQC spectra of 80 M freshly dissolved A40 in 20 mM deuterated Tris (pH 
7.4) with 50 mM NaCl and 10% D2O and titrated with (a) 1 and (b) 4 to the indicated 
molar ratios at 4 °C. Chemical shift perturbations were detected primarily for the amide 
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Figure 4.11. Chemical shift changes in low MW A40 induced by 1 and 4. (a) Chemical 
shift perturbations for A40 in the presence of 1 or 4 (1:2 molar ratio). The normalized 
chemical shift perturbation is equivalent to  . Normalized chemical shift 
perturbations for (b) 1 and (c) 4. (d) Residues with the largest chemical shift 
perturbations mapped onto the NMR structure of low MW A40 (PDB 2LFM). The 
residues with the largest chemical shift perturbations (> 0.02 ppm) are colored red, 




The similarity in the pattern of the chemical shift perturbations suggests 1 and 4 
bind to the same site in A40 (Figure 4.11a). Although the compounds also often 
preferred similar binding modes in the docking studies, there were some slight 
deviations among the results that could support the findings from ITC. For example, 
there were a few instances where 4 was oriented in a more favorable position to 
facilitate hydrogen bonding contacts while in some poses, 1 was more aligned with the 
helical portion of the peptide. Compound 2 could dock in similar positions as both 
ligands, as expected based on its structure, with most poses being situated near the N-
terminus in the area preceding the helical portion of the peptide, similar to the NMR 
results for compounds 1 and 2. Although the overall view of the ligand interactions with 
A40 from NMR and docking are relatively consistent with the ITC results, the magnitude 
of the interactions cannot be completely determined from either technique.  
As noted above, only moderate chemical shift perturbations were detected for 
specific regions of A40 at 1:1 and 1:2 protein-to-ligand molar ratios. At higher 
concentrations of compound 1 (1:5 A40:1), much larger changes in chemical shift were 
observed along with a strong reduction in intensity (Figure 4.13). The changes in 
chemical shift did not appear to match the pattern obtained at lower concentrations of 1, 
although for many residues a definite assignment could not be made. Two new negative 
(folded) broad peaks were also apparent in the SOFAST-HMQC spectra in the side-
chain region of the spectra below 7.5 ppm.  The appearance of a new species at higher 
ligand concentrations was also supported by a strong new peak at 7.64 ppm and three 
weaker doublets at 6.77, 6.83, and 6.89 ppm in the 1H spectrum of the ligand (Figure 
4.14). The intensity changes were not accompanied by the increase in linewidth that 
would be expected for exchange broadening, which suggests some of the peptide was 
lost instead to aggregation. The dramatic changes in the SOFAST-HMQC spectra 
suggest either a global conformational change may have taken place, or compound 1 
may have covalently attached to the peptide through Schiff base formation as has been 
























a −6.4 −6.3 −6.4 
b −5.9 −5.8 −5.9 
c −6.2 −6.2 −6.3 
d −5.8 −5.9 −5.8 
e −5.8 −5.9 −6.0 
f −5.8 −6.0 −5.7 
g −5.7 −5.8 −5.7 
h −6.0 −5.9 −6.0 
i −6.2 −5.9 −6.0  
 
Figure 4.12. Docking studies of 1, 2, and 4 with metal-free A40 (PDB ID 2LFM). Top: 
Cartoon (left) and surface (right) representations of the peptide are depicted with 1 
(pink), 2 (light blue) and 4 (yellow). Bottom: Summary of predicted binding energies for 
the ligands docked with A40. 
 
 


























Figure 4.13. Interaction of low MW A40 with a 5 equiv of 1. SOFAST-HMQC spectra of 
80 M freshly dissolved A40 in 20 mM deuterated Tris (pH 7.4) with 50 mM NaCl and 
10% D2O with a 5 equiv of 1 at 4 ºC. Large chemical shift changes indicate a global 









Figure 4.14. 1H spectra of low MW A40 titrated with 1 and 4. A solution of freshly 
dissolved A40 (80 M) in 20 mM deuterated Tris (pH 7.4) with 50 mM NaCl and 10% 
D2O was titrated with either 1 or 4 to the indicated molar ratios at 4 ºC New peaks at 
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Figure 4.15. Interaction of 1 and 4 with A40 fibrils by STD NMR. (a) STD NMR spectra 
of 1 and 4 at 10:1 ligand to peptide ratio using preassembled A40 amyloid fibrils. A 
comparison of STD signal intensity to the STD reference reflects the relative proximity 
of the corresponding proton to the  A40  fibril.  (b) Normalized STD intensities mapped 
onto each compound’s structure. Larger blue circles indicate a more intense STD effect. 
Note that the hydroxyl and amine protons were not detected by this experiment. 
 
In addition to binding to low MW A40, compounds 1 and 4 may have the 
capability to bind to other forms of A40, such as fibrils. To probe these possible 
interactions, we employed saturation difference (STD) NMR experiments to map the 
regions of the ligand, which bind to preformed fibrils of A40 (Figure 4.15).103 The 
normalized signal strengths (STD/STD reference) corresponding to each ligand atom 
are proportional to its proximity to the amyloid fibril, allowing an atomic-level map of the 
binding interactions from the ligand to the amyloid fibril to be made.103 The results from 
the STD NMR experiments show both 1 and 4 interact fairly strongly (mM to µM 
dissociation constant) with the fibril to elicit a relatively strong STD signal (approximately 
4.5% (compound 1) and 5.9% (compound 4) of the reference signal at a 3 second 
saturation power of 50 dB, similar in magnitude to previous results with other 
catechols103). The STD results show 1 and 4 bind similarly to the amyloid fibril (Figure 
4.15b). The STD effect was distributed relatively evenly throughout both compounds, 
suggesting the entire molecule is packed to some degree against the fibril. In both 
compounds the strongest interaction is at carbon 8 on the A ring, suggesting the ketone 
is pointed away from the fibril in both compounds. While the STD pattern is overall 




the corresponding carbon in compound 1. The increase in this region is an indication 
that the presence of the catechol group causes a reorientation of compound 4 to put the 
B ring in closer contact with the fibril, which may explain the somewhat higher affinity of 
compound 4 over compound 1 for the amyloid fibril. 
 
4.2.6. A aggregation in the absence and presence of aminoisoflavones 
The extent to which the aminoisoflavones could modulate A aggregation in the 
absence and presence of Cu(II) and Zn(II) was investigated.12,35-40,43,44,54,104,105 In the 
inhibition experiment (Figure 4.16), A40 or A42 (10 M) was incubated with or without 
the addition of CuCl2 or ZnCl2 (10 M) along with the aminoisoflavone (20 M) for 24 h 
at 37 °C with constant agitation. For the disaggregation studies (Figure 4.17), A40 or 
A42 (10 M) aggregates were intentionally formed upon 24 h incubation at 37 °C with 
constant agitation in the absence or presence of CuCl2 or ZnCl2 (10 M). The 
aminoisoflavones were then added to the solution of A aggregates for an additional 24 
h. For both studies, gel electrophoresis with Western blotting was used to visualize the 
molecular weight (MW) distribution of the resulting A species and transmission 
electron microscopy (TEM) was employed to detect changes to peptide morphology. 
 In the inhibition experiment, differences in A species distribution were observed 
in the metal-free and Cu(II)- or Zn(II)-containing A samples depending on the 
compound present (Figure 4.16). All of the aminoisoflavones were able to modulate 
metal-free A40 aggregation, as evidenced by a range of sizes visualized in the Western 
blot compared to the control of only A40 (Figure 4.16a, middle). In the presence of 
Cu(II) or Zn(II), however, the reactivity of the aminoisoflavones with A was distinct from 
that with metal-free A40. Both Cu(II)- and Zn(II)-mediated A40 aggregation were 
influenced by 2, 3, and 4, but not by 1. The A species generated with metal ions in the 
presence of 2, 3, and 4 were mainly below 75 kDa (Figure 4.16a, middle), which could 
indicate redirection of A aggregation as has been previously described for 
flavonoids.54,59,99,106,107 A slight difference in the Zn(II)–A40 samples was observed for 2 
compared to 3 and 4, where fewer high MW gel-permeable aggregates were detected 




substituents (i.e., Cl, OH) that are present in the A ring for 3 and 4 on aggregation 
relative to the unsubstituted analogue, 2. Typically, unstructured, amorphous A 
aggregates have been shown to be products the previously reported 
settings.54,59,99,106,107 Similarly, TEM images of the aggregates in the Cu(II)- and Zn(II)-
treated A samples treated with 4 appeared as smaller-sized, amorphous species while 
in the control samples for Cu(II)- and Zn(II)A40, large A aggregates were observed 
(Figure 4.16a, bottom). In contrast, the metal-free A40 sample in the presence of 4 
mainly displayed structured aggregates similar to the control. In addition, there were 
minimal morphological changes to the A aggregates from the samples (metal-free, 
Cu(II), and Zn(II)) treated with 1 compared to the controls suggesting that this 
compound may interact with A and metal–A species differently from 4.  
It is also relevant to consider the reactivity of these ligands with A42, which has 
been suggested to be abundant in the plaques and has been found to aggregate via 
different intermediates than A40.5,7,10,108 Overall, the pattern observed for A42 is 
analogous to those for A40 in the inhibition experiment (Figure 4.16a and b). Metal-free 
A42 aggregation was influenced to a lesser degree by 1 than 2, 3, and 4, which 
presented a modest influence on metal-free A42 aggregation. In the samples containing 
metal ions, 2, 3, and 4 clearly affected the aggregation pathway to a greater extent, 
generating a variety of A species having different MW. The size distribution among 
these samples was almost indistinguishable indicating that all three of the metal binding 
compounds (i.e., 2, 3, and 4) may alter metal-induced A42 aggregation similarly (Figure 
4.16b, middle). Comparison of TEM for the A42 samples treated with 1 and 4 was 
consistent with the gel results. Whereas compound-untreated metal-free A or 
metalA showed relatively structured peptides, mixtures of large, amorphous 
aggregates were observed in samples of metal-free or metal-induced A with 1 or 4, 
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Figure 4.16. Investigation of the ability of aminoisoflavones (1-4) to modulate the 
formation of metal-free and metal-induced A40 and A42 aggregates. Top: Scheme of 
the inhibition experiment. Middle: Analysis of the samples including (a) A40 and (b) 
A42 by gel electrophoresis followed by Western blotting (6E10). Lanes: (C) A± CuCl2 
or ZnCl2 (C = control), (1) C + 1; (2) C + 2; (3) C + 3; (4) C + 4. Bottom: TEM images of 
samples with 1 or 4 for (a) A40 and (b) A42. Experimental conditions: [A40 or A42] = 
10 M; [CuCl2 or ZnCl2] = 10 M; [aminoisoflavone] = 20 M; 1% v/v DMSO; 20 mM 
HEPES, pH 7.4, 150 mM NaCl; 24 h; 37 °C; agitation. 
 
The aminoisoflavones were also evaluated with preformed metal-free and metal-
associated A40 or A42 aggregates to determine whether they could transform 
structurally ordered peptide species (Figure 4.17). Similar to the inhibition results, a 
slight interaction between 1 or 3 but not 2 or 4 and metal-free A40 aggregates was 
observed; however, A aggregates formed in the presence of Cu(II) or Zn(II) produced 
a wide range of sizes when incubated with 2, 3, and 4 (Figure 4.17a, middle). In 
contrast to the inhibition experiment, a portion of gel permeable species with high MW 
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Figure 4.17. Disassembly of metal-free and metal-associated A40 and A42 aggregates 
by aminoisoflavones. Top: Scheme of the disaggregation experiment. Middle: Analysis 
of the samples containing (a) A40 and (b) A42 by gel electrophoresis followed by 
Western blotting (6E10). Lanes: (C) A± CuCl2 or ZnCl2, (1) C + 1, (2) C + 2, (3) C + 3, 
(4) C + 4. Bottom: TEM images of samples with 1 or 4 for (a) A40 and (b) A42. 
Experimental conditions: [A40 or A42] = 10 M; [CuCl2 or ZnCl2] = 10 M; 
[aminoisoflavone] = 20 M; 1% v/v DMSO; 20 mM HEPES, pH 7.4, 150 mM NaCl; 24 h; 
37 °C; agitation. 
 
unable to inhibit aggregation (Figure 4.16a), this slight difference for the disaggregation 
results suggests this compound may interact with folded peptides, allowing it to partially 
promote disaggregation for preformed Cu(II)A40 species (Figure 4.17a). Different from 
1, metal chelation via the catechol moiety in 2, 3, and 4 likely plays a role in redirecting 
preformed metal–A aggregates. As with the inhibition experiments using metal-
associated A40, there is a subtle difference in the MW distribution of the metal–A 
disaggregation samples depending on the substituents present in 2, 3, or 4. For 




or 4, compared to 2, which could arise from presence of the Cl or OH groups (Figure 
4.11a). The TEM images from the disaggregation samples showed a mixture of large 
and small aggregates for metal-free A40 in the presence of 1 and 4 (Figure 4.17a, 
bottom). For the samples of metalA species incubated with the compounds, their 
morphologies were less ordered and smaller in size compared to those of the controls. 
Finally, in the case of A42, it is challenging to discern which compounds were most 
efficacious against the pregenerated A aggregates. In the samples of metal-free A42 
and metalA42, various sizes of aggregates were detected throughout the entire gel 
matrix. TEM images of these samples also revealed the heterogeneity of the 
conformations with and without 1 or 4 (Figure 4.17b, bottom).  
For comparison, the methoxylated precursors of 1, 2, and 4 (i.e., 1a, 2a, and 4a, 
respectively; Scheme 4.1 for structures) were studied analogously in the inhibition and 
disaggregation experiments (Figure 4.18). Different from the demethoxylated molecules 
(1-4) described above, a minimal effect on only Cu(II)–A40 was observed upon 
incubation with 1a, 2a, and 4a based on the patterns of MW distribution compared to 
those of the corresponding inhibition and disaggregation controls. In all scenarios, 
Zn(II)-mediated A aggregation was unaffected by 1a, 2a, and 4a, and overall their 
reactivity with metal-free and Cu(II)A samples was also reduced noticeably compared 
to 1, 2, and 4. Thus, the catechol group for metal chelation, which has a high affinity for 
Cu(II) and could be capable of interacting with the peptide via hydrogen bonding based 
on ITC, NMR, and docking investigations, is suggested to be equally valuable for 
imparting proper metal/A binding interactions.  
Taken together, these results reveal the scope of flavonoid derivatives that can 
be used to modulate metal-free and metal-induced A aggregation and validate the 
requirement for sufficient metal binding and A interaction properties to suitably 
influence this reactivity. The inhibition results indicated aminoisoflavones may interact 
with metal-free and metal–A species in a manner similar to other flavonoids like 
EGCG, which can target metal-free and metal-induced A40 aggregation in vitro to 
different extents, although the MW distribution of A achieved by the aminoisoflavones 
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Figure 4.18. Inhibition and disaggregation experiments employing methoxylated 
aminoisoflavone precursors (1a, 2a, and 4a). Top: Structures of 1a (2-amino-7-
methoxy-3-phenyl-4H-chromen-4-one), 2a (2-amino-3-(3,4-dimethoxyphenyl)-4H-chro- 
men-4-one), and 4a (2-amino-3-(3,4-dimethoxyphenyl)-7-methoxy-4H-chromen-4-one). 
Analysis of inhibition (middle) and disaggregation (bottom) samples with A40 and A42 
by gel electrophoresis followed by Western blotting (6E10). (1) A± CuCl2 or ZnCl2, (2) 
1 + 1a, (3) 1 + 2a, (4) 1 + 4a. Experimental conditions: [A40 or A42] = 10 M; [CuCl2 or 
ZnCl2] = 10 M; [aminoisoflavone] = 20 M; 1% v/v DMSO; 20 mM HEPES, pH 7.4, 150 







it from inhibiting metal-induced A aggregation, but did allow for alteration of metal-free 
A aggregation. For Cu(II)- and Zn(II)-treated A samples, there were slight differences 
in the A distribution between the samples containing the different metal ions, which 
could be the result of altered peptide conformations or metalligand binding 
modes/affinity.5,109 In the case of disaggregation, the presence of a chelating group (i.e., 
catechol) in 2, 3, and 4 was required to significantly affect the distribution of A species 
in the presence of Cu(II) and/or Zn(II). To account for the reactivity in the inhibition and 
disaggregation experiments, insights from the studies of the solution speciation of 
Cu(II)–4 complexes (vide supra) could be cited. Based on these data, which indicated a 
high Kd value for Cu(II), it is possible that reactivity of the aminoisoflavones with metal–
A species could occur as a result of Cu(II) being partially sequestered from the metal-
bound peptide or obstructed from binding. Either of these possibilities might be involved 
in redirecting A aggregation in the inhibition experiment or facilitating A aggregate 
disassembly in the disaggregation experiment.36,43,54 Furthermore, the differing reactivity 
between metal-free and metal-associated A in vitro supports that metalA species 
could have a potentially relevant role in vivo, which can be investigated with small 
molecules. 
 
4.2.7. Antioxidant properties 
The antioxidant property of flavonoids has been investigated110-112 and structural 
similarity of aminoisoflavones to these compounds suggests this property. To 
investigate free radical scavenging and ROS quenching properties for the 
aminoisoflavone compounds, the Trolox antioxidant equivalence capacity (TEAC) assay 
and horseradish peroxidase (HRP)/Amplex Red assays, respectively, were employed 
(Figures 4.19 and 4.20).110 Compared to the vitamin E analogue Trolox, 3 was 2.60 ± 
0.06 times more effective to quench the radical (ABTS•+) radical. 2 and 4 could also 
reduce the amount of the radical in solution to a similar extent as Trolox. Among the 
aminoisoflavones, 1 showed the lowest TEAC value suggesting its limited utility as an 
antioxidant. Structurally, the most likely antioxidants among these molecules contain the 
catechol moiety and may be able to support the resulting ligand intermediate (e.g., 




absence of the catechol moiety in 1 may preclude its formation of a stable intermediate 
upon interacting with ABTS•+.110 To account for their lower TEAC value compared to 3, 
the possibility for a greater number of resonance forms of 2 and 4, which would possibly 
stabilize the structures and make them less capable of hydrogen atom donation, could 
be cited.110 Additionally, the Cl atom in 3 might be susceptible to radical generation that 
could also quench the ABTS•+. 
 



















Figure 4.19. Radical scavenging ability of aminoisoflavones (1-4) determined by the 
Trolox equivalence antioxidant capacity (TEAC) assay. TEAC values are calculated 
relative to Trolox, a vitamin E analogue, after 15 min incubation and represent the mean 
of four independent experiments. The experimental details are described in the main 
text. 
 
In AD, the generation of organic radicals as a secondary effect of A aggregation 
or another aspect of pathology might contribute to neurotoxicity,2,3,5,17 making the 
discovery of molecules to intercept such species desirable. From our studies, some of 
aminoisoflavones may be able to scavenge radicals leading to neuroprotection. 
Considering this property, their possible regulation of ROS is also of interest. Although 
flavonoid structures, including the aminoisoflavones, have been demonstrated as 
antioxidants, these properties do not necessarily correlate to control of ROS production. 
As redox active ligands, flavonoids can also participate in generation of ROS (i.e., pro-
oxidant). Furthermore, it has been suggested that Cu(II)A species may be capable of 
producing elevated amounts of ROS, which would lead to oxidative stress in the AD 




(Figure 4.20), Cu(II)A in the presence of a reducing agent produced a baseline 
amount of H2O2. This amount was lowered by the addition of EDTA, a strong Cu(II) 
chelator. With a considerably high binding affinity for Cu(II), it might be possible for the 
aminoisoflavones to sequester Cu(II) in a similar manner and eliminate the redox 
cycling of Cu(II/I) that produces ROS via the Fenton reaction. According to the results, 
addition of each aminoisoflavone to the reaction enhanced H2O2 generation by ca. 10-
30%, while EDTA lowered the amount of H2O2 by ca. 60% relative to Cu(II)A only. 
 
 
Figure 4.20. H2O2 production in the presence of A40, Cu(II), and ligands. Experimental 
conditions: [A40] = 200 nM, [CuCl2] = 400 nM, [ligand] = 800 nM, [ascorbate] = 10 M, 
[HRP] = 1 U/mL, [Amplex Red] = 50 M, room temperature. 
 
For 1, it would be expected to be unable to mitigate H2O2 production due to its lack of 
Cu(II) chelation structure. For 2, 3, and 4, Cu(II) binding to the catechol moiety has been 
suggested to facilitate oxidation of the ligand, which produces H2O2 as a byproduct in 
the reaction. Therefore, despite having an ability to scavenge organic free radicals that 
was demonstrated by the TEAC assay, these frameworks are also capable of 
enhancing ROS production, which might limit their utility as therapeutics for AD, which is 
characterized by its enhanced oxidative stress. 
 
4.2.8. Cell viability studies 
The ability of 1-4 to mediate toxicity induced by metal-free and metal-treated A 
species was probed in human neuroblastoma SK-N-AS (AS) and SK-N-BE(2)-M17 




4.23).12,35,36,38,39,43,44,54 First, the compounds were incubated with the cells in the 
absence and presence of CuCl2 or ZnCl2 in a 1:2 metal/ligand ratio. In the AS cell line 
all four compounds were relatively non-toxic with ca. 100% cell viability after 24 h 
(Figure 4.21a). When the cells were treated with 0.5 equiv CuCl2 or ZnCl2 in addition to 
the ligand, the cells were relatively unaffected; they maintained viability at or near 100% 
following 24 h treatment. Upon incubation in AS cells for 72 h, cell viability of the 
aminoisoflavones in the absence of externally added metal ions was reduced by ca. 
20% and cells treated with CuCl2 or ZnCl2 and the aminoisoflavones alone during this 
time indicated similar levels of survival (Figure 4.21b). All four compounds were 
relatively non-toxic in the AS with ca. 90-100% cells survival after 24 h (Figure 4.22). 
Subsequently, cell viability upon incubation of 1-4 with metal-free or metal-treated A40 
or A42 was analyzed (Figure 4.23). The cells were treated with A40 or A42 (5 M) and 
either no metal, CuCl2 (5 M), or ZnCl2 (5 M), followed by 1 or 2 equiv of the 
aminoisoflavone. Under this condition, the aminoisoflavones presented minimal toxicity 
in the absence and presence of the metal ions. With this low concentration of A, ca. 
80-90% cell survival was measured for the metal-free and Cu(II)- or Zn(II)-treated A 
species (Figure 4.23). With 1 equiv of compound present, the aminoisoflavones had a 
modest influence on cell survival for A40 (Figure 4.23a). Addition of 2 equiv of 
compound resulted in moderate enhancement of cell viability for 2, 3, and 4 for all 
conditions, while 1 had a minimal effect on the A40-treated cells in the absence or 
presence of metal ions (Figure 4.23a). A similar trend was observed for cells treated 
with A42; 2 equiv of compound more noticeably attenuated toxicity than 1 equiv (Figure 
4.23b). These cell studies support that the aminoisoflavone framework is potentially 
useful for applications in biological settings. In particular, the aminoisoflavones 
containing the catechol moiety could mediate toxicity from metal-free or metal-
associated A species in heterogeneous environments (i.e., cells), similar to the 








Figure 4.21. Cell viability for aminoisoflavones in the absence and presence of CuCl2 or 
ZnCl2 in human neuroblastoma SK-N-AS cells following (a) 24 h or (b) 72 h incubation. 
Cells were treated with various concentrations of aminoisoflavones (top), a 1:2 ratio of 
CuCl2/aminoisoflavone (middle) or a 1:2 ratio of ZnCl2/aminoisoflavone (bottom). Error 
bars represent the standard error for three independent experiments. Cell viability is 








Figure 4.22. Cell viability for aminoisoflavones in the absence and presence of CuCl2 or 
ZnCl2 in human neuroblastoma SK-N-BE(2)-M17 cells following 24 h incubation. Cells 
were treated with various concentrations of aminoisoflavones (top), a 1:2 ratio of 
CuCl2/aminoisoflavone (middle) or a 1:2 ratio of ZnCl2/aminoisoflavone (bottom). Error 
bars represent the standard error for three independent experiments. Cell viability is 
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Figure 4.23. Influence of aminoisoflavones on SK-N-BE(2)-M17 (M17) cell viability in 
the presence of metal-free and metal-associated A40 and A42. M17 cells were treated 
with A (5 M) followed by CuCl2 or ZnCl2 (5 M) and 1 or 2 equiv 1, 2, 3, or 4. Error 
bars represent the standard error for three independent experiments. Cell viability is 






4.2.9. Blood-brain barrier (BBB) permeability 
Consideration of potential for brain uptake is valuable when planning to apply a 
compound to applications in the brain. Recommended properties for diffusion across the 
BBB are derived from modified parameters applied to drug-like molecule design (i.e., 
Lipinski’s rules) and calculated logBB value.113,114 The restricted terms of Lipinski’s rules 
dictate that molecules for brain applications would generally adhere to having a 
molecular weight (MW) ≤ 450 g/mol, calculated logarithm of the octanol-water partition 
coefficient (clogP) ≤ 5, number of hydrogen bond donors (HBD) ≤ 5 and hydrogen bond 
acceptors ≤ 10, and polar surface area (PSA) ≤ 90 Å2.113 The logBB calculation 
estimates the expected permeability based on an equation that uses the clogP value 
and PSA; values ≤ −1.00 are expected to have poor diffusion.114 Most naturally 
occurring flavonoids poorly obey to these parameters and would not be expected to 
diffuse across the blood-brain barrier.  
Among the aminoisoflavones, 1 observes all of Lipinski’s rules and has a logBB 
value of −0.74. 2, 3, and 4 have additional HBD and HBA from the catechol group, 
which are still within the parameters; however, the PSA of these three molecules is 
above 90 Å2, leading to a logBB value below −1.00. Lipinski’s rules quantify parameters 
that tend to govern lipophilic molecules, but the solution speciation of the ligands can 
also suggest the likelihood of BBB permeability. Uncharged species are generally more 
permeable, so it would be expected that 1, 2, and 3 might be able to diffuse across the 
BBB given their neutral form dominating the solution speciation at pH 7.4 (Figure 4.2). 
Compound 4 is monodeprotonated and therefore should have more difficulty in entering 
the brain by diffusion. Using an in vitro parallel artificial membrane permeability assay 
for the blood-brain barrier (PAMPA-BBB), the likely in vivo activity can be predicted 
(Table 4.2). According the results of this assay, which employs an artificial lipid 
membrane to mimic the BBB, the −logPe values ranged from 6.13–6.57. Molecules with 
a known ability to enter the brain generally have a −logPe below 5.4. Therefore, despite 
adhering to most of Lipinski’s rules, these molecules may be too polar to passively 
diffuse across the BBB. Thus, to apply these molecules in further studies, minor 











MW HBD HBA PSA (Å2) clogP logBB
1 6.15 ± 0.08 30 CNS− 253 3 4 76.5 1.71 −0.74
2 6.37 ± 0.06 26 CNS− 269 4 5 96.7 1.03 −1.14
3 6.13 ± 0.07 25 CNS− 304 4 5 96.7 1.82 −1.02
4 6.57 ± 0.08 15 CNS− 285 5 6 117 0.45 −1.53
CNS+       −logPe < ~5.4                      (High BBB permeation predicted)
CNS− −logPe > ~5.7                     (Low BBB permeation predicted)
CNS+/−      5.7 > −logPe > 5.4              (BBB permeation uncertain)
 
a Molecular weight (MW), hydrogen bond donors (HBD), hydrogen bond acceptors 
(HBA), polar surface area (PSA), calculated log of the octanol-water partition coefficient 
(clogP), logBB = −0.0148 x PSA + 0.152 x clogP +0.130, n = number of replicates. 
 
4.3. Conclusion 
Advancement in AD research field has been challenged by the lack of cohesive 
evidence to explain the origins of the disease. It is becoming more accepted that 
formerly competing hypotheses may be intertwined, requiring novel approaches to 
investigate these relationships. To target the combined metal-amyloid hypothesis of AD, 
efforts to make molecules with multiple functions (i.e., metal chelation, A interaction) 
have been ongoing. New frameworks for this purpose are of perpetual interest, with 
hopes of devising a comprehensive structure-interaction-reactivity relationship to govern 
design of new chemical tools and/or therapeutics. The flavonoid framework has been 
identified as a potential avenue for growth of this field, as many flavonoids inherently 
have structural components for interacting with metal ions and A.12,54 The multiple 
naturally occurring structural derivations within flavonoids and relative ease of synthetic 
manipulation have also made them an attractive class of molecules to pursue. Moving 
toward identification of a suitable flavonoid family that can be easily adapted to tune the 




aggregation pathways, the aminoisoflavones (1-4) were designed and synthesized. The 
molecules, 2, 3, and 4 are composed of a catechol group for metal chelation, while 1 
lacks this moiety. Their Cu(II) and Zn(II) binding properties were characterized, and 
detailed spectroscopic investigations the Cu(II)4 complexes were conducted showing 
high binding affinity for Cu(II) and the presence of a mixture of possible Cu(II) 
complexes in solution (e.g., Cu(II)semiquinone, Cu(II)catecholate). Interaction of the 
aminoisoflavones with metal-free A was investigated by ITC, NMR, and docking 
studies implying that these compounds may be able to interact with the peptide through 
multiple binding modes; however, a defined binding site was observed for the 
aminoisoflavones with A in contrast to non-specific binding previously suggested for 
flavonoid derivatives. The independent abilities of these molecules to target metal ions 
and A were translated to their ability to control A40 and A42 aggregation in the 
absence and presence of metal ions in vitro. In particular, the inclusion of the catechol 
group was required to achieve a balance in interaction with metal ions and/or A to 
influence A aggregate formation or disassembly for preformed Aaggregates when 
metal ions are absent or present. The catechol group also seems to offer other 
potentially useful biological properties, such as antioxidant behavior and improved cell 
viability.63,64,72 To uncover more nuances of the structure-interaction-reactivity 
relationship, studies using a larger chemical library developed through further structural 
modification of the aminoisoflavones will be required (e.g., whether removal of NH2 
group influences reactivity). In the present study, the flavonoid framework was 
successfully applied to a synthetic design strategy in which minimal structural 
components were chosen and could facilitate the ability of the compounds to target 
metal-free and metal-associated A species and regulate their reactivity. The catechol 
moiety in this framework in combination with the unnatural primary amine imparts 
noticeable properties for interaction and reactivity with metals, A, and/or metalA(i.e., 
metal chelation, hydrophilic and hydrophobic contacts with peptide species) while 
additional functional groups (e.g., OH, Cl) did not significantly perturb these properties. 
Thus, this work demonstrates that flavonoids can be manipulated into simple structures 




vitro reactivity of metal-free and metal–A species, which offers preliminary insights on 
the structure-interaction-reactivity relationship for flavonoid structures with A and 
metalAspecies. 
 
4.4. Experimental  
 
4.4.1. Materials and methods 
All reagents and solvents were commercially available and used as received 
unless otherwise stated. The compounds 2-amino-7-hydroxy-3-phenyl-4H-chromen-4-
one (1), 2-amino-3-(3,4-dihydroxyphenyl)-4H-chromen-4-one (2), 2-amino-6-chloro-3-
(3,4-dihydroxyphenyl)-4H-chromen-4-one (3), and 2-amino-3-(3,4-dihydroxyphenyl)-7-
hydroxy-4H-chromen-4-one (4) were synthesized from the previously reported 
compounds (1a-4a) (Scheme 4.1).61,62 The 1H and 13C nuclear magnetic resonance 
(NMR) spectra of these molecules were recorded on a Varian Inova 500 spectrometer 
(Palo Alto, CA, USA) in DMSO-d6. Infrared (IR) spectra were measured on a Bruker 
Vector 22 spectrophotometer (Billerica, MA, USA). High-resolution mass spectra were 
obtained on an Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS (Santa Clara, 
CA, USA). Crude compounds (1-4) were purified by preparative reverse-phase HPLC 
(Waters Delta Prep 4000 system with Waters Prep LC 40 mm Assembly column C18 
(30 cm x 4 cm, 15 m particle), Milford, MA, USA) and eluted at a flow rate of 20 
mL/min with mobile phase solvent A (10% CH3CN + 0.1% trifluoroacetic acid (TFA) in 
H2O, v/v), and a linear gradient from 0 to 50% B (60%, CH3CN + 0.1% TFA in H2O, v/v) 
in 25 min. Analytical HPLC analyses were performed with a Beckman System Gold 
(Beckman Ultrasphere ODS column, 250 mm x 4.6 mm, 5 m particle, Brea, CA, USA). 
Analytical determinations of the products were carried out by HPLC in solvents A and B 
programmed at flow rate of 1 mL/min with linear gradients from 0 to 100% B in 25 min. 
A40 and A42 were purchased from AnaSpec (Fremont, CA, USA) (A42 = 
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA). An Agilent 8453 UV-
Visible (UV-Vis) spectrophotometer (Santa Clara, CA, USA) was used to measure the 
optical spectra. Electron paramagnetic resonance (EPR) spectroscopy was conducted 




liquid nitrogen cryostat. Electrochemical studies were obtained by a CH1000A 
Electrochemical Analyzer (CH Instruments, Inc., Austin, TX, USA). Isothermal 
calorimetric titrations were performed using a VP isothermal titration calorimeter 
(MicroCal, Northampton, MA, USA). Transmission electron microscopy (TEM) images 
were recorded on a Philips CM-100 transmission electron microscope in the Microscopy 
and Imaging Laboratory at the University of Michigan (Ann Arbor, MI, USA). A Molecular 
Devices SpectraMax M5 microplate reader (Sunnyvale, CA, USA) was employed for the 
measurement of absorbance for Trolox equivalence antioxidant capacity (TEAC) and 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays.  
 
4.4.2. General procedure for the preparation of hydroxylated 2-amino-3-aryl-4H-
chromen-4-ones (1-4) 
To a solution of the corresponding methoxylated 2-amino-3-aryl-4H-chromen-4-
one precursor (1a-4a, 1 mmol)62 in acetic acid (2.5 mL) and acetic anhydride (2.5 mL), 
57% v/v hydroiodic acid (5 mL) was added dropwise (Scheme 4.1). The mixture was 
refluxed for 6 h. After solvent evaporation in vacuo, water (10 mL) was added to the 
residue; the solid obtained was filtered and washed with water (2 x 5 mL) (76-86% 
yield). Each compound was purified by preparative reverse-phase HPLC as described 
above. 
2-Amino-7-hydroxy-3-phenyl-4H-chromen-4-one (1). Yield: 192 mg, 0.76 mmol, 
76%. EtOAc:Hx = 1:1; Rf = 0.56 (TLC). 1H NMR (500 MHz, DMSO-d6)/δ (ppm): 6.84 (s, 
1H, Ar), 6.95 (d, J = 8.5 Hz, 1H, Ar), 7.44 (m, 5H, Ar and NH2), 7.54 (m, 2H, Ar), 7.94 (d, 
J = 8.5 Hz, 1H, Ar), 10.58 (brs, 1H, OH). 13C NMR (125 MHz, DMSO-d6)/δ (ppm): 170.6, 
164.1, 162.4, 154.4, 132.1, 131.7, 129.2, 128.0, 127.0, 114.5, 113.1, 102.1, 99.2. 
HRMS (ESI+): Calcd for C15H11NO3 [M+H]+, 254.0817; found, 254.0863. IR (Nujol)/ 
(cm-1): 3465, 3319, 1628, 1603. 
 2-Amino-3-(3,4-dihydroxyphenyl)-4H-chromen-4-one (2). Yield: 221 mg, 0.82 
mmol, 82%. EtOAc:Hx = 1:1; Rf = 0.51 (TLC). 1H NMR (500 MHz, DMSO-d6)/δ (ppm): 
6.67 (m, 1H, Ar), 6.81 (s, 1H, Ar), 6.90 (m, 1H, Ar), 7.04 (s, 2H, NH2), 7.48 (m, 2H, Ar), 
7.73 (m, 1H, Ar), 7.94 (d, J = 8.5 Hz, 2H, Ar), 8.88 (s, 1H, OH), 8.94 (s, 1H, OH). 13C 




124.8, 124.4, 123.5, 122.4, 119.1, 116.8, 116.3, 99.7. HRMS (ESI+): Calcd for 
C15H11NO4 [M+H]+, 270.0766; found, 270.0765. IR (Nujol)/ (cm-1): 3453, 3165, 1642, 
1601. 
2-Amino-3-(3,4-dihydroxyphenyl)-6-chloro-4H-chromen-4-one (3). Yield: 261 mg, 
0.86 mmol, 86%. EtOAc:Hx = 1:1; Rf =  0.48 (TLC). 1H NMR (500 MHz, DMSO-d6)/δ 
(ppm): 6.67 (s, 1H, Ar), 6.81 (s, 1H, Ar), 6.88 (m, 1H, Ar), 7.22 (s, 2H, NH2), 7.55 (m, 
1H, Ar), 7.76 (m, 1H, Ar), 7.98 (s, 1H, Ar), 8.91 (s, 1H, OH), 8.95 (s, 1H, OH). 13C NMR 
(125 MHz, DMSO-d6)/δ (ppm): 168.9, 164.7, 151.1, 145.9, 145.6, 132.9, 129.7, 124.4, 
122.7, 122.4, 122.0, 119.3, 118.8, 116.6, 101.3. HRMS (ESI+): Calcd. for C15H10ClNO4 
[M+H]+, 304.0377; found, 304.0368. IR (Nujol)/ (cm-1): 3420, 3311, 1644, 1598. 
2-Amino-3-(3,4-dihydroxyphenyl)-7-hydroxy-4H-chromen-4-one (4). Yield: 228 
mg, 0.80 mmol, 80%. EtOAc:Hx = 1:1; Rf =  0.53 (TLC). 1H NMR (500 MHz, DMSO-
d6)/δ (ppm): 6.66 (m, 1H, Ar), 6.82 (m, 1H, Ar), 6.89 (m, 1H, Ar), 6.95 (m, 1H, Ar), 7.33 
(s, 2H, NH2), 7.76 (m, 1H, Ar), 7.93 (s, 1H, Ar), 8.87 (s, 1H, OH), 8.90 (s, 1H, OH), 
10.67 (brs, 1H, OH). 13C NMR (125 MHz, DMSO-d6)/δ (ppm): 170.5, 164.4, 162.1, 
154.2, 145.8, 145.4, 126.9, 122.6, 119.0, 116.5, 114.4, 113.2, 102.0, 99.4. HRMS 
(ESI+): Calcd. for C15H11NO5 [M+H]+ 286.0715; found, 286.0706. IR (Nujol)/ (cm-1): 
3419, 3327, 1631, 1609. 
 
4.4.3. Determination of solution speciation from acidity constants for 
aminoisoflavones and stability constants for Cu(II)4 complexes 
The acidity constants (pKa) for 1-4 were determined by spectrophotometric 
variable-pH titrations with modifications to the previously described methods.34,36-40,42-
44,68,69 A solution (10 mM NaOH, 100 mM NaCl, pH 12) containing 1 (30 M) was 
titrated with small aliquots of HCl to acquire at least 30 spectra in the range from pH 
1.5-12. Solutions of 2 (20 M), 3 (15 M), and 4 (30 M) in 200 mM HCl, 100 mM NaCl, 
pH 0.6 were titrated with small aliquots of NaOH and at least 30 spectra were acquired 
from pH 0.6-12.4. To measure the stability constants (log) for the Cu(II)4 complexes, 
4 (30 M) and CuCl2 in a ratio of 2:1 were added to a solution (10 mM NaOH, 100 mM 
NaOH) at pH 8. Following overnight incubation, the solution was titrated with small 




using the program HypSpec (Protonic Software, UK).115 Speciation diagrams were 
generated from the calculated values by the program HySS2009 (Protonic Software, 
UK).116 
 
4.4.4. Metal binding studies 
The ability of the aminoisoflavones to bind to Cu(II) or Zn(II) was investigated by 
UV-Vis in the absence and presence of A40.12,35-40,43,44,54,68,104 A solution of the 
aminoisoflavone (20 M, 1% v/v DMSO) in 20 mM HEPES [4-(2-hydroxyethyl)-1-
piperazineethane sulfonic acid], pH 7.4, 150 mM NaCl was incubated with 0.5-5 equiv 
CuCl2 for up to 2 h. Additionally, the interaction of 4 with CuCl2 in the presence of A40 
was also studied by measuring changes in the optical spectra. In the same buffered 
solution, A (10 M) was pre-incubated with CuCl2 (5 or 10 M) for 2 min, followed by 
the addition of 0.5, 1, or 2 equiv of 4. The Cu(II)–A solution was incubated with 4 at 
room temperature for up to 3 h. To determine Zn(II) binding properties, a solution of 100 
M aminoisoflavone in 20 mM HEPES, pH 7.4, 150 mM NaCl was incubated with ZnCl2 
(10 M) for 12-24 h and monitored by UV-Vis.   
 
4.4.5. Electron paramagnetic resonance (EPR) investigations of Cu(II)4 
complexes 
Samples were prepared for solutions in 20 mM HEPES, pH 7.4, 150 mM NaCl. 
Compound 4 (0.5 mM, 10% v/v DMSO) was incubated with CuSO4 (0.25 mM) and 
aliquots (350 L) of the solution were flash-frozen in liquid nitrogen after 0, 5, 30, and 60 
min. The buffer only or 4 only was prepared in the same buffered conditions and flash-
frozen in liquid nitrogen (350 L). Following partial electrochemical oxidation of 4 (250 
M, 10% v/v DMSO), a sample without or with ZnCl2 (125 M) in the same buffer was 
flash-frozen in liquid nitrogen. Finally, an EPR sample of CuSO4 (0.25 mM) and EDTA 
(2.5 mM, EDTA: 2-((2-[bis(carboxymethyl)amino]-ethyl)(carboxymethyl)amino)acetic 
acid) was prepared in the same buffer and flash-frozen in liquid nitrogen for the EPR 
measurement as a Cu(II) reference. The magnetic field was calibrated to the spectrum 




Aldrich, St. Louis, MO, USA) (gexpected = 2.00; gfound = 1.99). Spectra were collected at 77 
K with a modulation frequency of 100 kHz, microwave power of 20 mW, and modulation 
amplitude of 5 G. Simulations of EPR spectra were performed using SpinCount 
(Professor Michael Hendrich, Carnegie Mellon University, Pittsburgh, PA, USA). 
 
4.4.6. Electrochemistry of 4 
Cyclic voltammograms of 4 (250 M, 10% v/v DMSO) in the absence and 
presence of Cu(II) (125 M) were obtained at a scan rate of 10 mV/s in buffer (20 mM 
HEPES, pH 7.4, 150 mM NaCl). A three-electrode system consisting of glassy carbon 
as the working electrode, a Pt wire as the counter electrode, and the saturated calomel 
electrode (SCE) as the reference electrode was employed.117,118 For experiments in the 
absence of air, solutions were purged with N2 and experiments were conducted in a 
glove box. In a two component cell, bulk electrolysis was conducted on a solution of 4 
(250 M, 10% v/v DMSO) by applying 200 mV to the solution for ca. 1000 s to partially 
oxidize the ligand for EPR experiments (vide supra). A three-electrode system was used 
with a carbon mesh as the working electrode along with SCE as the reference in the 
ligand solution; a Pt wire was used as the counter electrode in the solution of only 
buffer. 
 
4.4.7. Isothermal titration calorimetry (ITC) for measurement of thermodynamic 
parameters for the interaction of 1, 2, or 4 with A 
Experiments were conducted with solutions of 1, 2, or 4 (200 M, 10% v/v 
DMSO) and A40 (20 M) in 20 mM HEPES buffer (pH 7.4, 150 mM NaCl).44 All 
solutions were degassed for 10 min before each titration. The ligand solution (10 L) 
was titrated into the A40 solution (1.43 mL) at 25 C over 1 s with 25 repetitions at a 
constant interval of 200 s via a 310 rpm rotating stirrer syringe using a motor driven 250 
L syringe. In a control experiment, the identical titrant solution was injected into the 
same buffer used with A40 to measure the heat of dilution. A reasonable heat of 
binding value was measured by subtracting the heat of dilution value from the 




software. The KA (binding constant) of each ligand and ΔH (binding heat exchange) 
upon binding interaction between each ligand and A40 were determined from a proper 
fitting model. The binding curves were best fit to a sequential binding site model with 
one identical site. ΔG and −TΔS were calculated via Gibb’s free energy relationship (ΔG 
= ΔH – TΔS; ΔG = −RTln(KA)). 
 
4.4.8. Docking studies of aminoisoflavones against A40 monomer 
Flexible ligand docking studies using AutoDock Vina119 using aminoisoflavones 
were conducted against the A40 monomer from the previously determined aqueous 
solution NMR structure (PDB 2LFM).97 Representative conformations were selected for 
docking from those within the PDB file (1, 3, 8, 10, 12, 13, 16, 17, 20 for 2LFM). The 
MMFF94 energy minimization in ChemBio3D Ultra 11.0 was used to optimize the 
structure of aminoisoflavones for the docking studies. Individual structures of Aand 
aminoisoflavones were prepared in AutoDock Tools.120 The search space was 
constrained to the dimensions of the peptide. The exhaustiveness for the docking runs 
was set at 1024. Docked models of the aminoisoflavones were visualized with A40 
using Pymol. 
 
4.4.9. NMR sample preparation 
Prior to the preparation of the A40 sample for NMR, the peptide was dissolved in 
ammonium hydroxide (NH4OH, 2% v/v aq) at 1 mg/ml to remove any preformed 
aggregates.121,122 Volumes equivalent to 0.1 mg (100 µL) were then aliquoted and 
lyophilized. The lyophilized peptide was initially dissolved in 1mM NaOH and then 
allowed to solubilize at 4 °C until the solution became clear (ca. 1 h). At this point the 
concentrated buffer was added to the solution and the pH was adjusted to the final 
value to generate freshly dissolved, low MW A40 samples. The final sample contained 
20 mM deuterated Tris (pD 7.0 or a calculated pH of 7.4) with 50 mM NaCl and 10% v/v 
D2O. Immediately prior to the experiment, compounds 1 and 4 were dissolved in 
deuterated DMSO at a concentration of 19.5 mM. The 1D 1H NMR and 2D 15N-1H 
SOFAST-HMQC (SOFAST = 2D band-selective optimized flip-angle short transient; 




using the freshly dissolved, low MW A40 samples. For saturation transfer difference 
(STD) NMR experiments on ligand binding to the amyloid fibrils, samples were prepared 
as above except that all of the solutions were prepared in D2O and the sample was 
allowed to incubate for 48 hours at 37 ºC in a shaker (model M from IKA) at 1000 rpm to 
generate amyloid fibrils.  
 
4.4.10. NMR measurements 
A 900 MHz Bruker Avance NMR spectrometer equipped with a triple-resonance 
z-gradient cryogenic probe (SOFAST-HMQC experiments) or a 500 MHz without 
cryoprobe was used to collect the spectra. SOFAST-HMQC spectra of 80 μM A40 in 
solution (20 mM Tris, pH 7.4, 50 mM NaCl) were recorded at 4 °C with 128 t1 
experiments, 16 scans, and a 100 ms recycle delay.123 The 2D 15N-1H SOFAST-HMQC 
data were processed using TOPSPIN 2.1 (from Bruker) and Sparky.124 Resonances 
were assigned based on previous assignments under similar conditions.125 For the STD 
experiments, both 1 and 4 were kept at a molar ratio of 10:1 relative to the fibril (200 µM 
to 20 µM).103 For the STD experiment, a 3 s train of Gaussian-shaped 50 ms pulses was 
employed to selectively saturate the amyloid fibril.103 The saturation pulses were 
centered on −2 and 100 ppm for on and off resonance respectively. The magnitude of 
the STD effect for each peak was calculated by dividing the normalized signal intensity 
in the on resonance spectrum by its corresponding intensity in the off resonance 
reference spectrum.  
 
4.4.11. Amyloid- (A) experiments 
A experiments were performed according to the previously published 
methods.12,35-40,43,44,54,104,105 Prior to experiments, A40 or A42 was dissolved in 
ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized overnight, and stored 
at −80 °C. For experiments described herein, a stock solution of A was prepared by 
dissolving the peptide in 1% NH4OH (10 L) and diluting with ddH2O. The concentration 
of A in solution was determined by measuring the absorbance of the solution at 280 
nm (= 1450 M-1 cm-1 for A40 and  = 1490 M-1 cm-1 for A42). The peptide stock 




solution containing HEPES (20 mM, pH 7.4) and NaCl (150 mM). For the inhibition 
studies,12,35-40,43,44,54,104,105 an aminoisoflavone (20 M, 1% v/v DMSO) was added to the 
sample of A (10 M) in the absence and presence of CuCl2 or ZnCl2 (10 M) followed 
by incubation at 37 °C with constant agitation for 24 h. For the disaggregation 
studies,12,35-40,43,44,54,104 A (10 M) with and without metal ions (10 M) was incubated 
for 24 h at 37 °C with constant agitation before adding the aminoisoflavone (20 M) to 
the sample. The resulting samples were incubated at 37 °C with constant agitation for 
24 h. 
 
4.4.12. Gel electrophoresis and Western blotting 
Samples from the inhibition and disaggregation experiments were analyzed by 
gel electrophoresis and visualized by Western blot using an anti-A antibody 
(6E10).12,35-40,43,44,54,105 Each sample was separated on a 10-20% Tris-tricine gel 
(Invitrogen, Grand Island, NY, USA) and transferred onto nitrocellulose. The 
nitrocellulose was blocked with bovine serum albumin (BSA, 3% w/v, Sigma-Aldrich) in 
Tris-buffered saline (TBS) containing 0.1% Tween-20 (TBS-T) overnight. The 
membranes were incubated with 6E10 (1:2000, Covance, Princeton, NJ, USA) in a 
solution of 2% BSA (w/v in TBS-T) for 4 h at room temperature. After washing, the 
horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:5000, 
Cayman Chemical, Ann Arbor, MI, USA) in 2% BSA was added for 1 h at room 
temperature. The ThermoScientific SuperSignal West Pico Chemiluminescent Substrate 
(Rockford, IL, USA) was used to visualize the protein bands. 
 
4.4.13. Transmission electron microscopy (TEM) 
TEM samples were prepared according to the previously reported method.12,35-
39,43,44,54,104,105 Glow-discharged grids (Formar/Carbon 300-mesh, Electron Microscopy 
Sciences, Hatfield, PA, USA) were treated with the A samples from both inhibition and 
disaggregation experiments (5 L) for 2 min at room temperature. Excess sample was 
removed using filter paper followed by washing with ddH2O twice. Each grid was 
incubated with uranyl acetate (1% w/v ddH2O, 5 L, 1 min) and upon removal of excess 




Philips CM-100 transmission electron microscope (80 kV, 25,000x magnification). 
 
4.4.14. Trolox equivalence antioxidant capacity (TEAC) Assay 
The TEAC assay was used to determine the antioxidant ability based on the 
extent of decolorization of ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
diammonium salt) cation radical relative to that of the vitamin E analogue, Trolox.126 The 
assay was performed according to the previously reported method with slight 
modifications.40,43,126,127 First, ABTS•+ was generated by dissolving ABTS (19 mg, 7.0 
mM) with potassium persulfate (3.3 mg, 2.5 mM) in 5 mL water and incubating for 16 h 
in the dark at room temperature. The resulting solution of ABTS•+ was diluted with EtOH 
to an absorbance of ca. 0.7 at 734 nm. The assay was conducted in a clear 96 well 
plate to which 200 L diluted solution of ABTS•+ was added and incubated at 30 C for 5 
min in the plate reader. Each ligand was added from a stock solution prepared in DMSO 
(1% v/v) or in EtOH (for Trolox) and was incubated with the solution of ABTS•+ at 30 C 
for different time periods (1, 3, 6, 10, 15, and 30 min). The percent inhibition was 
calculated according to the measured absorbance at 734 nm (% Inhibition = 100  (A0 − 
A)/A0) and was plotted as a function of ligand concentration. The TEAC value of 
compounds for each time point was calculated as a ratio of the slope of the standard 
curve of the compound to that of Trolox. The measurements were carried out in 
triplicate.  
 
4.4.15. Horseradish peroxidase (HRP)/Amplex Red assay for detection of H2O2  
The production of H2O2 generated by Cu(II)–A species in the presence of 
dioxygen (O2) and a reducing agent (ascorbate) was measured using the modified 
horseradish peroxidase (HRP)/Amplex Red assay.35,36,38,40,128,129 The assay was 
performed in situ and carried out in black polystyrene 96 well plates. In each well, fresh 
A40 (200 nM) in phosphate buffered saline (PBS, pH 7.4) was treated with CuCl2 (400 
nM) and was incubated for 1 h at room temperature with constant agitation. Each ligand 
(800 nM, 1% v/v DMSO) was introduced to the resulting solution followed by additional 
incubation at room temperature with constant agitation. After 1 h, the solution of 




containing Amplex Red (50 M) and HRP (1 U/mL) was treated to individual samples. 
After 15 min incubation, the fluorescence emission intensity was measured (ex/em = 
530/590 nm) using a microplate reader. Catalase (10 L of 100 U/mL) was used for the 
samples to confirm H2O2 production in the system. The total volume was 100 L in each 
well. 
 
4.4.16. Cell viability measurements 
The human neuroblastoma SK-N-BE(2)-M17 (M17) cell line was purchased from 
the American Type Cell Collection (ATCC, Manassas, VA, USA). M17 cells were 
maintained in media containing [1:1 Minimum Essential Media (MEM, Invitrogen)/Ham’s 
F12 Nutrient Mixture (Invitrogen), respectively], supplemented with 10% fetal bovine 
serum (FBS, Atlanta Biologicals, Atlanta, GA, USA) and 100 U/mL penicillin and 100 
g/mL streptomycin (Invitrogen). The cells were grown in a humidified atmosphere with 
5% CO2 at 37 °C. For the MTT assay, cells were seeded in a 96 well plate (20,000 
cells/100 L) according to the previously reported methods.12,35,36,38,39,43,44,54 The cells 
were treated with various concentrations of aminoisoflavones (0-10 M, 1% v/v DMSO) 
in the absence or presence of CuCl2 or ZnCl2 (1:2 metal/ligand ratio) and incubated for 
24 h in the cells. After incubation, 25 L MTT (5 mg/mL in phosphate buffered saline 
(PBS, Invitrogen), pH 7.4) was added to each well and the plate was incubated for 4 h 
at 37 °C. Formazan produced by the cells was solubilized using an acidic solution of 
N,N-dimethylformamide (50% v/v aq) and sodium dodecyl sulfate (SDS, 20% w/v) 
overnight at room temperature in the dark. The absorbance was measured at 600 nm 
using a microplate reader. Three independent experiments were conducted to estimate 
error. Cell viability was calculated relative to cells containing an equivalent amount of 
DMSO. 
 
4.4.17. Parallel artificial membrane permeability assay adapted for BBB (PAMPA-
BBB) 
The potential BBB permeability of the AIFs was determined using the PAMPA 
Explorer kit (Pion, Inc., Billerica, MA, USA) with previously reported modifications. Each 




200 L was added to the wells of the donor plate (number of replicates = 12). The BBB-
1 lipid formulation (5 L) was painted onto the polyvinylidene fluoride (PVDF, 0.45 m) 
membrane of the acceptor plate. The acceptor plate was placed on the donor plate to 
form a “sandwich” and brain sink buffer (BSB, 200 L, Pion) was added to the acceptor 
plate wells. The “sandwich” was incubated at room temperature without stirring for 4 h. 
UV-Vis spectra were acquired for the solutions in reference, acceptor, and donor plates 
using a microplate reader. The PAMPA Explorer software (v. 3.5, Pion) was used to 
calculate −logPe values. CNS± designations were assigned based on comparisons of 
known CNS± compounds in the literature.36,39,130-132 
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Alzheimer’s disease (AD) is a complex form of dementia that has a staggering 
worldwide impact, particularly on aging populations.1-3 A number of factors have been 
proposed to contribute to the onset and progression of the disease.2-5 Among these, the 
accumulation of amyloid- (A) peptides has been one of the most widely studied 
factors. The observation of proteinaceous deposits mainly composed of aggregated A 
peptides in the brain was early evidence viewed as supporting the contribution of A 
peptides to AD pathology and led to the establishment of the amyloid cascade 
hypothesis; however, subsequent research has demonstrated the complexity not only of 
this hypothesis but of the disease itself.2,4,6 Shortly after the amyloid cascade 
hypothesis was proposed, it was found that the A aggregates and neuropil from 
diseased human brain tissues contained high concentrations of transition metals, such 
as Fe, Cu, and Zn, compared to those of age-matched healthy controls.3,5,7-9 Thus, it 
was suggested that metal ion dyshomeostasis and miscompartmentalization in the brain 
could contribute to AD neuropathogenesis. 
Investigation of the relationship between metal ion 
dyshomeostasis/miscompartmentalization and AD could provide a better understanding 
of the role of metal ions in the disease and suggest a potential avenue for therapeutic 
intervention. Metal chelating agents have been employed as one approach to 
interrogate the involvement of metals in AD pathogenesis, and some have been 
suggested to be potential agents for metal chelation therapy (e.g., clioquinol, 
PBT2).3,7,10-16 Though this indirectly supports metal involvement in AD, these metal 
chelators have also been unable to offer substantial insight into the molecular 
mechanisms by which metal ions could contribute to the initiation and progression of the 
disease. In part, this results from the lack of available biophysical methods to directly 
investigate metal ions in tissue. For example, the electronic configuration of certain 
metal ions (e.g., Zn(II)) renders them silent to traditional spectroscopic methods which 
can impede detailed characterization of their chemical environment.17 Additionally, 
changes in metal content and distribution ideally would be measured in a way that 
maintains the integrity of the sample (i.e., minimal sample preparation, nominal damage 




contaminants.18-20 To circumvent these physical limitations, synchrotron-based 
spectroscopic techniques such as X-ray fluorescence (XRF) imaging and X-ray 
absorption spectroscopy (XAS) offer a convenient way to directly probe metal ions 
within biologically relevant tissues from diseased states, including neurodegenerative 
diseases.17,19,21-28  
Previous studies have exploited X-ray-based techniques to explore various 
aspects of metal content in AD brain tissues.24-29 Miller and co-workers identified 
regions of human AD brain tissue where Cu and Zn were co-localized, even though 
most of the metal content was heterogeneously distributed.24 This work was followed by 
studies connecting metal content to protein density, showing that when considering 
protein density, only Zn was elevated in plaques from the APPswe/PS1E9 transgenic 
mouse model of AD.25 Recently, Feng and co-workers described the progression of 
metal levels in the brains of AD mice (APP/V717I) upon aging from pre-symptomatic to 
late stages of AD, including analysis of the oxidation states of Fe and Cu within the 
tissue.28 In agreement with the previous literature, Fe, Cu, and Zn were also elevated in 
that AD model.26,28 Expanding upon previous observations of metal contents in AD brain 
tissues, we report additional information regarding the elemental content and 
distribution in regions of brain tissue of late-stage (16-18 month-old) double-transgenic 
AD mice (APPswe/PS1E9) by microbeam X-ray fluorescence (-XRF) microscopy. 
 
5.2. Results and discussion 
 
5.2.1. Metal contents and distributions in hippocampal and cortical tissues from 
the brains of AD and wild-type mice by -XRF imaging  
Bioavailable metals such as Fe, Cu, and Zn are unambiguously correlated with 
AD, but a consensus with respect to their connection to neuropathogenesis has yet to 
be reached. As further indication regarding the potential role, if any, that these metals 
play in development of the disease, the content and distribution of these metals were 
measured by -XRF microscopy in brain tissues of APPswe/PS1E9 and wild-type 
(WT) control mice (Figures 5.1 and 5.2). In the mouse brain tissue, several non-




scan with 5 x 5 m beam resolution. Overall, the AD tissue presented mostly diffuse 
distributions of Fe, Cu, and Zn throughout the tissue; however, discrete, localized 
regions of the metals could also be identified in various areas.  
 
 
Figure 5.1. Visualization of Fe, Cu, and Zn in brain tissues of AD (APPswe/PS1E9 
(APPswe), left) and wild-type (WT, right) mice by microbeam X-ray fluorescence (-
XRF) imaging. Metal distribution was measured in the cortex (top) and hippocampus 
(bottom) and scaled to the same color levels representing the metal content in g/cm2. 
Non-overlapping regions with dimensions of 200 m x 1000 m were scanned with 5 
m x 5 m beam resolution and 5 m step size. 
 
 
Within these tissues, the average absolute metal concentrations were quantified 
relative to standards of known concentration (Table 5.1). Averages were taken from 
several independent areas for the cortex and hippocampus of APPswe/PS1E9 and 
WT mice brain samples. In general, the metal concentrations were slightly higher in the 
diseased cortex than in the WT control cortex; Fe was approximately the same while Cu 





Figure 5.2. Visualization of Fe, Cu, and Zn in brain tissues APPswe mice by microbeam 
X-ray fluorescence (-XRF) imaging. Metal distribution was measured in the cortex (top) 
and hippocampus (bottom) and scaled to the same color levels representing the metal 
content in g/cm2.  
 
sensitive to changes in amount of metals. In the AD mice hippocampus, Fe, Cu, and Zn 
amounts were found to be approximately 2, 6, and 2 times higher, respectively, than 
those in the hippocampus of WT mice. Comparison of the cortex and hippocampus from 
WT mice revealed that average metal concentrations were higher in the cortex (Table 
5.1). In contrast, the amount of each metal was approximately similar in the two brain 
areas for the diseased mice. Along with changes in the average metal composition, 
there were striking differences in the distribution of metal for the WT versus the 
diseased samples. In the former, all of the metals have relatively narrow, approximately 
Gaussian distribution. In contrast, the distribution of metal concentrations was 
noticeably broader and, for Fe and Cu in the hippocampal tissue, obviously bimodal 
(Figure 5.3).  
These observations are consistent with a redistribution of metals in the brain as 
the disease progresses, suggesting a disruption of typical metal homeostasis. In the 
previous reports, Fe and Zn content of the same AD mice (56 weeks old) were reported 




approximately the same in both regions.26 Our findings indicated higher average 
quantity of Fe in the hippocampus and of Cu and Zn in both brain regions in the AD 
model relative to those in WT mice, which may be related to the fact that the mice in this 
study were approximately two to four months older than those in previously reported 
studies with the same AD mouse model.26   
In a different AD mouse model that expresses only an APP mutation within the 
A sequence (APP/V717I), Feng and co-workers have reported metal distributions and 
quantifications for Fe, Cu, and Zn in mice aged 1, 4, 12, and 18 months.28 Several 
comparisons can be made between their data set and ours, especially since the mice in 
the present study are similar in age to the oldest mice in the previous study. The cortical 
concentrations of Fe in the APPswe/PS1E9 mice were within the range of 
concentrations measured in the APP/V717I mice, while a higher quantity of Cu and Zn 
was measured in the APPswe/PS1E9 model.  
 
Table 5.1. Average metal contents in cortical and hippocampal regions of 




APPswe WT APPswe WT 
mg/cm2 mM mg/cm2 mM mg/cm2 mM mg/cm2 mM 
Fe  0.194 ± 0.024 700 ± 80 0.180 ± 0.014 640 ± 50 0.238 ± 0.043 850 ± 150 0.104 ± 0.001 372 ± 3 
Cu  0.204 ± 0.015 640 ± 50 0.118 ± 0.001 373 ± 3 0.233 ± 0.013 730 ± 40 0.0388 ± 0.0009 122 ± 3 
Zn  0.541 ± 0.026 1660 ± 80 0.346 ± 0.006 1059 ±	18 0.582 ± 0.085 1800 ± 300 0.302 ± 0.028 920 ± 90 
 
In the hippocampus, Fe was moderately higher in the APPswe/PS1E9 model 
over the APP/V717I model, but the WT control mice in the present study contained 
slightly less Fe than the range presented in the previous report. Zn was slightly higher in 
the hippocampus of APPswe/PS1E9 mice than the APP/V717I mice model, while the 
WT controls in both experiments were more comparable. Cu concentrations were 
similar in the hippocampus of the WT mice for both studies, while in the 
APPswe/PS1E9 model the amount of Cu measured in the tissue was outside the 




In summary, Feng and co-workers established that in the APP/V717I transgenic 
mice, Fe and Cu were enriched in the cortex, and only Cu was enriched in the 
hippocampus. Our findings were similar for Cu, which was elevated in both the cortex 
and hippocampus of the APPswe/PA1E9 double transgenic mice; however, we 
additionally observed that these AD mice also accumulated larger amounts of Fe and 
Zn in the hippocampus as well. Thus, despite minor differences, comparable values and 
sites of accumulation were obtained for the amount of Fe, Cu, and Zn in the 
APPswe/PS1E9 mice used in our study compared with the different AD mouse model 
at similar ages. Taken together, these results may support that dyshomeostasis and 
miscompartmentalization of metal ions can possibly occur upon progression of the 
disease. 
 
Figure 5.3. Histograms of Fe, Cu, and Zn amounts in selected brain tissue regions of 
AD APPswe (top) or WT (bottom) mice. The occurrence of the metal is plotted as 
frequency in counts versus the amount in g/cm2. 
 
5.2.2. Metal correlations  
 In addition to defining the distribution of individual metals in the brain tissue, it 
would be valuable to understand their potential co-localization. To accomplish this, 
correlation plots illustrating the co-incidence of two metals’ amounts (g/cm2) in each 




(Figure 5.4). Overall, the trends in these scatterplots were variable, reflecting the 
heterogeneity of the tissue. One observable feature was that for the WT distributions 
there was, generally, a modest linear correlation between each of the metals over a 
narrow range. This is consistent with cells having, on average, similar metal 
concentrations, with the observed variation resulting primarily from changes in the 
amount of cells that are illuminated by the beam. In contrast, the diseased tissue 
appears to show more pronounced structure, suggesting that there are regions that are 
selectively enhanced in Cu, or Fe, or Zn.  
 
Figure 5.4. Correlation of metal contents (g/cm2) in regions of APPswe (top) and WT 
(bottom) mice brain tissue according to co-incident metal concentrations. Color gradient 
indicates counts of overlapping pixels within the scanned regions. 
 
Within the AD cortex and hippocampus regions depicted in Figure 5.1, there was 
a slight correlation between the amounts of Cu and Zn. Since that APPswe/PS1E9 
mice of this age have extensive A plaque deposition,30 it is possible that the observed 




work by Miller and co-workers identified Cu and Zn together in hot spots from human 
AD brain, as well as co-localized within plaques.24 Thus, Cu and Zn may be able to co-
localize similarly in the tissues of diseased mice. Compared to the other correlation 
plots and those in the WT mice, there was a less obvious connection between the 
localization of Fe with Cu or Zn, particularly in the cortex. Within the cortex of AD mice, 
increased amounts of Cu and Zn were observed compared to WT. In the hippocampus, 
however, both the amounts and the localization of Fe corresponding to Cu or Zn were 
noticeably different. This may indicate sensitivity to changes in metal ion homeostasis in 
the hippocampus upon AD progression compared to WT mice. Considering the small 
size of the scanned areas, it is difficult to be certain that there is a gross correlation 
between these metals in the entire cortex, hippocampus, or full brain. Overall, it is 
possible that Cu and Zn ion homeostasis could be mutually altered in the brains of AD, 
but this could be highly dependent on the specific region in the tissue. 
 
5.3. Conclusion 
 In order to accelerate the development of novel therapeutic strategies to tackle 
AD, additional research is needed to continue exploring the complex underlying causes 
of the disease. Mounting experimental evidence supports the view that transition 
metals, such as Fe, Cu, and Zn, contribute to AD neuropathogenesis, yet uncertainty 
remains about the extent of their involvement. Using synchrotron XRF imaging, we 
investigated the distribution of Fe, Cu, and Zn in the cortex and hippocampus of an AD 
mouse model relative to WT control mice. In 16-18 month-old AD mice, concentrations 
of Fe, Cu, and Zn were increased in both cortical and hippocampal regions over the 
age-matched WT mice. The absolute amounts of metals in these tissues were also 
higher than reported previously in a relatively younger AD mouse model,26 but only 
slightly higher than a different AD mouse model of the same age.28 Therefore, along 
with the normal aging process, progression of AD might trigger the changes in contents 
and distributions of metals in the tissue. While most of the metal appeared to be 
uniformly distributed throughout the tissue, at least at the 5 m resolution limit, certain 
regions were found to contain highly concentrated metals. Overall, these results and 




ion regulation may be disrupted in the AD diseased state. As a future direction, it will be 
worthwhile to obtain a better understanding of the mechanisms leading to 
dyshomeostasis and miscompartmentalization of metals in the brain in an effort to 




5.4.1. Animal care and tissue preparation 
The double-transgenic Alzheimer’s disease mouse line (APPswe/PS1E9) was 
bred and maintained at the University of Michigan animal husbandry facility. For these 
studies, 16-18 month-old female double-transgenic mice and age- and gender-matched 
littermate wild-type (WT) controls were euthanized by anesthetic overdose of a 
xylazine/ketamine mixture followed by cardiac perfusion with phosphate buffered saline 
(PBS) and a 4% paraformaldehyde solution. At this age, APPswe/PS1E9 mice have a 
high density of A deposits (i.e., plaques) throughout the brain parenchyma.30 Following 
dissection, brains were cryoprotected in 30% sucrose and stored frozen at −80 °C. For 
imaging, 50 m thick coronal slices were prepared on a sledge microtome retrofitted 
with a Duraedge PTFE-coated microtome blade. Tissue sections were carefully 
mounted for -XRF imaging using Kapton tape. The University Committee on Use and 
Care of Animals (UCUCA) at the University of Michigan approved all mouse studies. 
 
5.4.2. Synchrotron -X-ray fluorescence (-XRF) microscopy 
Analyses of metal contents and distributions were conducted in non-overlapping 
regions of interest (ROI; 200 x 1000 m) of cortical and hippocampal tissues from 
APPswe/PS1E9 (5 or 7 ROIs, n = 3) using -XRF at the Biophysics Collaborative 
Access Team (BioCAT) beamline 18 at the Advanced Photon Source (APS) at Argonne 
National Laboratory (Argonne, IL, USA). The synchrotron X-ray beam was tuned to 10 
keV using a Si(111) double crystal monochromator. The incident beam was focused to 
5 m x 5 m at the sample using Kirkpatrick-Baez mirrors. Spectra were collected with a 
dwell time of 250 ms/pixel and 5 m step size. Variations due to beam flux were 




concentrations were determined by comparison with the intensity from thin metal foils 
(Fe, 0.1 m, Cu, 0.1 m, and Zn, 0.08 m) measured under identical conditions. The 
approximate molar concentrations were determined by accounting for the thickness of 




1. Alzheimer's Association. Alzheimers Dement. 2012, 8, 131-168. 
2. Jakob-Roetne, R.; Jacobsen, H. Angew. Chem. Int. Ed. 2009, 48, 3030-3059. 
3. DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H. Chem. Soc. Rev. 
2012, 41, 608-621. 
4. Anand, R.; Kaushal, A.; Wani, W. Y.; Gill, K. D. Pathobiology 2012, 79, 55-71. 
5. A. Rauk. Chem. Soc. Rev. 2009, 38, 2698-2715. 
6. Hardy, J.; Selkoe, D. J. Science 2002, 297, 353-356. 
7. Scott, L. E.; Orvig, C. Chem. Rev. 2009, 109, 4885-4910. 
8. Frederickson, C. J.; Koh, J.-Y.; Bush, A. I. Nat. Rev. Neurosci. 2005, 6, 449-462. 
9. Lovell, M. A.; Robertson, J. D.; Teesdale, W. J.; Campbell, J. L.; Markesbery, W. 
R. J. Neurol. Sci. 1998, 158, 47-52. 
10. Pithadia, A. S.; Lim, M. H. Curr. Opin. Chem. Biol. 2012, 16, 67-73. 
11. Rodríguez-Rodríguez, C.; Telpoukhovskaia, M.; Orvig, C. Coord. Chem. Rev. 
2012, 256, 2308-2332. 
12. Tõugu, V.; Tiiman, A.; Palumaa, P. Metallomics 2011, 3, 250-261. 
13. Perez, L. R.; Franz, K. J. Dalton Trans. 2010, 39, 2177-2187. 
14. Cherny, R. A.; Atwood, C. S.; Xilinas, M. E.; Gray, D. N.; Jones, W. D.; McLean, 
C. A.; Barnham, K. J.; Volitakis, I.; Fraser, F. W.; Kim, Y.-S.; Huang, X. D.; 
Goldstein, L. E.; Moir, R. D.; Lim, J. T.; Beyreuther, K.; Zheng, H.; Tanzi, R. E.; 
Masters, C. L.; Bush, A. I. Neuron 2001, 30, 665-676. 
15. Adlard, P. A.; Cherny, R. A.; Finkelstein, D. I.; Gautier, E.; Robb, E.; Cortes, M.; 
Volitakis, I.; Liu, X.; Smith, J. P.; Perez, K.; Laughton, K.; Li, Q.-X.; Charman, S. 
A.; Nicolazzo, J. A.; Wilkins, S.; Deleva, K.; Lynch, T.; Kok, G.; Ritchie, C. W.; 
Tanzi, R. E.; Cappai, R.; Masters, C. L.; Barnham, K. J.; Bush, A. I. Neuron 2008, 
59, 43-55. 
16. Faux, N. G.; Ritchie, C. W.; Gunn, A.; Rembach, A.; Tsatsanis, A.; Bedo, J.; 
Harrison, J.; Lannfelt, L.; Blennow, K.; Zetterberg, H.; Ingelsson, M.; Masters, C. 
L.; Tanzi, R. E.; Cummings, J. L.; Herd, C. M.; Bush A. I. J. Alzheimers Dis. 
2010, 20, 509-516. 
17. Penner-Hahn, J. E. Coord. Chem. Rev. 2005, 249, 161-177. 
18. Ralle, M.; Lutsenko, S. Biometals 2009, 22, 197-205. 
19. Fahrni, C. J. Curr. Opin. Chem. Biol. 2007, 11, 121-127. 
20. Barrea, R. A.; Gore, D.; Kondrashkina, E.; Weng, T.; Heurich, R.; Vukonich, M.; 
Orgel, J.; Davidson, M.; Collingwood, J. F.; Mikhaylova, A.; Irving, T. C. Proc. 8th 




21. Collingwood, J. F.; Mikhaylova, A.; Davidson, M. R.; Batich, C.; Streit, W. J.; 
Eskin, T.; Terry, J.; Barrea, R.; Underhill, R. S.; Dobson, J. J. Phys.: Conf. Ser. 
2005, 17, 54-60. 
22. Strange, R. W.; Feiters, M. C. Curr. Opin. Struct. Biol., 2008, 18, 609-616. 
23. Popescu, B. F. G.; Nichol, H. CNS Neurosci. Ther. 2011, 17, 256-268. 
24. Miller, L. M.; Wang, Q.; Telivala, T. P.; Smith, R. J.; Lanzirotti, A.; Miklossy, J. J. 
Struct. Biol. 2006, 155, 30-37. 
25. Leskovjan, A. C.; Lanzirotti, A.; Miller, L. M. NeuroImage 2009, 47, 1215-1220. 
26. Leskovjan, A. C.; Kretlow, A.; Lanzirotti, A.; Barrea, R.; Vogt, S.; Miller, L. M. 
NeuroImage 2011, 55, 32-38. 
27. Wang, H.-J.; Wang, M.; Wang, B.; Meng, X.-Y.; Wang, Y.; Li, M.; Feng, W.-Y.; 
Zhao, Y.-L.; Chai, Z.-F. J. Anal. At. Spect. 2010, 25, 328-333. 
28. Wang, H.; Wang, M.; Wang, B.; Li, M.; Chen, H.; Yu, X.; Zhao, Y.; Feng, W.; 
Chai, Z. Metallomics 2012, 4, 289-296. 
29. Wang, H.; Wang, M.; Wang, B.; Li, M.; Chen, H.; Yu, X.; Yang, K.; Chai, Z.; 
Zhao, Y.; Feng, W. Metallomics 2012, 4, 1113-1118.  
30. Rodríguez-Lebrón, E.; Gouvion, C. M.; Moore, S. A.; Davidson; B. L.; H. L. 




Chapter 6: Concluding Remarks and Perspectives 
 
In the past decade, chemists have contributed to the continued efforts to 
understand the role of metal–A species in AD by recognizing the potential for targeting 
and modulating these complexes using small molecules. As a result, the literature now 
hosts several libraries of compounds with various frameworks and structural derivatives, 
which have been used to uncover some nuances of the metal-peptide interaction and its 
impact on aggregation and toxicity. Ongoing efforts in this area will be valuable as the 
onset and progression of AD are determined.  
The work presented in Chapters 2-4 of this dissertation demonstrates the 
importance of exploring compounds’ mode of action at the molecular level as a critical 
step toward logical advancements in new molecule design using the flavonoid family of 
compounds. Flavonoids have been long known to have biological properties suitable for 
a number of disease targets, and this work reveals explanations for their reactivity with 
metal-associated A species by considering the balance between both metal chelation 
and A interacting properties to modulate the in vitro reactivity of these complexes. 
From these studies, we now understand that a combination of hydrophobic and 
hydrophilic groups facilitates ligand-peptide contacts in addition to tuning metal binding 
affinity. Furthermore, evidence of a compact A–flavonoid complex may rationalize an 
observed alternate aggregation pathway, which results in non-toxic, amorphous 
aggregates. In the presence of metal ions, the generation of a ternary complex 
consisting of A, a metal ion, flavonoid, could account for a similar observation to the 
metal-free scenario, whereby small, amorphous aggregates are the end product of 
flavonoid-mediated metal-associated A aggregation. With this in mind, individual 
aspects of each structure, such as the presence of a catechol or pyrogallol group, can 
be investigated and future generations of molecules can be systematically designed to 




In terms of ligand design, several strategies would be valuable in the near future 
to elaborate on the structure-interaction-reactivity relationship such as (1) altering A 
targeting groups, (2) tuning metal binding affinities, (3) improving BBB permeability, and 
(4) stabilizing structures to withstand physiological conditions. The aminoisoflavone 
framework could serve as a template on which minor modifications could be made 
initially. For a comparison of structure, interaction, and reactivity, analogues of 1-4 
should be prepared without the primary amine to determine how that chemical structure 
alters reactivity. It would be insightful to know whether the presence of this group serves 
as a targeting moiety for the peptide or if it aids in compound solubility. Clearly, between 
1-4 and their methoxylated precursors 1a-4a, the catechol group played a valuable role 
in mediating A interaction and in metal chelation as it is known to bind well to metal 
ions such as Cu(II) and Fe(III).  In the aminoisoflavones, compound 4, which has this 
moiety, binds to Cu(II) with high affinity. Therefore, another step in modification of these 
compounds could include variation of the donor atoms for metal binding. To tune the 
binding affinity and potentially the selectivity for other cations (e.g., Cu(I)), substitution of 
the oxygen atoms with nitrogen or sulfur could be explored. Derivatives having these 
various metal chelation moieties could then be useful to examine the involvement of 
lesser studied, biologically relevant metal ions in AD. 
Another improvement to this framework would be introduction of groups to 
improve BBB permeability. Using both naturally occurring and synthetic compounds, 
simple modifications could be made to increase the likelihood of passive uptake into the 
brain. For example, esterification of the hydroxyl groups might be one method to 
facilitate BBB permeability. Alternatively, other groups have used pro-drug approaches 
that exploit receptors and transporters in the brain, such as GLUT-1. According to this 
method, sugar groups are used to mask the metal chelation site and minimize systemic 
metal binding. This moiety is then recognized by the transporters which then facilitate 
transport into the brain; cleavage of the sugar group reveals the active, metal chelating 
compound.1,2 Pursuit of compounds with BBB targeting moieties or combination 
approaches to improve delivery of the present molecules will be an ongoing effort for 




render compounds less susceptible to metabolism, such as the inclusion of fluorine 
atoms, might be worthwhile to consider. 
Subsequently, with an expanded flavonoid library, more extensive in vitro tests 
could be conducted to investigate the interplay of these molecules with other proteins 
and biomolecules relevant to AD, as well as intracellular mechanisms that may be 
affected by these compounds. Flavonoids are known to have numerous biological 
targets, including enzymes that may be relevant in AD.3 Screening of the newly 
designed flavonoid derivatives against various enzymes and proteins, in addition to 
evaluating their interaction and reactivity with metal-free and metal associated A, 
would help to illuminate more details of the biological relevance of these compounds to 
AD. This finding would provide a comprehensive view of the structure-interaction-
reactivity relationship and allow for more systematic compound development toward 
therapeutics or diagnostics.  
In the next several years, the field will benefit from the continued compound 
development and chemical insights on the structure-interaction-reactivity relationships 
between small molecules and metal–A species. Furthermore, optimization of 
properties that would be relevant to biological application (e.g., toxicity, BBB 
permeability, metabolic stability) for these and other lead compounds will be required. 
Moving forward, the field is well poised to begin to explore ways to employ these 
compounds as chemical tools to probe metal–A species using in vivo models. In the 
near future, fundamental knowledge on the roles of metal ions in AD should be more 
clearly revealed using in vitro models and AD animal models. Thus, the exact types of 
molecules could subsequently be designed more efficiently and specifically. 
Collaborations across disciplines, such as medicinal chemistry, biology, biophysics, and 
neuroscience, will enhance these efforts, since the multiple parameters that must be 
considered in more complex systems.   
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Appendix A: Quantifying Potential Changes in Metal Homeostasis in 
Glaucoma by Synchrotron -X-ray Fluorescence (-XRF) Imaging 
 
The work presented herein was conducted in collaboration with Professor Samuel D. 
Crish and Professor Cornelis van der Schyf at the Northeastern Ohio Medical 
Universities, as well as Professor James Penner-Hahn at the University of Michigan. 
Brain and retina tissue samples from mice were obtained from Professor Crish. 
Experiments were conducted at BioCAT, Sector 18 at the Advanced Photon Source at 
Argonne National Laboratory in collaboration with Dr. Aniruddha Deb and with beamline 
support from Dr. Raul Barrea. Kevin O’Neill assisted in processing images in MatLab. 
 
A.1. Introduction 
 Glaucoma is a visual neuropathy leading to vision loss that accounts for 912% 
of blindness and affects almost 60 million people worldwide, including 3 million 
Americans.1 Deterioration of retinal ganglion cell (RGC) neurons and axons, which 
compose the optic nerve, is cited as source of vision loss in the disease.2 Like 
Alzheimer’s disease (AD), glaucoma is incurable; however, it can be treated if detected 
early through routine eye exams.1 There are three forms of glaucoma: primary open 
angle, angle closure, and normal-tension glaucoma. The most common form of 
glaucoma, primary open angle glaucoma, is characterized by elevated intraocular 
pressure (IOP) in the eye, due to improper fluid drainage. In angle closure glaucoma, 
IOP is elevated, but the pressure increases rapidly. Normal-tension glaucoma is rare 
and is characterized by damage to the optic nerve without an increase in IOP.  
Glaucoma can be diagnosed at any age and in some cases there may be no outward 
symptoms.1 Risk increases with age, family history, diabetes, or extreme 
nearsightedness.1 Elevated IOP is the only modifiable symptom of the disease, but 
lowering the IOP does not always guarantee that vision loss will be stopped.3,4 
Although the exact cause of glaucoma is unknown, it was long-believed to affect 
only the retina and other areas of the eye. Its consideration as a neurodegenerative 




researchers address the problem.2 It has been demonstrated that areas of the brain 
may provide early signs of neurodegeneration in conjunction with the onset of 
glaucoma. In particular, degeneration of the optic nerve could be an early sign of 
disease progression. Crish et al. recently presented evidence to support this 
hypothesis.2 Using a glaucoma mouse model, early injury to axons in the optic nerve 
was found to damage transport of a fluorescent dye between the retina and brain.2 
Furthermore, their results showed the sectorial nature of glaucoma; progression of the 
disease is independent in each eye and pathological features can occur in various, 
discrete sections of the retina.2 Interestingly, they suggested that impaired transport 
was an early sign of glaucoma that preceded the damage to the retina.2 These studies 
demonstrated the involvement of the entire visual system in glaucoma and justified its 
classification as a form of neurodegeneration.  
Along with this paradigm shift, it has been recognized that other external factors 
could contribute to the complexity of glaucoma. For example, glaucoma incidence 
correlates with AD, suggesting their respective neuropathogenesis may be similar. 
According to several reports, the abnormally folded protein (i.e., amyloid- (A)) of AD 
have been found in the eye.4,5 Interestingly, Ito et al. suggested that A42 expression in 
the retina increased as glaucoma progressed in the monkeys.3 Furthermore, evidence 
of retinal degeneration has been observed in AD mice models, along with deposition of 
A in the retina.4 It has also been observed that soluble oligomeric forms of A, which 
are currently implicated in AD as a potentially toxic species,6 can induce apoptosis of 
RGCs in glaucoma.4,5  
 In AD and other neurodegenerative diseases, including glaucoma, oxidative 
stress is pervasive, leading some researchers to suggest a disruption of metal ion 
homeostasis in affected tissues could be a contributing factor.6-10 With some similar 
features in glaucoma (e.g., oxidative stress), it is possible that metal ions in the retina, 
optic nerve, and/or brain could be disrupted as well; however, there have been only a 
few attempts to address this question. A recent report implied that Cu and Zn could be 
involved in pseudoexfoliation syndrome (PEX), which is prevalent in Turkish populations 
and can lead to a glaucoma.11 Most research on metals in glaucoma to date, however, 




produce reactive oxygen species (ROS; e.g., H2O2), accumulation of Fe has been linked 
to retinal degradation and some Fe overload diseases have accompanying vision loss.13 
For example, deficiency of ceruloplasmin, a ferroxidase, can lead to the accumulation of 
Fe in the retina and subsequent retinal damage.13 Farkas et al. mapped genetic 
changes in monkeys with glaucoma to uncover changes in transferrin, ceruloplasmin, 
and ferritin expression. In mild glaucoma, there was no change to transferrin expression 
in mild cases of glaucoma but increased in moderate-to-severe cases.12 Ceruloplasmin 
was 1.3-fold higher than the control for mild glaucoma while monkeys with severe 
glaucoma had a six-fold increase in gene expression. Finally, ferritin presented a 2.2-
fold increase in both mild and severe cases compared to the control.12 As a result, the 
authors suggested that Fe, and potentially Cu, could be involved in neurodegeneration. 
Thus, changes in the expression of transferrin, ceruloplasmin, and ferritin could be 
neuroprotective, where upregulation of these proteins is intended mitigate the 
consequences of abnormal transition metal ion homeostasis.  
To expand on these previous works, it would be valuable to directly determine if 
changes to the metal distribution (i.e., quantity, localization) occur. A variety of 
approaches have been utilized to probe this question in neurodegenerative diseases.14 
Among them, X-ray techniques have been employed to investigate the distribution, 
localization, and quantification of transition metals in AD brain tissue. Synchrotron -X-
ray fluorescence (-XRF) provides a quantifiable, metal-specific approach to identify 
discrete accumulations of metals in tissue.14 Its requirements for sample preparation are 
minimal and it is relatively non-destructive, making it an ideal method to interrogate 
metal homeostasis in biological tissues. With the mounting evidence suggesting the 
involvement of metals in AD and other neurodegenerative diseases,6-10 it would be 
interesting to consider their possible role in glaucoma as well. To the best of our 
knowledge, there have been no reports of -XRF applied to tissue derived from a 
glaucoma mouse model to determine metal ion concentration or distribution in the retina 
or brain.  
 In the present study, a mouse model of glaucoma, DBA2/J, which is known to 
display age-related IOP elevation, was used to measure changes in metal ion 




brain, compared to a non-disease control mouse model C57BL/6. Young mice (2-5 
months), which do not show glaucoma pathology, were compared with older mice (10-
12 months) that have signs of the disease (i.e., retinal degradation). Two sets of -XRF 
data were collected independently for preliminary investigations of the metal content 
changes in regions of the retina and brain of glaucoma-affected mice. The outcomes of 
these preliminary experiments will be discussed herein. 
 
A.2. Results and discussion 
 
A.2.1. Imaging of metals and quantification of Fe, Cu, and Zn in the retina and 
superior colliculus 
 To date, there have been few reports on the metal contents and their potential 
changes in glaucoma-affected tissues.11-13 Using -XRF, initial attempts have been 
made to visualize the distribution of metals, particularly Fe, Cu, and Zn, in the 
retinorecipient layer of the retina, which is affected by glaucoma, and in the SC of the 
brain. Furthermore, the amounts of these metals were quantified by comparison with 
known standards.  
In the first data set, multiple, non-overlapping sections of retina tissue were 
scanned. Representative images are shown in Figure A.1. The images show both 
discrete and diffuse concentrations of metal within the particular region. In both the 
control and diseased mice, Fe was found in mainly localized areas. Cu and Zn were 
more dispersed with overall higher amounts in the diseased mice over the controls. The 
quantification of all tissues from these regions suggested, however, that overall there 
were no changes to the amounts of metals present in the retina depending on age or 
strain (Figure A.2). In the retina, the amount of Zn was highest among all samples, while 
Fe and Cu levels remained relatively constant. In the brain tissues, the overall 
concentrations of Cu and Zn were much lower than that of the retina; the amount of Fe 
was approximately the same as the retina. There was a slight overall decrease in Fe in 
the young and old diseased mice brain tissue, which might indicate a potential change 
with glaucoma progression compared to healthy aging. It is worthwhile to point out that 




tissue that are not affected in glaucoma due to the dimensions of the scan area. 
Therefore, in order to draw conclusions for these data, quantification of metals in the 
brain tissues should be refined to more specifically characterize the SC, which is limited 
to the top 300 m of the brain slice.  
 
 
Figure A.1. Images depicting the concentration of Fe, Cu, Zn, K, and Ca in retinal 
tissues from first sample set (10m x 10 m beam size). Concentrations are in g/cm2 
for Fe, Cu, and Zn and in total counts for K and Ca. 
 
 
In the first set of samples, the beam size was small and representative regions of 
the tissue were scanned. To probe whether we could obtain useful information with less 
sensitivity, the second set of data was collected using a larger beam. Fewer samples 
were measured, but the larger beam size afforded the opportunity to investigate a single 
large area of the retina; regions of the brain tissue remained small to focus on the SC 




significantly higher than in the first sample set, possibly as a result of the larger scan 
area (Figure A.4). Comparison of the retina results suggests that Fe and Cu may be 
decreased in old mice compared to younger mice and in the control mice versus the 
diseased mice at a young age. Young and old diseased mice had similar amounts of Fe 








































Retina (mg/cm2) SC (mg/cm2) 
Fe Cu Zn Fe Cu Zn 
C57 (Normal), Young 0.068 ± 0.006 0.052 ± 0.007 0.121 ± 0.014 0.067 ± 0.017 0.020 ± 0.005 0.031 ± 0.008 
C57 (Normal), Old 0.076 ± 0.013 0.058 ± 0.011 0.141 ± 0.024 0.098 ± 0.003 0.031 ± 0.001 0.035 ± 0.008 
DBA2/J (Disease), Young 0.061 ± 0.007 0.055 ± 0.008 0.141 ± 0.015 0.057 ± 0.010 0.025 ± 0.001 0.044 ± 0.002 
DBA2/J (Disease), Old 0.096 ± 0.048 0.070 ± 0.021 0.172 ± 0.030 0.046 ± 0.015 0.024 ± 0.008 0.040 ± 0.020  
 
Figure A.2. Quantification of Fe, Cu, and Zn content in retinal and brain (SC) tissue 
from first sample set. Error bars represent the mean of several independent sections 
measured across multiple retinas from n = 2 mice per group, which are considered to be 
independent samples. 
 
There have been several challenges to data collection and analysis that should 
be considered for future success in this project. First, one challenge arises from the 
nature of the tissue samples. The retina tissues can be non-uniform in thickness since 
they are obtained through dissection, whereas the brain tissues are sliced to an even 
thickness by a microtome. Transmission of the X-ray beam through areas of different 
thickness could misrepresent the actual metal contents. The retina is ca. 300 m thick 
and can vary by 20-50 m locally. Furthermore, the top three layers of the retinal cells 
(ca. 20-30 m) contain the cells of interest in this disease. Therefore, transmission of 







Figure A.3. Images depicting the concentration of Fe, Cu, and Zn in brain tissues from 
second sample set (20m x 20 m beam size). Concentrations are in g/cm2 for Fe, 

























































Retina (mg/cm2) SC (mg/cm2) 
Fe Cu Zn Fe Cu Zn 
C57 (Normal), Young 0.926 1.266 1.298 0.799 0.861 1.098 
C57 (Normal), Old 0.409 0.563 1.084 0.930 0.813 1.323 
DBA2/J (Disease), Young 0.453 0.546 1.139 0.579 0.607 1.004 
DBA2/J (Disease), Old 0.487 0.664 1.544 0.516 0.817 1.187  
 
 
Figure A.4. Quantification of Fe, Cu, and Zn content in retinal and brain (SC) tissue 





A.3. Conclusion and Future Directions 
Although there have been many efforts to investigate the role of metal ion 
dyshomeostasis in neurodegenerative diseases such as AD, relatively few efforts have 
been made to explore if metals have a connection to the progression of glaucoma. The 
present study was conducted to determine the amounts and localization of metals in 
retina and brain tissues from healthy and diseased mice. Based on the data presented 
herein, metal contents may be affected based on age and disease state. Some of the 
preliminary results suggest that Fe may be constant or slightly higher in the diseased 
mice retinas compared to the young diseased mice, as was previously suggested,13 
while Cu and Zn are relatively unchanged. For the brain tissue, more detailed data 
analysis would be beneficial to refine the conclusion. Based on these preliminary 
findings, further efforts to comprehensively characterize metal ion homeostasis in 
glaucoma with larger sample sizes will be worthwhile as the outcomes from such 
studies could shed light on a new target areas for glaucoma research.  
It appears that glaucoma could originate from multiple factors. As protein 
aggregation and metal dyshomeostasis are hallmarks of AD and other 
neurodegenerative diseases like AD, it is possible that these are found and may be 
interconnected in glaucoma as well. As next steps in this project following the 
determination of metal concentrations, relating those observations to specific proteins 
might be of interest. Broadly, it will be interesting to see if correlations between 
glaucoma and other diseases can be made more conclusively. There have been 
suggestions that glaucoma and AD may be linked, for example. Thus, it will be valuable 
to elucidate the pathological connection, if any, between glaucoma and AD, perhaps 
using metal ions and/or A as a mediating player, as efforts continue to find ways to halt 




A.4.1. Animal care and tissue preparation 
The DBA2/J glaucoma mice and C57BL/6 control mice were purchased from 




(NEOMED) animal husbandry facility. For these studies, young (2 or 5 month) and old 
(10 or 12 month) DBA2/J mice were compared with age-matched controls. The older 
glaucoma mice used in the study have been shown to express glaucoma pathology 
while the young mice do not display neurodegeneration. There were at least 2 animals 
for each age and strain; each eye is an independent sample. The mice were deeply 
anesthetized followed by cardiac perfusion with 0.9% w/v NaCl and a 4% 
paraformaldehyde solution. The eyes were removed and stored in 0.9% w/v NaCl. 
Brains were also removed and stored in either 0.9% w/v NaCl or 20% w/v sucrose. 
Retinas were removed from the eyes by microdissection and placed within the open 
region of the sample holder. For imaging, 50 m thick brain slices were prepared. The 
samples were prepared by affixing double sided tape to the XRF sample holder. Tissue 
sections (retina and brain) were carefully mounted between two sheets of Ultralene film 
(SPEX Sample Prep, Metuchen, NJ, USA). The Institutional Animal Care and Use 
Committee at NEOMED approved all mouse studies. 
 
A.4.2. Synchrotron -X-ray fluorescence (-XRF) microscopy 
Analyses of metal contents and distributions were conducted in non-overlapping 
regions of interest (ROI) of various sizes within the RGC layers in the retina and the SC 
region of the brain using -XRF at the Biophysics Collaborative Access Team (BioCAT) 
beamline 18 at the Advanced Photon Source (APS) at Argonne National Laboratory 
(Argonne, IL, USA). The synchrotron X-ray beam was tuned to 10 keV using a Si(111) 
double crystal monochromator. In the retinal tissue, several non-overlapping of 600 m 
x 1000 m (for 10 x 10 m beam) or a single large regions of interest (ROI) (for 20 x 20 
m beam) were scanned. In the brain tissue, the SC is restricted to the upper 300 m of 
the tissue that remains upon removal of the cortex; an ROI sufficiently large to 
encompass this area was scanned. The incident beam was focused to 10 m x 10 m 
or 20 m x 20 m at the sample using Kirkpatrick-Baez mirrors. Spectra were collected 
with a dwell time of 250 ms/pixel and 10 or 20 m step size. Variations due to beam flux 
were normalized based on changes in I0. Metal concentrations were determined by 




m) measured under identical conditions. The approximate molar concentration was 
determined by accounting for the thickness of the tissue, assuming a density of 1 g/cm3 
and dividing by the atomic weight of these elements.  
Data were processed in MatLab using a program adapted by Dr. Aniruddha Deb. 
To circumvent some of these data processing challenges described above, another 
MatLab program written in the Penner-Hahn group could be applied to selectively 
analyze specific ROIs from within a larger area. This program would be particularly 
useful for eliminating aberrant background contributions and focus only on areas of the 
scan that contained tissue. Additionally, this program could be used to generate images 
and quantify the metal in a specific set of pixels. It has been applied to some of the data 
that was obtained in the second set to evaluate the metal contents in the SC as 
compared to the rest of the brain tissue slice. Given the limitations mentioned above, 
the quantified data resulting from use of the program would be more useful on future 




2. Crish, S. D.; Sappington, R. M.; Inman, D. M.; Horner, P. J.; Calkins, D. J. Proc. 
Natl. Acad. Sci. U. S. A. 2010, 107, 5196-5201. 
3. Ito, Y.; Shimazawa, M.; Tsuruma, K.; Mayama, C.; Ishii, K.; Onoe, H.; Aihara, M.; 
Araie, M.; Hara, H. Mol. Vis. 2012, 18, 2647-2657. 
4. Chiu, K.; Chan, T. F.; Wu, A.; Leung, I. Y.; So, K.-F.; Chang, R. C.-C. Age 2012, 
34, 633-649. 
5. Yin, H.; Chen, L.; Chen, X.; Liu, X. Med. Hypotheses 2008, 71, 77-80. 
6. Savelieff, M. G.; Lee, S.; Liu, Y.; Lim, M. H. ACS Chem. Biol. 2013. 
7. DeToma, A. S.; Salamekh, S.; Ramamoorthy, A.; Lim, M. H. Chem. Soc. Rev. 
2012, 41, 608-621. 
8. Pithadia, A. S.; Lim, M. H. Curr Opin Chem Biol 2012, 16, 67-73. 
9. Kepp, K. P. Chem. Rev. 2012, 112, 5193-5239. 
10. Faller, P. Free Radical Biol. Med. 2012, 52, 747-748. 
11. Ceylan, O. M.; Can Demirdöǧen, B.; Mumcuoǧlu, T.; Aykut, O. Biol. Trace Elem. 
Res. 2013 153, 28-34. 
12. Farkas, R. H.; Chowers, I.; Hackam, A. S.; Kageyama, M.; Nickells, R. W.; 
Otteson, D. C.; Duh, E. J.; Wang, C.; Valenta, D. F.; Gunatilaka, T. L.; Pease, M. 
E.; Quigley, H. A.; Zack, D. J. Invest. Ophthalmol. Vis. Sci. 2004, 45, 1410-1417. 
13. He, X.; Hahn, P.; Iacovelli, J.; Wong, R.; King, C.; Bhisitkul, R.; Massaro-
Giordano, M.; Dunaief, J. L. Prog. Retin. Eye Res. 2007, 26, 649-673. 
14. Bourassa, M. W.; Miller, L. M. Metallomics 2012, 4, 721-738. 
